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Abstract: Zusammenfassung Die homöostatische Kontrolle von systemischem Phosphat (Pi) wird weit-
gehend durch die Balance von renaler Reabsorption von Pi aus dem Ultrafiltrat und intestinaler Absorp-
tion von Pi aus der Nahrung aufrecht erhalten. Die renale Reabsorption von Pi findet hauptsächlich in
den proximalen Tubuli statt wofür die Na/Pi-Kotransporter Slc34a1/NaPi-IIa, Slc34a3/NaPi- IIc und
Slc20a2/Pit-2 verantwortlich sind. Diese Transportproteine sind in der apikalen Membran lokalisiert und
werden durch verschiedene Hormone reguliert, wie z.B. durch das Parathormon (PTH) oder durch den
“fibroblast growth factor 23“ (FGF23). Aufgrund der Daten die von NaPi-IIa und NaPi-IIc defizienten
Mausmodellen erhalten wurden geht hervor, dass NaPi-Ila quantitativ die Hauptrolle bei der renalen Re-
absorption von Pi spielt, wohingegen NaPi-Ilc eine wohl eher geringere Rolle spielt und eventuell auf junge
Tiere beschränkt ist. Im Gegensatz zu der Maus, wurden beim Menschen verschiedene Mutationen im
NaPi-IIc Gen beschrieben, welche mit dem Krankheitsbild HHRH (hereditary hypophosphatemic rickets
with hypercalciurie) assoziert sind. Das Ziel der vorliegenden Arbeit war es ein Mausmodell zu gener-
ieren, in welchem das NaPi- llc Gen nierenspezifisch und induzierbar ausgeschaltet werden kann. Dieses
Modell basiert auf dem loxP:Cre Rekombinase-System. Transgene Mäuse, welche homozygote Träger
des gefloxten NaPi-Ilc (NaPi-IIcf/f) Gens waren, wurden mit Pax8rtTA/LC1 Tieren verpaart. Damit
wurden Mäuse erhalten in denen die Expression der Cre-Rekombinase nierenspezifisch durch Doxycy-
clin (Doxy) induziert werden konnte. Zu Beginn der Experimente wurde die Cre Aktivität in 3 bis 4
Wochen alten Mäusen durch die Gabe von 2 mg/ml Doxy im Trinkwasser während 10 Tagen induziert.
Als Negativkontrollen dienten Wurfgeschwister. Urinproben wurden während den letzten 24 Stunden des
Versuchsprotokolls gesammelt und am Ende wurden Blut, Nieren und Ileum entnommen. Diese Behand-
lung führte zu einer kompletten Reduktion von NaPi-llc mRNA und Protein in den Nieren. Allerdings
war die Ausscheidung von Pi im Urin bei allen Doxy behandelten Tieren erhöht, mit gleichzeitiger re-
duzierter Ausscheidung von Na + - und K+ - Ionen. Dies deutete darauf hin, dass die Behandlung mit
2 mg/ml Doxy entweder zu unspezifischen renalen Effekten führte, oder möglicherweise eine intestinale
Veränderung bewirkte. Um die Dosierung von Doxy zu optimieren wurden NaPi-IIc+/+ und NaPi-IIcf/f
Mäuse zunächst während 10 Tagen entweder mit 1, 0.5 oder 0.25 mg/ml Doxy behandelt, gefolgt von
einer Erholungsperiode von 15 Tagen mit normalem Trinkwasser. Bei Tieren, die 1 respektive 0.5 mg/ml
Doxy erhielten war die Ausscheidung von Na+ -Ionen im Urin immer noch reduziert, aber nicht mehr in
Mäusen die mit 0.25 mg/ml behandelt wurden. In NaPi-IIcf/f Mäusen wurde die Expression von NaPi-IIc
mRNA durch die Gabe von 1 respektive 0.5 mg/ml Doxy beinahe komplett unterdrückt, wohingegen 25%
der Expression der NaPi-llc mRNA nach einer Dosis von 0.25 mg/ml erhalten blieben. Aufgrund dieser
Resultate wurde ein neues Doxy Dosierungsprotokoll erarbeitet, nach dem die Tiere zunächst für 5 Tage
mit 0.5 mg/ml Doxy und anschliessend für weitere 5 Tage mit 0.25 mg/ml Doxy behandelt wurden. Nach
einer 15-tägigen Erholungsphase wurden die Tiere erneut untersucht. Als Indikator für unspezifische
Effekte wurde wieder die Konzentration von Na+ -Ionen im Urin gemessen. Die Ausscheidung von Na+-
Ionen im Urin bei behandelten Tieren war vergleichbar zu den Kontrollen, was darauf schliessen liess, dass
dieses Induktionsprotokoll keine unspezifischen renalen Effekte hervorrufte. Die folgenden Experimente
wurden deshalb mit diesem optimierten Protokoll durchgeführt. Die Expression von NaPi-IIc mRNA und
NaPi-llc Protein waren vergleichbar in NaPi-IIc+/+ Kontrollmäusen die entweder mit Doxy oder nur
mit Saccharose im Trinkwasser behandelt wurden. Erwartungsgemäss führte die Behandlung mit Doxy
zu einer 50%-igen beziehungsweise 90%-igen Reduktion der Menge von NaPi-llc mRNA und Protein in
NaPi- IIcf/+ und NaPi-IIcf/f Tieren. Allerdings hatte das Fehlen von NaPi-Ilc in den Nieren der NaPi-
IIcf/f Mäusen keinen Effekt auf die Na/Pi-Kotransport Aktivität in isolierten renalen Bürstensaummem-
branen und es wurden auch keine Aenderungen der Mengen der anderen renalen Na/Pi-Kotransporter,
NaPi-Ila und Pit-2 beobachtet. Ebenso blieb die Menge von NaPi-Ilb in Enterozyten unverändert. Dies
deutete darauf hin dass keine Kompensation durch andere Na/Pi-Kotransporter in NaPi-Ilc defizien-
ten Mäusen stattfindet. In Mäusen mit NaPi-IIc defizienten Nieren waren die Ausscheidung von Pi im
Urin und die Plasmakonzentration von Pi normal. Die Konzentrationen der phosphaturischen Hormone
PTH und FGF23 waren unverändert. Die Konzentrationen von Ca2+ im Plasma und Urin sowie des
zirkulierenden 1,25(OH)2D3 waren ebenfalls unverändert. Die Expression der 1￿- Hydroxylase und der
24-Hydroxylase mRNA waren vergleichbar in NaPi-IIc+/+ und NaPi-IIcf/f Mäusen. Die Daten, die mit
den induzierbaren nierenspezifischen NaPi-IIc defizienten Mäusen erhalten wurden, sind nur teilweise
übereinstimmend mit den Beobachtungen, die für konstitutiv NaPi-IIc defiziente Mäuse beschrieben
wurden. Obwohl in konstitutiv NaPi-IIc defizienten Mäusen die Pi Ausscheidung im Urin und die Plas-
makonzentration von Pi ebenso normal blieben, ging die konstitutive Defizienz von NaPi-IIc mit einer
Hyperkalzämie und Hyperkalziurie, sowie einer erhöhten Konzentration von 1,25(OH)2D3 einher. Dies
lässt darauf schliessen, dass nach einer konstitutiven Deletion des NaPi-llc Gens, das Fehlen von NaPi-
IIc in extrarenalen Geweben zu den beobachteten Änderungen des Calcium-Haushaltes führt. Zusam-
mengefasst haben wir ein Maussmodell generiert, bei welchem das Na/Pi- Kotransporter NaPi-llc Gen
SLC34a3 nierenspezifische und induzierbar inaktiviert werden kann. Die Analyse dieses Mausmodells
zeigte, dass im Gegensatz zum Menschen, die renale Reabsorption von Pi durch NaPi-IIc minimal ist.
Das hier beschriebene neue Mausmodell (floxed NaPi-IIc) erlaubt es, die noch weitgehend unbekannte
Rolle von NaPi-IIc in verschiedenen Organen neben der Niere zu untersuchen. Summary Homeostatic
control of inorganic phosphate (Pi) is largely achieved by renal reabsorption and intestinal absorption of
Pi. Renal reabsorption of Pi takes place preferentially in the proximal tubules and is mediated by the
Na/Pi-cotransporters Slc34a1/NaPi-IIa, Slc34a3/NaPi-IIc and Slc20a2/Pit-2. The abundance of these
cotransporters is regulated by several hormones including parathyroid hormone (PTH) and fibroblast
growth factor23 (FGF23). Based on constitutively deficient NaPi-IIa and NaPi-IIc mouse models, it has
been postulated that NaPi-IIa plays a major quantitative role in the renal reabsorption of Pi in rodents,
whereas the contribution of NaPi-IIc is considered to be less important and probably restricted to young
animals. However, in humans several mutations have been identified in the NaPi-IIc gene that cause
hereditary hypophosphatemic rickets with hypercalciuria (HHRH). The aim of this study was to gener-
ate a renal-specific and inducible mouse model deficient of NaPi-IIc to investigate the contribution of this
cotransporter to Pi reabsorption in young animals. This model is based on the loxP: Cre recombinase
system. Mice harboring both floxed-NaPi-IIc alleles (NaPi-IIcf/f) were bred with Pax8rtTA/LC1 mice in
which the renal- specific expression of Cre-recombinase can be induced by doxycycline (Doxy). Further
mating resulted in homozygous (NaPi-IIcf/f) and heterozygous mutants (NaPi-IIcf/+) as well as wild
type (NaPi-IIc+/+) mice that also expressed Pax8 and Cre. Initially, Cre activity was induced in 3 to 4
weeks old mice by providing them water supplemented with 2 mg/ml Doxy in 2% sucrose for 10 days; as
negative control, littermates drank 2% sucrose. Urinary samples were collected during the last 24 hours
and at the end of the experimental protocol blood, kidney and ileum were extracted. The treatment with
Doxy led to no changes in the expression of NaPi-IIc mRNA and protein in NaPi-IIc+/+ mice. However,
it resulted in a 50% reduction of the cotransporter mRNA and protein in NaPi-IIcf/+ animals and almost
full depletion in NaPi-IIcf/f mice compared to sucrose treated controls. Notably, the urinary excretion
of Pi was increased in both NaPi-IIc+/+ and NaPi-IIcf/f Doxy treated mice, whereas excretions of Na+
and K+ were reduced in all the groups of mice treated with Doxy compared to controls. These findings
suggested that the treatment with 2 mg/ml Doxy produced some non-specific effects, either in the kidney
or secondary to intestinal changes possibly due to effects on the gut flora. Hence, in order to optimize the
dosage of Doxy, NaPi-IIc+/+ and NaPi-IIcf/f mice were treated with 1, 0.5 or 0.25 mg/ml Doxy for 10
days, followed by a recovery period of 15 days during which mice drank normal tap water. The excretion
of Na+ was still reduced in NaPi-IIc+/+ mice that received 1 and 0.5 mg/ml Doxy, but not in mice
subjected to 0.25 mg/ml. In NaPi-IIcf/f mice, the mRNA expression of NaPi-IIc was almost completely
depleted upon 1 and 0.5 mg/ml Doxy induction, but 25% of mRNA still remained at the dosage of 0.25
mg/ml. Therefore, we setup a final Doxy treatment protocol consisting of 5 days administration of 0.5
mg/ml Doxy followed by 5 days with 0.25 mg/ml Doxy and a final recovery period of 15 days during which
mice received normal drinking water. At the end of the protocol, we measured the concentration of Na+
in urine as an indicator for non-specific effects. The excretion of Na+ was comparable in all the groups
of mice treated with either Doxy or sucrose, indicating that the final induction protocol did not produce
non-specific effects. All subsequent experiments were performed with this optimized protocol. The ex-
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pression of NaPi-IIc mRNA and protein was comparable in NaPi-IIc+/+ mice drinking Doxy or sucrose,
whereas the Doxy treatment reduced by 50% and 90% the expression of the cotransporter mRNA and
protein in NaPi-IIcf/+ and NaPi-IIcf/f animals, respectively. The absence of NaPi-IIc in the kidneys of
NaPi-IIcf/f mice did not affect the Na/Pi-cotransport activity in renal brush border membrane vesicles
(BBMVs). Moreover, the expression of other renal Na/Pi-cotransporters, namely NaPi-IIa and Pit-2,
remained unaffected. Similarly, the abundance of NaPi-IIb in intestinal BBM did not changed upon
removal of NaPi-IIc. This suggests the absence of compensatory changes of other Na/Pi-cotransporters
in NaPi-IIc depleted mice. The urinary excretion of Pi and the concentration of Pi in plasma were
normal upon depletion of NaPi-IIc in the kidney. Moreover, the circulating levels of the phosphaturic
hormones PTH and FGF23 remained unchanged. The concentration of Ca 2+ in plasma and urine as
well as circulating levels of 1,25(OH)2D3 also remained unchanged. Furthermore, the mRNA expression
of the 1￿-hydroxylase and 24-hydroxylase were comparable in NaPi-IIc+/+ and NaPi-IIcf/f mice. The
data that we obtained with the renal-specific and inducible NaPi-IIc deficient mice are only partially
in agreement with observations reported in constitutive NaPi-IIc deficient mice. Thus, in constitutive
NaPi-IIc depleted mice the urinary excretion and plasma Pi are normal, similar to our renal-specific
model. However, the constitutive depletion of NaPi-IIc resulted in hypercalcemia and hypercalciuria as
well as in increased 1,25(OH)2D3. Together these findings suggested that depletion of NaPi-IIc in some
extra-renal tissues might explain the changes in Ca2+ homeostasis in the constitutive NaPi-IIc knock-
outs. Moreover, the absence of changes in Pi and Pi-related parameters in both the constitutive and
renal- specific NaPi-IIc deficient models suggests that unlike in humans, NaPi-IIc has a minor role in the
renal reabsorption of Pi in mice. In conclusion, we have generated a renal-specific and inducible NaPi-IIc
deficient mouse model. This study indicated that unlike in humans, the reabsorption of Pi by NaPi-IIc
is minimal in mouse kidney. The inducible system (floxed NaPi-IIc: Cre recombinase) will allow us to
further investigate the role of NaPi-IIc in different organs other than in the kidney.
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1. Zusammenfassung 
Die homöostatische Kontrolle von systemischem Phosphat (Pi) wird weitgehend durch die 
Balance von renaler Reabsorption von Pi aus dem Ultrafiltrat und intestinaler Absorption von 
Pi aus der Nahrung aufrecht erhalten. Die renale Reabsorption von Pi findet hauptsächlich in 
den proximalen Tubuli statt wofür die Na/Pi-Kotransporter Slc34a1/NaPi-IIa, Slc34a3/NaPi-
IIc und Slc20a2/Pit-2 verantwortlich sind. Diese Transportproteine sind in der apikalen 
Membran lokalisiert und werden durch verschiedene Hormone reguliert, wie z.B. durch das 
ParathorŵoŶ ;PTHͿ oder durĐh deŶ ͞fiďroďlast groǁth faĐtor Ϯϯ͞ ;FGFϮϯͿ. AufgruŶd der 
Daten die von NaPi-IIa und NaPi-IIc defizienten Mausmodellen erhalten wurden geht hervor, 
dass NaPi-Ila quantitativ die Hauptrolle bei der renalen Reabsorption von Pi spielt, 
wohingegen NaPi-Ilc eine wohl eher geringere Rolle spielt und eventuell auf junge Tiere 
beschränkt ist. Im Gegensatz zu der Maus,  wurden beim Menschen verschiedene 
Mutationen im NaPi-IIc Gen beschrieben, welche mit dem Krankheitsbild HHRH (hereditary 
hypophosphatemic rickets with hypercalciurie)  assoziert sind.  
 
Das Ziel der vorliegenden Arbeit war es ein Mausmodell zu generieren, in welchem das NaPi-
llc Gen  nierenspezifisch und induzierbar ausgeschaltet werden kann. Dieses Modell basiert 
auf dem loxP:Cre Rekombinase-System. Transgene Mäuse, welche homozygote Träger des 
gefloxten NaPi-Ilc (NaPi-IIcf/f) Gens waren, wurden mit Pax8rtTA/LC1 Tieren verpaart. Damit 
wurden Mäuse erhalten in denen die Expression der Cre-Rekombinase nierenspezifisch 
durch Doxycyclin (Doxy) induziert werden konnte.  
 
Zu Beginn der Experimente wurde die Cre Aktivität in 3 bis 4 Wochen alten Mäusen durch 
die Gabe von 2 mg/ml Doxy im Trinkwasser während 10 Tagen induziert. Als 
Negativkontrollen dienten Wurfgeschwister. Urinproben wurden während den letzten 24 
Stunden des Versuchsprotokolls gesammelt und  am Ende wurden Blut, Nieren und Ileum 
entnommen. Diese Behandlung führte zu einer kompletten Reduktion von NaPi-llc mRNA 
und Protein in den Nieren.  Allerdings war die Ausscheidung von Pi im Urin bei allen Doxy 
behandelten Tieren erhöht, mit gleichzeitiger reduzierter Ausscheidung von  Na+ - und K+ -
Ionen. Dies deutete darauf hin, dass die Behandlung mit 2 mg/ml Doxy entweder zu 
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unspezifischen renalen Effekten führte, oder möglicherweise eine intestinale Veränderung 
bewirkte.  
 
Um die Dosierung von Doxy zu optimieren wurden NaPi-IIc+/+ und NaPi-IIcf/f Mäuse zunächst 
während 10 Tagen entweder mit 1, 0.5 oder 0.25 mg/ml Doxy behandelt, gefolgt von einer 
Erholungsperiode von 15 Tagen mit normalem Trinkwasser. Bei Tieren, die 1 respektive 0.5 
mg/ml Doxy erhielten war die Ausscheidung von Na+ -Ionen im Urin immer noch reduziert, 
aber nicht mehr in Mäusen die mit 0.25 mg/ml behandelt wurden. In NaPi-IIcf/f Mäusen 
wurde die Expression von NaPi-IIc mRNA durch die Gabe von 1 respektive 0.5 mg/ml Doxy 
beinahe komplett unterdrückt, wohingegen 25% der Expression der NaPi-llc mRNA nach 
einer Dosis von 0.25 mg/ml erhalten blieben. Aufgrund dieser Resultate wurde ein neues 
Doxy Dosierungsprotokoll erarbeitet, nach dem die Tiere zunächst für 5 Tage mit 0.5 mg/ml 
Doxy und anschliessend für weitere 5 Tage mit 0.25 mg/ml Doxy behandelt wurden.  Nach 
einer 15-tägigen Erholungsphase wurden die Tiere erneut untersucht. Als Indikator für 
unspezifische Effekte wurde wieder die Konzentration von Na+ -Ionen im Urin gemessen. Die 
Ausscheidung von Na+-Ionen im Urin bei behandelten Tieren war vergleichbar zu den 
Kontrollen, was darauf schliessen liess, dass dieses Induktionsprotokoll keine unspezifischen 
renalen Effekte hervorrufte. Die folgenden Experimente wurden deshalb mit diesem 
optimierten Protokoll durchgeführt. 
 
Die Expression von NaPi-IIc mRNA und NaPi-llc Protein waren vergleichbar in NaPi-IIc+/+ 
Kontrollmäusen die entweder mit Doxy oder nur mit Saccharose im Trinkwasser behandelt 
wurden. Erwartungsgemäss führte die Behandlung mit Doxy zu einer 50%-igen 
beziehungsweise 90%-igen Reduktion der Menge von NaPi-llc mRNA und Protein in NaPi-
IIcf/+ und NaPi-IIcf/f Tieren. Allerdings hatte das Fehlen von NaPi-Ilc in den Nieren der NaPi-
IIcf/f Mäusen keinen Effekt auf die Na/Pi-Kotransport Aktivität in isolierten renalen 
Bürstensaummembranen und es wurden auch keine Aenderungen der Mengen  der anderen 
renalen Na/Pi-Kotransporter, NaPi-Ila und Pit-2 beobachtet. Ebenso blieb die Menge von 
NaPi-Ilb in Enterozyten unverändert. Dies deutete darauf hin dass keine Kompensation durch 
andere Na/Pi-Kotransporter in NaPi-Ilc defizienten Mäusen stattfindet. 
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In Mäusen mit NaPi-IIc defizienten Nieren waren die Ausscheidung von Pi im Urin und die 
Plasmakonzentration von Pi normal. Die Konzentrationen der phosphaturischen Hormone 
PTH und FGF23 waren unverändert. Die Konzentrationen von Ca2+ im Plasma  und Urin sowie 
des zirkulierenden 1,25(OH)2D3  ǁareŶ eďeŶfalls uŶǀeräŶdert. Die EǆpressioŶ der  ϭα-
Hydroxylase und der 24-Hydroxylase mRNA waren vergleichbar in NaPi-IIc+/+ und NaPi-IIcf/f 
Mäusen.  
 
Die Daten, die mit den induzierbaren nierenspezifischen NaPi-IIc defizienten Mäusen 
erhalten wurden, sind nur teilweise übereinstimmend mit den Beobachtungen, die für 
konstitutiv NaPi-IIc defiziente Mäuse beschrieben wurden. Obwohl in konstitutiv NaPi-IIc 
defizienten Mäusen die Pi Ausscheidung im Urin und die Plasmakonzentration von Pi ebenso 
normal blieben, ging die konstitutive Defizienz von NaPi-IIc mit einer Hyperkalzämie und 
Hyperkalziurie, sowie einer erhöhten Konzentration von 1,25(OH)2D3  einher. Dies lässt 
darauf schliessen, dass nach einer konstitutiven Deletion des NaPi-llc Gens, das Fehlen von 
NaPi-IIc in extrarenalen Geweben zu den beobachteten Änderungen des Calcium-Haushaltes 
führt. 
 
Zusammengefasst haben wir ein Maussmodell generiert, bei welchem das Na/Pi-
Kotransporter NaPi-llc Gen SLC34a3 nierenspezifische und  induzierbar inaktiviert werden 
kann. Die Analyse dieses Mausmodells zeigte, dass im Gegensatz zum Menschen, die renale 
Reabsorption von Pi durch NaPi-IIc minimal ist. Das hier beschriebene neue Mausmodell 
(floxed NaPi-IIc) erlaubt es, die noch weitgehend unbekannte Rolle von NaPi-IIc in 
verschiedenen Organen neben der Niere zu untersuchen. 
 
 
 
 
 
 
  Summary 
4 
2. Summary  
Homeostatic control of inorganic phosphate (Pi) is largely achieved by renal reabsorption 
and intestinal absorption of Pi. Renal reabsorption of Pi takes place preferentially in the 
proximal tubules and is mediated by the Na/Pi-cotransporters Slc34a1/NaPi-IIa, 
Slc34a3/NaPi-IIc and Slc20a2/Pit-2. The abundance of these cotransporters is regulated by 
several hormones including parathyroid hormone (PTH) and fibroblast growth factor23 
(FGF23). Based on constitutively deficient NaPi-IIa and NaPi-IIc mouse models, it has been 
postulated that NaPi-IIa plays a major quantitative role in the renal reabsorption of Pi in 
rodents, whereas the contribution of NaPi-IIc is considered to be less important and 
probably restricted to young animals. However, in humans several mutations have been 
identified in the NaPi-IIc gene that cause hereditary hypophosphatemic rickets with 
hypercalciuria (HHRH).  
 
The aim of this study was to generate a renal-specific and inducible mouse model deficient 
of NaPi-IIc to investigate the contribution of this cotransporter to Pi reabsorption in young 
animals. This model is based on the loxP: Cre recombinase system. Mice harboring both 
floxed-NaPi-IIc alleles (NaPi-IIcf/f) were bred with Pax8rtTA/LC1 mice in which the renal-
specific expression of Cre-recombinase can be induced by doxycycline (Doxy). Further 
mating resulted in homozygous (NaPi-IIcf/f) and heterozygous mutants (NaPi-IIcf/+) as well as 
wild type (NaPi-IIc+/+) mice that also expressed Pax8 and Cre.  
 
Initially, Cre activity was induced in 3 to 4 weeks old mice by providing them water 
supplemented with 2 mg/ml Doxy in 2% sucrose for 10 days; as negative control, littermates 
drank 2% sucrose. Urinary samples were collected during the last 24 hours and at the end of 
the experimental protocol blood, kidney and ileum were extracted. The treatment with Doxy 
led to no changes in the expression of NaPi-IIc mRNA and protein in NaPi-IIc+/+ mice. 
However, it resulted in a 50% reduction of the cotransporter mRNA and protein in NaPi-IIcf/+ 
animals and almost full depletion in NaPi-IIcf/f mice compared to sucrose treated controls. 
Notably, the urinary excretion of Pi was increased in both NaPi-IIc+/+ and NaPi-IIcf/f Doxy 
treated mice, whereas excretions of Na+ and K+ were reduced in all the groups of mice 
treated with Doxy compared to controls. These findings suggested that the treatment with 2 
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mg/ml Doxy produced some non-specific effects, either in the kidney or secondary to 
intestinal changes possibly due to effects on the gut flora.  
 
Hence, in order to optimize the dosage of Doxy, NaPi-IIc+/+ and NaPi-IIcf/f mice were treated 
with 1, 0.5 or 0.25 mg/ml Doxy for 10 days, followed by a recovery period of 15 days during 
which mice drank normal tap water. The excretion of Na+ was still reduced in NaPi-IIc+/+ mice 
that received 1 and 0.5 mg/ml Doxy, but not in mice subjected to 0.25 mg/ml. In NaPi-IIcf/f 
mice, the mRNA expression of NaPi-IIc was almost completely depleted upon 1 and 0.5 
mg/ml Doxy induction, but 25% of mRNA still remained at the dosage of 0.25 mg/ml. 
Therefore, we setup a final Doxy treatment protocol consisting of 5 days administration of 
0.5 mg/ml Doxy followed by 5 days with 0.25 mg/ml Doxy and a final recovery period of 15 
days during which mice received normal drinking water. At the end of the protocol, we 
measured the concentration of Na+ in urine as an indicator for non-specific effects. The 
excretion of Na+ was comparable in all the groups of mice treated with either Doxy or 
sucrose, indicating that the final induction protocol did not produce non-specific effects. All 
subsequent experiments were performed with this optimized protocol. 
 
The expression of NaPi-IIc mRNA and protein was comparable in NaPi-IIc+/+ mice drinking 
Doxy or sucrose, whereas the Doxy treatment reduced by 50% and 90% the expression of 
the cotransporter mRNA and protein in NaPi-IIcf/+ and NaPi-IIcf/f animals, respectively. The 
absence of NaPi-IIc in the kidneys of NaPi-IIcf/f mice did not affect the Na/Pi-cotransport 
activity in renal brush border membrane vesicles (BBMVs). Moreover, the expression of 
other renal Na/Pi-cotransporters, namely NaPi-IIa and Pit-2, remained unaffected. Similarly, 
the abundance of NaPi-IIb in intestinal BBM did not changed upon removal of NaPi-IIc. This 
suggests the absence of compensatory changes of other Na/Pi-cotransporters in NaPi-IIc 
depleted mice.  
 
The urinary excretion of Pi and the concentration of Pi in plasma were normal upon 
depletion of NaPi-IIc in the kidney. Moreover, the circulating levels of the phosphaturic 
hormones PTH and FGF23 remained unchanged. The concentration of Ca2+ in plasma and 
urine as well as circulating levels of 1,25(OH)2D3 also remained unchanged. Furthermore, the 
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mRNA expression of the 1α-hydroxylase and 24-hydroxylase were comparable in NaPi-IIc+/+ 
and NaPi-IIcf/f mice.  
 
The data that we obtained with the renal-specific and inducible NaPi-IIc deficient mice are 
only partially in agreement with observations reported in constitutive NaPi-IIc deficient 
mice. Thus, in constitutive NaPi-IIc depleted mice the urinary excretion and plasma Pi are 
normal, similar to our renal-specific model. However, the constitutive depletion of NaPi-IIc 
resulted in hypercalcemia and hypercalciuria as well as in increased 1,25(OH)2D3. Together 
these findings suggested that depletion of NaPi-IIc in some extra-renal tissues might explain 
the changes in Ca2+ homeostasis in the constitutive NaPi-IIc knockouts. Moreover, the 
absence of changes in Pi and Pi-related parameters in both the constitutive and renal-
specific NaPi-IIc deficient models suggests that unlike in humans, NaPi-IIc has a minor role in 
the renal reabsorption of Pi in mice.  
 
In conclusion, we have generated a renal-specific and inducible NaPi-IIc deficient mouse 
model. This study indicated that unlike in humans, the reabsorption of Pi by NaPi-IIc is 
minimal in mouse kidney. The inducible system (floxed NaPi-IIc: Cre recombinase) will allow 
us to further investigate the role of NaPi-IIc in different organs other than in the kidney.  
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3. Introduction 
3.1 Phosphate (Pi) homeostasis and its importance 
Phosphate (H2PO4
-, HPO42- ; abbreviated as Pi)   is an inorganic anion present in all the body 
fluids and is present in organic and inorganic forms. Pi is essential for all living organisms and 
plays a pivotal role in most biological processes, including cellular energy metabolism, 
nucleic acid synthesis, cellular signaling, cell membrane integrity, enzymatic activities, 
mineralization of bone, and lipid metabolism. Therefore, it is important to maintain the 
extracellular concentration of Pi in balance within a narrow range. In humans, the plasma Pi 
concentration ranges between 0.8 to 1.5 mM and in rodents between 2 to 4 mM. In both 
species these values varies with age. At the physiological pH of 7.4, the monovalent (H2PO4
-) 
and divalent (HPO42-) phosphate are present in a ratio of 1:4. Pi makes up approximately 1% 
of total bodyweight. The skeleton is the major storage organ of Pi in the body and contains 
approximately 10g of Pi per 100 g dry fat-free tissue, whereas muscle contains 0.2 g and the 
brain 0.33 g of Pi per 100 g dry fat free tissues, and approximately 1% is present in the 
extracellular fluid (Figure 1). In the skeleton Pi complexes with calcium in the form of 
hydroxyapatite crystals, which are the main inorganic constituent of the mineralized bone 
matrix. In mammals, Pi is obtained from dietary sources and is absorbed in the intestine in 
the form of H2PO4
- or HPO4
2- Pi ions.  
 
The maintenance of the extracellular concentration of Pi depends on intestinal absorption, 
on the exchange between intracellular and extracellular pools from bone and skeletal 
muscles and on the reabsorption and excretion by the kidneys. Under normal physiological 
conditions, small intestinal absorption of Pi approximately equals the sum of fecal and renal 
excretion per day (Figure 1). Renal excretion does not always remain constant because of 
the daily changes of hormones and metabolic factors that regulate the Pi homeostasis.  
 
Given the extensive distribution of Pi in the body, decreased levels of Pi in the serum may 
lead to clinical symptoms such as weakening of muscle, rhabdomyolysis, functional 
alterations of leukocytes and defects in bone mineralization leading to rickets or 
osteomalacia. On the other hand, elevated serum Pi levels as observed in patients with 
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chronic renal failure contribute to the pathogenesis of secondary hyperparathyroidism and 
may lead to vascular calcification [1].  
             
Figure 1 Phosphate homeostasis under normal physiological condition. The maintenance of constant serum phosphate 
levels by the intestinal absorption of phosphate from daily diet and renal excretion. The movement of phosphate into bone 
also helps to maintain serum phosphate levels [2]. (Image taken from: Keith A. Hruska et al., 2008, Kidney International).  
 
3.2 Epithelial transport of phosphate 
In the small intestine and in renal proximal tubules absorption or reabsorption of Pi 
represents a transepithelial transport process, which in principle, can occur transcellularly or 
paracellularly. Transcellular uptake of Pi is mediated by secondary active Na-dependent Pi-
cotransporters which depend on the Na+-gradient maintained by the Na+/K+ ATPase pump 
which is localized at the basolateral membrane [3]. In both intestine and kidney, 
transcellular transport of Pi is mediated by members of the SLC34 and SLC20 families of 
solute carriers. The SLC34 family includes NaPi-IIa (Slc34a1), NaPi-IIb (Slc34a2) and NaPi-IIc 
(Slc34a3) and the SLC20 family includes Pit-1 (Slc20a1) and Pit-2 (Slc20a2).  All these Na/Pi-
cotransporters are specifically localized at the apical (brush border) membrane (BBM) with 
an exception that NaPi-IIb expression was also observed in basolateral membrane of 
proximal tubules [4]. In intestinal epithelial cells, transport of Pi is mediated by NaPi-IIb, Pit-1 
and Pit-2 whereas in the kidney, transport is mediated by NaPi-IIa, NaPi-IIc and Pit-2 (Figure 
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2A and 2B) [5-8]. However, in both epithelia the identity of the basolateral transporter that 
transfers Pi in-to the interstitium is not known yet.   
 
In small intestine, the possibility of Pi absorption via a paracellular route has also been 
observed [9-11]. The paracellular barrier is formed by the interaction between 
complementary adhesive proteins of adjacent cells which form the tight junctions. These 
tight junction proteins include claudins and occludins which allow the permeation of 
selected ions across the epithelium.  Until now, many claudins have been identified and 
were shown to determine the paracellular permeability of ions [12-16]. However, transport 
of Pi through the tight junction barrier has not been yet characterized. Sabbagh et al. has 
shown in NaPi-IIb deficient mice fed with low Pi diet followed by a phosphorus bolus that 
serum Pi levels increased less than in wild type [17]. This suggests that, transport of Pi 
absorption via the paracellular route might have a higher contribution.  
 
       
 
 
Figure 2 Transport of Pi across the epithelial cells of the intestine and kidney. A) In intestine, transport of Pi is mediated by 
the Na/Pi- cotransporters NaPi-IIb, Pit-1 and Pit-2. B) In renal proximal tubules, transport of Pi is mediated by NaPi-IIa, NaPi-
IIc and Pit-2. All the Na/Pi- cotransporters are expressed at the apical (brush border) membrane of the epithelial cells. The 
identity of the protein responsible for the transport of Pi through the basolateral membrane is still unknown.  
 
3.3 SLC34 Na/Pi-cotransporters 
The SLC34 solute carrier family consists of three isoforms: NaPi-IIa (SLC34A1), NaPi-IIb 
(SLC34A2) and NaPi-IIc (SLC34A3) [18]. These three isoforms represent the main secondary 
active transport proteins for Pi (re)absorption in mammalian intestine and kidney. Although  
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predominantly expressed in epithelial cells of small intestine and proximal tubules these 
Na/Pi-cotransporters are also expressed in different organs such as the lung, liver, bone, 
salivary and mammary glands and testis.  
 
SLC34 isoforms are an unique class of membrane proteins that do not share any structural 
homology with other transporter proteins. Based on the biochemical approach of cysteine 
scanning mutagenesis and electrophysiological methods, SLC34 proteins have been 
proposed to be functional monomers [19]. Later, using a modified split-ubiquitin membrane 
yeast two-hybrid system (MYTH), it was also observed that SLC34 proteins may dimerize via 
protein-protein interactions with the help of PDZ-binding motifs [20]. Recently Fenollar 
Ferrer et al. [21] suggested based on homology modelling that the SLC34 isoform NaPi-IIa 
structure may consist of two inverted repeat units (RU1, RU2) plus a C-terminal region with 
the extension of two transmembrane helices (Figure 3). These two units containing 
conserved inverted repeat motifs separated by a large extracellular loop consist of two N-
linked glycosylation sites and a disulfide bond. RU1 and RU2 are composed of residues 86-
256 and 335-489. Both C-terminal and N-terminal regions are also important components of 
the protein and are localized in the cytoplasm. There are several residues predicted as 
coordination sites for Na+ and Pi interaction for each transport cycle. These residues when 
mutated (S164, T195, S196 in RU1 and Q417, S418, S419 in RUC2), alter phosphate transport 
characteristics [18, 21].  
 
Based on the information obtained with the SLC34A1 and SLC34A3 proteins, the C-terminal 
end is involved in protein-protein interactions that take part in the translocation, trafficking 
and regulation of the transporters by different physiological factors.  
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Figure 3 Topology model of SLC34 isoform NaPi-IIa. The model consists of two structural repeat units (RU1 and RU2) are 
indicated green and red containing transmembrane helices (numbered). The conserved repeat motifs separated by large 
extracellular loop. (Image taken from: Fenollar-Ferrer et al, 2014) 
 
The kinetic properties of all three isoforms have been studied after expression in oocytes of 
Xenopus. laevis by electrophysiology and tracer flux studies using radioactive Pi (summarized 
in Table 1). All SLC34 family members preferentially transport divalent Pi (HPO42-) and 
require Na+ ions as driving cosubstrate to import Pi into cells [22]. Recently it was shown that 
Li+ -ions are partially able to substitute for at least one of the Na+ -ion during the transport 
cycle (Table 1)[23]. The transport capacity of SLC34 transporters depends on the 
extracellular pH, which determines the distribution of extracellular monovalent/divalent Pi. 
Moreover, the kinetic properties of these transporters are influenced by protons due to 
competition with Na+ binding [24]. The rate of Pi influx is higher at pH 7.4 for all three 
isoforms, and all isoform that have similar Km- values for Pi (0.1 mM) and for Na+ 
(approximately 40 mM) [25] with the exception of mammalian NaPi-IIb has different 
apparent Pi affinity (10 µM) [26, 27].  
 
SLC34 isoforms can be distinguished based on their functional properties. NaPi-IIa and NaPi-
IIb transport one net-positive charge into the cell per transport cycle, therefore these two 
proteins are electrogenic whereas no net-charge is transported by NaPi-IIc, an electroneutral 
transporter (Table 1). The electrogenic isoforms are sensitive to the membrane potential and 
transport rate is a function of membrane potential. In contrast, electroneutal NaPi-IIc is 
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insensitive to the membrane potential. The transport capacity of electrogenic isoforms for Pi 
is approximately 100- folds higher compared to NaPi-IIc [22, 28, 29]. Voltage clamp 
flurometric studies on NaPi-IIa and NaPi-IIb indicated that 2 Na+ ions bind sequentially 
followed by binding of Pi and the third Na+ before the rate-limiting reorientation of the fully 
loaded carrier occurs [30]. For NaPi-IIc, to complete transport cycle 3 Na+ bind but only 2 Na+ 
are translocated into the cytosol [31]. The order of substrate release to the cytosol has not 
been demonstrated yet. 
 
There are several reports indicating that SLC34 Na/Pi-cotransporters can be inhibited by 
specific inhibitors which are able to block the transport process. Arsenate is a structural 
analogue to Pi and competitively inhibits the NaPi-IIb mediated transport in the small 
intestine whereas it shows low affinity towards NaPi-IIa and NaPi-IIc in the kidney [27]. 
Phosphonoformic acid (PFA) is another competitive inhibitor of all SLC34 isoforms and blocks 
the Na/Pi-cotransport in the small intestine and kidney [25, 32]. In contrast, PFA has very 
low affinity for the SLC20 transporters [33, 34].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 Kinetic properties of SLC34 and SLC20 proteins expressed in Xenopus laevis oocytes [18] (Adapted from: Forster IC 
et al, 2012) 
 
 
Family 
 
                              SLC34        SLC20 
Isoform NaPi-IIa 
(Slc34a1) 
NaPi-IIb 
(Slc34a2) 
NaPi-IIc 
(Slc34a3) 
Pit-1/Pit-2 
(Slc20a1/2) 
Pi species preference HPO4
2-
 HPO4
2-
 HPO4
2-
 H2PO4
-
 
Driving substrate Na
+
 (Li
+
) Na
+
 (Li
+
) Na
+
  Na
+
,  Li
+
 
Electrogenicity (charge/cycle) 1 1 0 1 
Stoichiometry (Na:Pi) 3:1 3:1 2:1 2:1 
Presteady-state  currents Yes Yes  No  n.d 
K0.5
Pi
 (µM) 50, 54 250, 7, 29, 31 70, 80 120, 24, 25 
K0.5
Na
 (mM) 40, 50 25, 42, 46, 67 48, 43 50 
pH dependence (pH   ) Strong Strong, weak Strong  Weak 
Arsenate (Ki
As
) (mM) 1.08 0.05 1.01 3.61 (3.95) 
PFA (Ki
PFA
) (mM) 1.05 0.16 0.9 2.71 (4.63) 
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3.3.1 Sodium dependent phosphate cotransporter-IIa (NaPi-IIa) 
NaPi-IIa is encoded by the gene SLC34A1 and it was the first SLC34 Na/Pi cotransporter 
identified in mammalian kidney [5]. NaPi-IIa translocate one net positive charge into the cell 
per cotransport cycle. NaPi-IIa preferentially transports HPO4
2- and mediates transport with 
a stoichiometry of 3 Na+ -ions to 1 HPO4
2- (Table 1).Therefore, NaPi-IIa is electrogenic (Table 
1). The apparent substrate affinity (Km) of human and rat NaPi-IIa are approximately 100 µM 
and 40 mM for divalent Pi and Na+ ions, respectively [35, 36].   
 
Many studies have been performed to unravel a structural model of mammalian NaPi-IIa 
Na/Pi-cotransporter. NaPi-IIa protein consists of 640 amino acids [37-41]. The disulfide bond 
between extracellular glycosylation sites is not required for NaPi-IIa transport function [37, 
38]. The C-terminal tail contains a conserved PDZ (post-synaptic density protein PSD95, 
Drosophila disc large tumor suppressor DIgA, and zonula occludens-1 protein ZO-1) binding 
motif represented by the last three residues (TRL) (Figure 3). The TRL motif acts as PDZ 
binding motif and is important for protein-protein interactions, that have been suggested to 
play a role in the apical sorting and/or regulation [42]. Gisler et al. [43] screened cDNA 
libraries from adult mouse kidney using the Yeast two-hybrid (Y2H) method and identified 
several proteins that interact with the PDZ binding motif (TRL) of the cotransporter. These 
interacting proteins include the Na+/H+ exchanger regulatory factors 1, 2 (NHERF1 and 
NHERF2), PDZK1/NaPi-Cap1 (NHERF3) and PDZK2/NaPi-Cap2 (NHERF4) as well as Shank2E 
[43, 44]. All these proteins colocalize with NaPi-IIa in the BBM of proximal tubular cells [43].  
 
NHERF-1/2 consist of two PDZ domains [44] and their carboxyl regions contain a Moesin-
Ezrin-Radixin-Merlin (MERM) binding domain, which connects them to cytoskeleton proteins 
[45]. NHERF-3/4 consist of four PDZ domains and interact with cytoskeleton proteins via 
association with NHERF-1. The first PDZ domain of NHERF-1/2 is involved in interaction with 
NaPi-IIa whereas interaction of NHERF-3/4  with NaPi-lla depends on the third PDZ domain 
[46].  
 
The interaction of all these proteins with NaPi-IIa depends on the presence of the TRL motif. 
After transfection of a TRL-truncated NaPi-IIa in OK cells, expression of NaPi-IIa was partly 
blunted and accumulation of the protein in the cytoplasm was observed [47, 48]. In mice, 
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depletion of NHERF-1 results in a reduced abundance of NaPi-IIa at the BBM which is 
associated with hypophosphatemia and hyperphosphaturia [49]. Together, these studies 
suggest that the interaction of NHERF-1 with the C-terminal region of NaPi-IIa might be 
critical for NaPi-IIa targeting to the membrane. Interestingly, BBM expression of NaPi-IIa and 
urinary excretion of Pi was not altered in PDZK-1 deficient mice [50]. 
 
Shank2E also belongs to the PDZ protein family and has been shown to interact with NaPi-IIa 
via its single PDZ domain [51]. In rats, expression of Shank2E was detected in proximal 
tubular BBM and in isolated membrane fractions. In addition, Shank2E colocalized with GFP-
tagged NaPi-IIa in OK cells and specifically binds to the TRL region of NaPi-IIa[51]. 
 
In addition to these PDZ-proteins, Reining et al. [52] demonstrated a role of the GABA(A) 
receptor-associated protein (GABARAP) in determining the apical abundance of NaPi-IIa. In a 
GABARAP deficient mouse model, the BBM expression of NaPi-IIa is increased, which leads 
to increased renal Pi uptake and reduced Pi excretion. In addition, expression of NHERF-1 
was also upregulated in these mice.  However, the molecular mechanism of how GABARAP 
affects NaPi-IIa expression is unknown.   
 
3.3.1.1 Expression of NaPi-IIa and its contribution to renal Pi handling 
Based on early micro-puncture studies in rats, it was proposed that the reabsorption of Pi 
takes place in superficial and juxtamedullary nephrons [53, 54]. Later on, the expression of 
NaPi-IIa mRNA was detected in isolated proximal tubules and the protein was observed in 
proximal tubular BBM by immunofluorescence [55]. The highest mRNA expression was 
found in proximal convoluted tubular segments, less in the straight proximal tubules [55]. 
Abundant NaPi-IIa mRNA and protein expression has been detected mostly in juxtamedullary 
nephrons [55, 56]. This suggested an important role of NaPi-IIa in the reabsorption of Pi in 
the proximal tubule. To study the ontogeny of NaPi-IIa expression, Taufiq et al. [57] 
investigated the expression of the cotransporter in rats of various ages. Interestingly, they 
observed highest protein expression in weaning rats as compared with adult rats without 
changes in mRNA levels. The uptake of Pi was also observed in BBM which was parallel to 
the expression of NaPi-IIa in these animals [57]. In contrast, the abundance of NaPi-IIa was 
decreased in BBM of weaned rats [58]. In addition, the expression of NaPi-IIa was lower in 
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the BBM of superficial nephrons whereas expression was higher in the juxtamedullary 
nephrons [58]. This internephron (superficial and juxtamedullary nephrons) heterogenic 
expression of NaPi-IIa after weaning might be related to the requirement for dietary Pi in an 
age dependent manner [58].  
 
Most notably, the homozygous gene deletion of Slc34a1 in mice (NaPi-IIa-/-) leads to severe 
phenotypic changes such as phosphaturia with hypophosphatemia [59]. In addition, NaPi-IIa-
/- mice exhibited hypercalcemia, hypercalciuria and reduced serum FGF23 and PTH with 
elevated active 1,25 dihydorxy vitamin D (1,25(OH)2D3). The impaired Ca
2+ metabolism might 
be an effect of increased serum 1,25(OH)2D3 which is known to increase the abundance of 
TRPV6 a channel involved in the absorption of Ca2+ in the small intestine [60]. Transport 
studies in NaPi-IIa-/- mice indicated that the Pi uptake was reduced by 70% in isolated renal 
BBMVs compared to BBMVs isolated from wild type mice [59]. This data suggested that 
NaPi-IIa critically contributes to the reabsorption of Pi in mouse kidney. Hypercalciuria is one 
of the known risk factors for inducing nephrocalcinosis. Therefore, kidneys of adult NaPi-IIa-/- 
mice were examined for calcification, von Kossa staining indicated mineral (Ca2+ and Pi) 
deposits in kidney sections from NaPi-IIa-/- and calcification was further detected  by 
microcomputed tomography of intact kidneys [61].  
 
Heterozygous mutations in the SLC34A1 gene were reported in three patients with 
hypercalciuria, hypophosphatemia and nephrolithiasis [62]. In one patient, the mutation 
results in a residue substitutions at position 48 (A48F) and in the two other patients, 
substitution at position 147 (V147M) is evident. These mutations are located in the N-
terminal tail and second TMD of NaPi-IIa, respectively. As all three patients were 
heterozygous the authors proposed that mutations might have dominant negative effects 
that lead to reduced transport activity of NaPi-IIa. However, these findings could not be 
reproduced independently using the X. laevis oocyte expression system [63]. Recently, a 
homozygous in-frame duplication of 21 bp in NaPi-IIa from two related patients was 
identified and this mutation leads to severe Pi wasting with rickets and renal Fanconi`s 
syndrome [64]. Together, these data indicate that NaPi-IIa might have a dominant role in 
renal Pi handling in both humans and rodents.  
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3.3.2 Sodium dependent phosphate cotransporter-IIc (NaPi-IIc) 
NaPi-IIc is encoded by the SLC34A3 gene and has been identified as a growth related protein 
that consists of 599 amino acids. NaPi-IIc was cloned from human and rat cDNA using 
expressed sequence tags (EST) [7]. To analyze the transport properties of NaPi-IIc, Segawa et 
al [7] expressed NaPi-IIc in Xenopus laevis oocytes and proposed that NaPi-IIc transports two 
Na+ ions along with one HPO4
2- ion (2:1). Therefore, transport mediated by NaPi-IIc is 
electroneutral [7, 22]. The sequence of substrate binding and translocation into the cell for 
NaPi-IIc is different from other two SLC34 proteins. Kinetic studies of NaPi-IIc using the 
oocyte expression system suggested that 3 Na+ ions bind to the carrier protein but only 2 
Na+ ions are released inside the cytoplasmic space [31].  
 
Sequence comparison indicated that there is a high degree of sequence identity, especially 
high in the TMDs, between NaPi-IIa and NaPi-IIc [7]. This suggests that there may be minor 
differences in the amino acid sequence which profoundly affect the electrophysiological 
properties of NaPi-IIa and NaPi-IIc. To identify which residues are responsible for the 
electroneutrality NaPi-IIa/NaPi-IIc chimeras were constructed, followed by single and triple 
mutants and their transport features were analyzed in oocytes. These studies allowed the 
identification of 3 residues within the third TMD that are critical for electrogenicity: Gly195, 
A 218 and A 224 of NaPi-IIc are replaced by Asp 224, Ala 218 and Ala 224 in the equivalent 
position of NaPi-IIa [22].  
 
In contrast to NaPi-IIa, TRL motifs are absent in C-terminal region of NaPi-IIc. Recently Ito et 
al. [65] identified an internal WLHSL motif within the C-terminal tail of mouse NaPi-IIc. The 
deletion of this WLHSL motif leads to failure of apical sorting when constructed chimeras 
were expressed in OK and MDCK cells [65]. Several proteins interact with NaPi-IIc and are 
involved in stabilization and cargo sorting to the plasma membrane. Based on the two-
hybrid system, NHERF-1 and 3 were found to interact with NaPi-IIc. Interaction with NHERF-1 
depends on an internal PDZ binding motif and the first PDZ domain of NHERF-1. The 
association with NHERF-3 requires the last 3 residues of NaPi-IIc (QQL) and the second PDZ 
domain of NHERF-3.  The interactions with these two proteins were confirmed in OK cells 
and rat kidney cortex by coimmunoprecipitation [66]. In renal BBMVs of rats fed with low Pi 
diet, the yield of coprecipitation of NaPi-IIc-NHERF3 complexes was increased whereas the 
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amount of NaPi-IIc-NHERF1 complexes was unchanged [66]. This different pattern of 
coprecipitation indicates that the interactions of NaPi-IIc with these two partners may be 
different. Thus, NHERF1 interaction may be required for basal level of NaPi-IIc expression at 
the apical membrane whereas NHERF3 may be required for the response to low Pi diet [66]. 
In addition, the cellular localization and transport activity of truncated NaPi-IIc lacking the 
last three amino acids (QQL) at the C-terminal tail are similar to the full length protein [66]. 
This suggests that these three amino acids may not be required for membrane expression in 
contrast to NaPi-IIa.  
 
3.3.2.1 Expression of NaPi-IIc and its contribution to renal Pi handling 
The abundance of NaPi-IIc in proximal tubules is predominant in weaning rodents and 
diminishes with age [7]. It was also found that age regulates the expression of NaPi-IIc mRNA 
and that Pi uptake was higher in oocytes injected with mRNA isolated from kidneys of young 
rats compared to adult animals [7]. In addition, Na/Pi-cotransport induced in oocytes 
expressing mRNA from young rats is still observed even after depletion of NaPi-IIa transcript. 
In oocytes expressing mRNA from adult animals, depletion of NaPi-IIa mRNA fully abolished 
the Pi uptake whereas depletion of NaPi-IIc had no effect [67]. These results demonstrate 
the importance of NaPi-IIc in young animals. In terms of protein levels, abundant expression 
of NaPi-IIc was found in renal BBM of the S1 segment of proximal convoluted tubules (PCT) 
of weaning rats. In contrast, the abundance was massively reduced in adult rats [7]. Recently 
it has also been shown that NaPi-IIc is expressed exclusively in the S1/S2 segments of the 
proximal convoluted tubule (PCT) in mouse kidney [68].  
 
Unlike NaPi-IIa, the constitutive depletion of NaPi-IIc in mice does not affect the circulating 
levels and renal excretion of Pi. The uptake of Pi into renal BBMVs of NaPi-IIc-/- mice is similar 
to renal BBMVs isolated from wild type mice even though the expression of NaPi-IIa remains 
unchanged [69]. This data demonstrated that, in mice, NaPi-IIc plays a minor role in Pi 
reabsorption in the kidney after weaning. As in NaPi-IIa-/- mice, 1,25(OH)2D3 is higher in 
serum of constitutive NaPi-IIc-/- mice, which leads to increased serum and urinary excretion 
of Ca2+. In addition, serum FGF23 levels were significantly lower in NaPi-IIc-/- mice. Based on 
these data it has been suggested that NaPi-IIc may be involved in Ca2+ metabolism and 
regulation of the 1,25(OH)2D3 - FGF23 axis [69]. However, the mechanisms that lead to these 
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changes are unknown. Recently, it has been shown that NaPi-IIc mRNA is expressed in 
several tissues other than kidney. Although the highest expression was found in the kidney, 
lower levels were also found in ovary, testis and spinal cord [70]. However, the expression of 
NaPi-IIc at the protein level in extra renal tissues has not been analyzed.  
 
Recently a NaPi-IIa/NaPi-IIc double knockout (DKO) mouse model has been characterized 
and showed greater changes in the phenotype than the single deficient mice [71]. The 
excretion of Pi is increased in DKO mice compared to NaPi-IIa deficient mice and DKO mice 
suffered from severe hypercalcemia and hypercalciuria, at levels higher than those of single 
deficient mice [71]. The changes in Pi and Ca2+ balance associated with rickets in DKO mice. 
These severe biochemical changes in DKO mice are similar to the phenotype observed in 
patients with HHRH. Considering these data, it cannot be ruled out that NaPi-IIc plays a 
minor contribution to renal reabsorption of Pi in mice.  
  
Several studies have revealed that diverse mutations in the human NaPi-IIc gene (SLC34A3) 
(Figure 4) lead to hereditary hypophosphatemic rickets with hypercalciuria (HHRH). Patients 
with HHRH have higher renal Pi excretion, hypercalciuria and increased plasma 1,25(OH)2D3, 
which leads to defects in bone mineralization [72]. Expression of mutated human NaPi-IIc in 
X. laevis oocytes results in reduced Na/Pi-cotransport activity. These data indicated that, 
unlike in rodents, NaPi-IIc plays a very important role in renal Pi reabsorption in humans. 
  
Figure 4 The predicted structural model of human NaPi-IIc showing different mutations identified in patients with 
hereditary hypophosphatemic rickets with hypercalciuria (HHRH) [73].  Image taken from: Segawa H et al., 2009. 
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3.3.3 Sodium dependent phosphate cotransporter-IIb (NaPi-IIb) 
NaPi-IIb is encoded by SLC34A2 and was cloned in 1998 on the basis of a homologous 
sequence of EST clones isolated from a mouse embryo [6]. The transport characteristics of 
NaPi-llb have been analyzed in voltage clamp studies after expression of NaPi-IIb cRNA 
inXenopus laevis oocytes. The mouse and rat NaPi-IIb exhibits substrate affinities of 
approximately 10 µM and 40 mM for divalent Pi and Na+ at pH 7.4. Changes in pH do not 
alter the Na/Pi-cotransporter activity. NaPi-IIb is an electrogenic transporter and mediates 
the transport of 3 Na+ together with 1 HPO42- [6].  
 
3.3.3.1 Expression of NaPi-IIb in different tissues and its importance in Pi 
handling 
The expression of NaPi-IIb at the protein level was first found in the apical BBM of the small 
intestine [6]. However, NaPi-IIb shows a wider range of tissue distribution and 
immunohistological studies have shown its expression in lungs, hepatocytes, salivary glands, 
epididymis, mammary glands, testis and recently also in kidney [74-76]. In lungs, NaPi-IIb is 
expressed in the apical membrane of type-II alveolar cells and may be involved in the 
synthesis of surfactants. In the liver, it has been proposed that NaPi-IIb mediates the uptake 
of Pi from the primary bile. In salivary glands, the expression of NaPi-IIb was found in the 
apical side of the duct cells whereas expression was observed predominantly at the 
basolateral membrane of acinar cells [75]. In c-ros KO mice, expression of NaPi-IIb in the 
epididymis is required for sperm production and involved in male fertility [76]. Recently, 
NaPi-IIb was localized in the basolateral side of renal proximal tubules in rats fed with high Pi 
diet [4]. In addition, NaPi-IIb mRNA has also been identified in lymphoid tissue, placenta, 
uterus, prostate, pancreas, thyroid and colon [6, 74, 75].  
 
The expression of NaPi-IIb is essential during embryonic development. In mice, constitutive 
depletion of NaPi-IIb results in embryonic lethality likely due to a defect of the transport of 
Pi from the maternal circulation to the fetus [77]. Sabbagh et al. [17] generated a conditional 
NaPi-IIb deficient mice. The depletion of NaPi-IIb (NaPi-IIb-/-) in adult mice leads to increased 
fecal excretion of Pi with hypophosphaturia, but serum Pi levels remain unchanged.  The 
hypophosphaturia was explained by an increased expression of  NaPi-IIa associated with 
decreased FGF23 in NaPi-IIb-/- mice [17]. In addition, the uptake of Pi was reduced by 90% in 
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BBMVs isolated from the ileum of NaPi-IIb-/- mice. Furthermore, low Pi diet followed by Pi 
bolus results in approximately 50% reduced overall Pi absorption in NaPi-IIb-/- mice 
compared to wild type mice [17]. These findings suggest that NaPi-IIb plays a major role in 
the absorption of Pi in the small intestine. However, the relative contribution of transcellular 
versus paracellular mechanisms for overall intestinal Pi absorption remains unknown.  
 
As mentioned above, NaPi-llb is also present in alveolar type ll cells and testis and mutations 
in NaPi-IIb lead to pulmonary alveolar and testicular microlithiasis in humans [78]. This 
suggests an important role of NaPi-IIb in the regulation of Pi balance in lungs and testis. 
However the role of NaPi-llb in these two organs remains to be clarified.  
 
3.4 SLC20 Na
+
 coupled phosphate cotransporters 
The solute carrier family SLC20 consists of two members Pit-1 (SLC20A1) and Pit-2 
(SLC20A2). Originally, both Pit-1 and Pit-2 were identified as retroviral receptors for Gibbon 
ape leukemia virus (Glvr-1; Pit-1) and for rat amphotropic virus (Ram-1; Pit-1) [79, 80] but 
later on Na-dependent Pi transport of these proteins was demonstrated. 
 
The transport kinetics suggest that SLC20 proteins preferentially transport monovalent Pi 
(H2PO4
-) together with two Na+ with a Na+:Pi stoichiometry of 2:1 (Table 1) [34]. This 
transport kinetics is the most important feature which distinguishes the SCL20 transporters 
from the SLC34 members. The typical substrate binding affinity of SLC20 proteins for Pi is 
≥ϭϬϬ µM aŶd for Na+ approximately 50 mM. It was shown for Pit-1 that, lithium (Li+) ions can 
replace Na+ ions as a driving substrate although the transport rate was reduced (Table 1) 
[34].  Unlike SLC34 proteins that are pH sensitive, the rate of maximum transport for Pit-1 
remains constant over changes of 3 pH units between 5 to 7.4. In addition, studies on Pit-2 
expressed in X. laevis oocytes demonstrated that decreasing the pH from 7.5 to 6 leads to an 
increase in the Pi transport influx suggesting that protons might be replacing Na+ ions or that 
the availability of monovalent Pi increases [33, 81].  
 
The current structural topology of SLC20 proteins is based on bioinformatic tools and 
biochemical (epitope tagging, cysteine scanning) and in vitro glycosylation methods. The 
predicted topology suggests that SLC20 isoforms consist of 12 transmembrane helices with 
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extracellular amino (-NH2) and carboxy (-COOH) termini (Figure 5). Structural topology shows 
one extracellular glycosylated loop and a large intracellular linker region present between 
transmembrane segments 7 and 8 (Figure 5).  
 
                     
Figure 5 Topology and structure-function features of SLC20 proteins. This topology model for mammalian SLC20 proteins is 
based on the human PiT-2 sequence. The 12 predicted TMDs were assigned according to Salaun et al., 2001. The model was 
drawn using TOPO2 software. Residues important for SLC20 function that have been identified by mutagenesis (Bottger & 
Pedersen, 2004; Salaun, et al., 2004; Bottger & Pedersen, 2005) are shown enlarged. Blue: PD1131 homology domains 
(amino acid blocks that are conserved among all the family members has been identifies) (Salaun et al., 2001). Two regions 
involving the large intracellular loop have been deleted: the ΔL183-V483 deletion causes loss of transport function with 
partially compromised viral receptor function (green) and the ΔR254-V483 leaves transport function intact but 
compromises viral receptor function 46 (orange) (Bottger & Pedersen 2011). Acidic residues important for transport 
function (D28, E55, D506, E575) (red) and those not critical for transport function (E68, D78, E91) (pink) are indicated. The 
protein is N-glycosylated at Asp-81. A region in the 1st extracellular loop of PiT-1, also conserved in PiT-2 was subjected to 
SCAM, and sites accessible from the external medium have been identified [18]. (Image taken from: Forster IC et al., 2012). 
 
3.4.1 Expression and role of Pit-1 and Pit-2 in Pi handling 
Expression of SLC20 Na/Pi-cotransporters has been found ubiquitously in all tested 
mammalian tissues including intestine, kidney, liver, brain, heart, thymus, parathyroid gland, 
bone and vascular smooth muscles  [8, 82-85]. Similar to SLC34 proteins, the distribution of 
SLC20 transporters within same tissues varies in different species. For example, in mice, 
abundant expression of Pit-2 was observed in the jejunum [82] whereas its expression was 
lower in rat small intestine [86]. In mouse and rat kidneys, expressions of both Pit-1/2 were 
detected at the level of mRNA [87, 88].   
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Under normal dietary conditions, Pit-1 protein is localized along the apical BBM of rat 
intestine. The highest expression of Pit-1 protein was found in the duodenum and jejunum, 
whereas lower levels of Pit-2 were found across all segments of the small intestine [83]. In 
mice, the precise intestinal expression of Pit-1 remains unknown, whereas Pit-2 expression 
was found at the level of mRNA and protein in the ileum, where the transporter is located at 
the apical BBM [89]. This suggests that the differential distribution of Pit-1/2 across the small 
intestine might be species specific.  
 
In mouse and rat kidneys, expressions of both Pit-1/2 were detected at the level of mRNA 
[87, 88] . While SLS20 transporters have been shown to be expressed in several organs, their 
physiological relevance in each organ is not known. Recently Beck et al. [90] generated a 
mouse model deficient for Pit-1, which resulted in embryonic lethality due to impaired liver 
development, bone marrow function and growth retardation [90]. This suggests that Pit-1 
may have an impact on early stages of fetal development. Pit-2 has not yet been 
characterized by using gene deficient animal models. As mentioned above, Miyamoto and 
his colleagues [73] characterized a mouse model deficient in both Slc34a1 and Slc34a3. They 
observed hypophosphatemia with hyperphosphaturia, but a residual amount of Pi is still 
reabsorbed in the kidney, which may be mediated by Pit-1 and Pit-2 [71]. Apparently, the 
relative abundance of SLC20 transporters mRNA in the kidney is very low and, in terms of 
preserving Pi balance, SLC20 Na/Pi-cotransporters might be responsible only for 5% Pi 
(re)absorption in kidney and intestine [91]. In humans, familial idiopathic basal ganglia 
calcification is probably caused by the loss of Pit-2 function. In these patients several 
mutations have been identified in Pit-2 that leads to loss of functional protein. Thus, Pit-2 
absence might results in deposition of Pi in the basal ganglia, a brain region that express 
higher levels of Pit-2 [92]. 
 
Increased expression of Pit-1 mRNA was observed in parathyroid gland of 1,25(OH)2D3 
deficient rats and also in animals fed with low Pi diet [84]. Furthermore, Pit-1 expression was 
also found in bone derived osteoclasts and osteoblasts and may have a role in bone 
remodeling [93]. Moreover, calcification in vasculature was observed along with increased 
Pit-1 mRNA levels upon treatment with high Ca2+ and PDGF [94] [95]. In contrast, a reduced 
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effect on calcification in smooth muscle cells was observed in response to stimuli after 
inhibition of Pit-1 expression [96]. In patients with Werner syndrome (WS), soft tissue 
calcification is one of the important clinical symptoms. The overexpression of Pit-1 that was 
observed in fibroblasts and skin may be associated with tissue calcification in WS patients 
[97]. Another pivotal role of Pit-1 is that it may participate in cell proliferation and the 
control of cell death (apoptosis) as shown in human leukemic cells (U937) and HeLa cells, an 
effect that seems to be dependent of its Pi transport activity [98]. The depletion of Pit-1 
mRNA by small hairpin RNA (Sh-RNA) in HeLa and HepG2 cell lines results in diminished cell 
proliferation and blunted mitosis which lead to the postponing of the cell cycle [86].  
 
Pit-1 is regulated in response to different stimuli. In vitro studies indicated that the 
calcification of human vascular smooth muscle cells (VSMC) by high Pi influx leads to 
phenotypic changes of VSMC to osteoblast-like cells. Li and colleagues [99] observed that the 
increased Pit-1 expression in response to bone morphogenic protein 2 (BMP-2) leads to 
enhanced Pi uptake in human VSMC [99]. BMP-2 is a cytokine known to be involved in bone 
mineralization by inducing osteoblastic cell differentiation. Moreover, Pit-1 is also regulated 
by insulin-like growth factor-1 (IGF-1) in rat osteoblasts, human osteogenic cells and VSMC 
without changes on Pit-2 expression [100, 101]. Together these data demonstrate the 
clinical importance of Pit-1.  
 
3.5 Phosphate handling by the kidney 
In mammals, control of extracellular Pi largely depends on active reabsorption of Pi from the 
primary urine that is produced by filtration of the blood in the glomeruli. Active reabsorption 
occurs through a transcellular process located in the proximal tubules along which 
approximately 80% of filtered Pi is reabsorbed. There is no clear evidence for Pi reabsorption 
in the loop of Henle but a small amount of Pi may be reabsorbed in the distal tubules [102]. 
However, this mechanism has not been characterized yet. 
 
Renal proximal tubular epithelial cells are characterized by numerous microvilli which 
increase the luminal surface and are the site of active reabsorption of filtered components. 
The transport of Pi into proximal tubular cells depends on the presence of Na+ ions [103]. 
The reabsorption of Pi is mediated by members of the SLC34 (NaPi-IIa; NaPi-IIc) and SLC20  
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(Pit-2) families of solute carriers [104] which are localized at the brush border membrane 
(BBM) of proximal tubular epithelial cells (Figure 6).  
 
                                       
Figure 6 Na
+
 dependent Phosphate (Pi) cotransporters in the BBM of proximal tubular epithelial cell. The transport of Pi is 
mediated by SLC34 (NaPi-IIa, NaPI-IIc) and SLC20 (Pit-2) cotransporters. These cotransporters mediate a secondary active 
transport of Pi using the electrochemical gradient of Na
+
 as driving force [105]. Image taken from: Alizadeh Naderi, A. S. & 
Reilly, R. F. 2010, Nature Reviews.  
 
Under normal dietary conditions NaPi-IIa is predominantly expressed in the S1 segment of 
juxtamedullary nephrons and its expression decreases in S2/S3 segments [55]. NaPi-IIc is 
expressed in S1 segments of superficial and juxtamedullary nephrons, but has not been 
detected in S2/S3 segments [106]. In addition, Pit-2 has also been identified in S1 segment 
and weakly in S2 segment of both superficial and juxtamedullary nephrons.  
 
3.6 Physiological regulation of Na/Pi-cotransport in the 
kidney 
The extent of reabsorption of Pi by the proximal tubular cells depends on the abundance of 
Na/Pi-cotransporters which are localized at the BBM. Numerous studies have described the 
control of Pi reabsorption in the proximal tubule under different physiological conditions. 
Thus far, all studies indicated that proximal tubular reabsorption of Pi is regulated by an 
alteration of the abundances of Na/Pi-co transporters in the microvilli that depends on the 
rate of protein synthesis, trafficking into the apical membrane and rate of endocytosis. 
These processes are controlled by many hormonal and metabolic factors (listed in Table 2) 
by mechanisms that are only partially understood. In the following sections, the impact on 
renal handling of Pi of some of these factors is discussed in more detail.      
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Table 2 Regulation of Pi reabsorption in proximal tubule in response to hormonal and non-hormonal factors 
 
3.6.1 Dietary phosphate 
Dietary intake of Pi is a major regulator of renal Pi reabsorption. Renal reabsorption of Pi is 
increased in low dietary Pi condition whereas it is reduced in response to high Pi diet. 
Adaptive changes to the content of Pi in the diet are observed after few hours (acute 
adaptation) as well as several days (chronic adaptation) after dietary restrictions [7, 8, 107]. 
In renal BBM vesicles isolated from animals fed with low Pi the rate of Na/Pi-cotransport is 
higher compared to BBMVs isolated from animals fed a high Pi-diet. Changes in Pi 
reabsorption are achieved by membrane insertion or retrieval of NaPi-IIa, NaPi-IIc and Pit-2 
into or from the apical membrane [7, 8, 11, 107].  
 
Intake of dietary Pi differentially regulates the Na/Pi-cotransporters in the BBM. The 
abundance of NaPi-IIa changes within few hours after dietary switches, whereas regulation 
of NaPi-IIc and Pit-2 abundance is much slower. In response to high Pi-diet NaPi-IIa is 
endocytosed and degraded in lysosomes whereas a decrease of the abundance of the NaPi-
llc cotransporter occurs via a different mechanism that is still not understood [108]. The 
increased abundance and translocation of NaPi-IIa and NaPi-IIc is a microtubule-dependent 
mechanism [108, 109].  
 
To address the relative contribution of the different Na/Pi-cotransporters to the dietary 
adaptive changes, wild type and NaPi-IIa deficient mice were chronically and acutely 
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challenged with high and low Pi diets. This study suggests that NaPi-IIa is responsible for the 
acute phase of adaptation [110]. Moreover, the abundance of NaPi-IIa was increased after 4 
hours switch from high to low Pi even though FGF23 levels remained higher [110]. It is 
known that the stability of Na/Pi-cotransporters at the BBM is dependent on the interacting 
PDZ binding proteins. Phosphaturia was observed with decreased NaPi-IIa expression at BBM 
in NHERF-1 deficient mice challenged with chronic low Pi diet [111, 112]. Chronic treatment, 
but not acute feeding, may also result in changes of mRNA levels, at least in the adult mice 
[113]. In weaning mice, chronic low Pi dietary intake leads to higher NaPi-IIa protein 
abundance without mRNA changes, whereas NaPi-IIc expression increases at mRNA and 
protein levels [114].  
 
The mechanism(s) that elucidate rapid changes of the renal abundance of Na/Pi-
cotransporters due to altered intake of dietary Pi is (are) not known. Recently it has been 
shown that  administration of a Pi bolus into the rat duodenum was associated with higher Pi 
excretion after 15 minutes without changes in the serum PTH and FGF23 [115]. This rapid 
adaptive response in the kidney suggested the presence of Pi sensor or sensing mechanism 
in the kidney or extra renal tissues, e.g. in the small intestine.  
 
3.6.2 Parathyroid hormone  
Parathyroid hormone (PTH) is synthesized by the chief cells of the parathyroid gland. The 
production and secretion of PTH is a tightly regulated mechanism and depends on the 
extracellular Ca2+ concentration. The secretion of PTH is regulated by the Ca2+ sensing 
receptor (CaR) and 1,25(OH)2D3. Activation of the CaR reduces the PTH levels via 
transcriptional and post-translational mechanisms through different intracellular signaling 
pathways [116]. PTH secretion is also inhibited by 1,25(OH)2D3 by blocking the transcription 
[117]. In addition to its primary effect on Ca2+ homeostasis, it is well known that PTH acts on 
the kidney to decrease Pi reabsorption by reducing the apical abundance of Na/Pi-
cotransporters (Figure 7) without changing the mRNA levels [118].  
 
In rodents, it has been demonstrated that NaPi-IIa is almost completely removed from the 
apical membrane within 1 hour after PTH addition, whereas a decrease of the NaPi-IIc 
abundance is slower and observed only after 4 to 8 hours [118-120]. In addition, Pit-2 
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abundance is also reduced 30 minutes after PTH infusion [106]. Tracking-racer image 
spectroscopy analysis showed that PTH induced internalization of both NaPi-IIa and NaPi-IIc 
requires myosin VI (a motor protein in microvilli) [121]. PTH treatment leads to rapid 
internalization of NaPi-IIa via clathrin coated pits. Internalized NaPi-IIa, but not NaPi-IIc and 
Pit-2, is subsequently degraded in the lysosomes [106, 119, 120, 122].  
 
PTH did not stimulate the internalization and degradation when NaPi-IIa was mutated at a 
KR motif located in the last cytoplasmic loop (Figure 3) [123]. As the KR motif is absent in 
NaPi-IIc, this could explain the different internalization rates of both cotransporters in 
response to PTH. PTH acts on a G-protein coupled receptor (PTHR1) that is located at both 
the apical and the basolateral membranes of the proximal tubular cell. The PTH signal from 
the apical side results in activation of Gq/phospholipase C/protein kinase C. Signaling of PTH 
receptors located at the ďasolateral side leads to aĐtiǀatioŶ of Gαs/adenylate cyclase, which 
increases cyclic adenosine monophosphate (cAMP) levels leading to activation of PKA. 
Activation of both signaling cascades leads to internalization of NaPi-IIa from the BBM [124, 
125]. Furthermore, inhibition of ERK1/2 partially prevented the PTH induced down 
regulation of NaPi-IIa, suggesting the involvement of the MAPK pathway [126]. NHERF-1 is a 
NaPi-IIa interacting partner involved in the stabilization of the cotransporter at the BBM. 
Immunohistochemical analysis suggested that the endocytosis of NaPi-IIa in reponse to PKC 
activation is impaired in NHERF1-/- deficient mice [127]. Upon PTH administration, NHERF-1 
is phosphorylated at a serine residue (S77) located in the first PDZ domain and it has been 
suggested that this phosphorylation of, NHERF-1 leads to a dissociation of the NaPi-IIa/ 
NHERF-1 complex and thereby allows the endocytosis of NaPi-IIa [48].  
 
3.6.3 Dietary potassium 
Potassium (K+) deficiency is one of the factors that regulate Pi reabsorption in the kidney. 
Low dietary K+ leads to increased Pi excretion that is paralleled by decreased Na/Pi-
cotransport activity in renal BBMVs. Breusegem et al. [128] observed hypophosphatemia 
with increased Pi excretion in the urine of low K+ fed animals compared to controls. They 
also found decreased abundance of NaPi-IIc and Pit-2 at protein and mRNA levels in K+ 
deficient rats and mice. Moreover, the Na/Pi-cotransport activity was also decreased in 
these animals. The decreased abundance of these two transporters might contribute to 
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phosphaturia although NaPi-IIa abundance was increased [128]. The reduced transport 
activity suggests the contribution of NaPi-IIc and Pit-2 to Pi reabsorption in the kidney. 
Paradoxically, the decreased transport activity is associated with an increased abundance of 
NaPi-IIa and Pit-1 proteins [129]. Furthermore, low K+ diet leads to increased levels of 
several lipids in renal BBM (sphingomyeline, glycosylceramide and ganglioside GM3) and 
decreased lipid fluidity [129]. Interestingly, when glycosylceramide synthesis was inhibited, 
increased BBM transport activity was observed in animals fed with control and low K+ diet, 
although the abundance of NaPi-IIa protein as well as its mRNA expression remains 
unchanged. Therefore, K+ deficiency might lead to alterations in the lipid composition of 
BBM that regulate posttranscriptionally the abundance and activity of NaPi-IIa [129]. 
Analysis based on scanning fluctuation correlation spectroscopy showed that the diffusion of 
NaPi-IIa in the BBM occurred slowly but the cluster size increased in mice fed low K+ diet 
[130].  
 
3.6.4 1,25 dihydroxy vitamin D  
Although active 1,25 dihydorxy vitamin D (1,25(OH)2D3) plays a major role in Ca
2+ 
homeostasis it is also involved in Pi homeostasis. Proximal tubular epithelial cells express 
tǁo eŶzǇŵes, ϭα-hydroxylase (Cyp27b1) and 24-hydroxylase (Cyp24a1), that regulate 
1,25(OH)2D3 ŵetaďolisŵ. The aŶaďoliĐ eŶzǇŵe ϭα-hydroxylase converts the inactive 25-
hydroxy vitamin D3 to the active form 1,25(OH)2D3, whereas 24-hydroxylase inactivates the 
active form. The synthesis of 1,25(OH)2D3 is regulated mainly by PTH and FGF23 (Figure 7). 
PTH aĐts oŶ the proǆiŵal tuďule to iŶĐrease the eǆpressioŶ of ϭα-hydroxylase. In contrast to 
PTH, FGF23 impairs the 1,25(OH)2D3 sǇŶthesis ďǇ iŶhiďitiŶg the ϭα-hydroxylase mRNA 
expression and by increasing 24-hydroxylase mRNA [131, 132] (Figure 7).  
 
In 1,25(OH)2D3 deficient rats, the abundance of NaPi-IIa protein and mRNA were decreased 
in the juxtamedullary cortex of kidney whereas expression was unchanged in superficial 
cortex [133]. Moreover, the injection of 1,25(OH)2D3 into 1,25(OH)2D3 deficient rats leads to 
increased Na/Pi-cotransport activity due to an increase of the abundance of NaPi-IIa mRNA 
and protein [133]. Furthermore, the abundance of NaPi-IIa in BBM was reduced in vitamin D 
receptor (VDR) deficient mice compared to wild type [134].  
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1,25(OH)2D3 treatment in TPTX rats increased the serum level of FGF23, suggesting an 
indirect of action of 1,25(OH)2D3 on renal Pi handling[135].In mice, treatment with 
1,25(OH)2D3 leads to increased expression of FGF23 in bone [136]. Together, these data 
demonstrate the presence of negative feedback mechanism between these two hormones 
associated with a kidney-intestine-bone axis that regulates the Pi homeostasis (Figure 7).  
 
3.6.5 Metabolic acidosis   
Besides the many functions of Pi, Pi is an important urinary buffering component for keeping 
acid base balance [137]. Metabolic acidosis (MA) increases the excretion of Pi into urine. 
During metabolic acidosis, there is an increased resorption of Pi from the bone which along 
with increased H+ excretion and absorption of bicarbonate (HCO3
-) in the proximal tubule 
contributes to balance acid-base status. It was also reported that MA is compensated by 
ammonia (NH3) and citrate excretion which act together with Pi as a buffer system to 
increase the excretion of H+ along the nephron [138]. In rats, induction of chronic MA led to 
a massive reduction of Pi uptake into isolated renal BBM vesicles. Reduced transport activity 
was associated with downregulation of NaPi-IIa mRNA and protein abundance [139]. 
Microarray gene profiling analysis in the kidney of mice challenged with chronic acid load 
also showed decreased expression of NaPi-IIa and NaPi-IIc mRNAs [138] whereas the 
expression of Pit-1/Pit-2 mRNAs was higher in acid loaded mice [68]. However, the protein 
abundance of NaPi-IIa and NaPi-IIc increased in acid loaded mice despite the higher Pi 
excretion [68] . The increased abundance of both cotransporters is associated with higher 
Na/Pi-cotransport into BBM vesicles isolated from acid loaded mice which is in contrast to 
the observations made with rats. These findings suggest that the phosphaturia induced by 
MA is independent of the abundance of NaPi-IIa/NaPi-IIc, and may be due to inhibition of 
Na/Pi-cotransporters by the high concentration of H+ in the lumen of proximal tubule.  
 
3.6.6 Phosphatonins 
In 1994, Cai and Econs identified factors called phosphatonins that are responsible for 
severe Pi wasting in the urine. They observed inhibition of Pi reabsorption and altered 
1,25(OH)2D3 metabolism in patients with tumor-induced osteomalacia (TIO) [140, 141]. 
Incubation with supernatant from tumor cell cultures lead to inhibition of Na/Pi-cotransport 
in OK cells. In contrast to PTH action these phosphatonins did not increase cAMP levels and 
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their activity was also not inhibited by PTH receptor antagonists [140]. The phosphaturic 
factors include fibroblast growth factor-23 (FGF23), secreted frizzled related protein-4 (sFRP-
4), matrix extracellular phosphor-glycoprotein (MEPE) and fibroblast growth factor-7 (FGF7) 
[115, 142].   
 
3.6.6.1 Fibroblast growth factor23 (FGF23) 
FGF23 is a bone-derived peptide hormone which is synthesized in osteoblasts and 
osteocytes [143]. Expression of FGF23 has also been found in several other tissues, including 
the small intestine, heart, liver and parathyroid gland. FGF23 has been identified as the gene 
mutated in patients with autosomal dominant hypophosphatemic rickets (ADHR), a Pi 
wasting genetic disease. Based on the positional cloning, seǀeral ͞gaiŶ of fuŶĐtioŶ͟ 
mutations of FGF23 were identified in ADHR patients. These mutations lead to the absence 
of a furin proconvertase site, and thereby to resistance to inactivation by proteolysis [144, 
145]. The proteolytic resistance results in elevated intact FGF23, which triggers 
phosphaturia,and blocks 1α-hydroxylase release resulting in  lower levels of circulating 
1,25(OH)2D3 and rickets. 
 
The synthesis of FGF23 by the bone is known to be regulated by 1,25(OH)2D3 [136]. In dialysis 
patients, treatment with 1,25(OH)2D3 led to increased circulating FGF23. Similarly, 
administration of 1,25(OH)2D3 to mice lead to increased serum FGF23 along with increased 
mRNA expression in bone [136, 146]. Moreover, it was also demonstrated in mice that 
chronic high Pi dietary intake resulted in elevated FGF23 levels in serum and low levels 
under low Pi diet [115]. Increased serum FGF23 negatively regulates the synthesis of active 
vitamin D by inhibiting the 1α-hydroxylase mRNA (Figure 7). This correlation of both FGF23 
and 1,25(OH)2D3 metabolism suggests the presence of a feedback loop between bone-
kidney axes (Figure 7).  
  
Intraperitoneal administration and intravenous injection of recombinant FGF23 in mice 
resulted in low serum Pi and a dose-dependent increased fractional excretion of Pi [147]. 
Implantation of plasmids containing FGF23 into nude mice also results in hypophosphatemia 
and Pi wasting in urine [145]. In addition, FGF23 decreased the expression of 1α-hydroxylase 
mRNA (Cyp27b1) and rickets were observed by morphological analysis in long bones [145]. 
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In agreement with this findings, incubation of OK cells with FGF23 results in inhibition of 
Na/Pi-cotransport activity [148]. Similar findings were observed in transgenic mice 
overexpressing FGF23, which show reduced abundance of NaPi-IIa in the BBM [149]. 
Conversely, these phenotypic changes were reversed in FGF23 deficient mice, for which 
higher 1,25(OH)2D3 levels in serum were reported [132].  
 
FGF23 induces phosphaturia by downregulating the expression of NaPi-IIa, NaPi-IIc and Pit-2 
[150]. However, the time course of FGF23 to reduce the abundance of each cotransporter is 
not known. This effect of FGF23 involves its binding to fibroblast growth factor receptor-1 
(FGFR-1) and probably to FGFR-4 in the presence of klotho as coreceptor [151]. FGF23 
reduces the abundance of Na/Pi-cotransporters at least partially via the MAPK pathway 
[150, 152, 153]. The highest expression of FGFR-1, -4 and klotho complexes were observed in 
the distal tubules compared to proximal tubules, whereas the biological actions of FGF23 are 
in the proximal tubule [154-156]. The mechanisms underlying the differential effects of 
FGF23 to regulate the Na/Pi reabsorption in vivo are unclear. There are two conflicting 
theories through which FGF23 acts on the kidney to downregulate the Na/Pi-cotransporters. 
The administration of FGF23 in mice leads to activation of phospho-ERK1/2 only within distal 
tubules [153]. However, microperfusion studies in isolated proximal tubules showed reduced 
BBM abundance of NaPi-IIa in response to FGF23 [157]. Thus, FGF23 actions on the proximal 
tubule may be indirect, possibly via stimulation of distal tubule and release of paracrine 
factors that regulate the proximal tubular reabsorption of Pi (i.e., distal-to-proximal tubular 
feedback mechanism) [158]. As discussed for PTH regulation, FGF23 induced downregulation 
of NaPi-IIa seems to involve phosphorylation of NHERF-1 [159].  
 
Klotho belongs to the family of β1 glycosidases and the extracellular domain of klotho shares 
40% sequence homology with mammalian lactase glycosylceramidase. In the kidney, as 
mentioned earlier that the highest expression was found in the distal tubule but was also 
observed in the proximal tubules [155]. The expression of klotho has also been described in 
several endocrine organs including the parathyroid gland, pancreas, ovaries, testis and 
placenta. This broad tissue distribution explains its role in several tissues. Kuro [160] 
identified klotho as an age suppressor gene in mice [160]. Mice deficient in klotho exhibited 
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premature aging syndromes associated with growth retardation, osteopenia, vascular 
calcification, skin atrophy and sarcopenia [161].  
 
Membrane klotho acts as a co-receptor for FGF23 binding to FGF receptors and is required 
for biological activity of FGF23 in the kidney. Thus, klotho deficient mice exhibited not only 
premature aging but also hyperphosphatemia with tissue calcification and elevated FGF23 
levels [160]. In addition, klotho deficient mice exhibited increased abundances of NaPi-IIa 
and NaPi-IIc, although FGF23 was elevated. Initially it was described that FGF23 acts on the 
distal tubule and inhibits the Pi reabsorption in proximal tubules via paracrine function 
[158]. However, microperfusion studies in isolated proximal tubules showed reduced BBM 
abundance of NaPi-IIa in response to FGF23 [157]. In support of this, the expression of 
klotho in the proximal tubules was also demonstrated [162].  
 
 
 
 
 
 
 
 
 
 
        
                      
 
Figure 7 Factors effecting the regulation of phosphate homeostasis. Pi is absorbed in the intestine from diet and stored into 
bones. The reabsorption and excretion of Pi occurred by the kidney. 1,25(OH)2D3 is synthesized in the kidney and stimulates 
the absorption of Pi in the intestine. FGF-23 produced in bone and increases the renal Pi excretion by downregulting NaPi-
IIa and NaPi-IIc. FGF-23 also inhibits the synthesis of 1,25(OH)2D3 and may inhibit the parathyroid hormone (PTH) secretion. 
PTH inhibits the Pi reabsorption and stimulates the synthesis of 1,25(OH)2D3 [116]. Image taken from: Bergwitz & Juppner, 
2010, Annual Review of Medicine. 
 
3.7 Phosphate absorption in the intestine 
Dietary Pi is absorbed in the small intestine and released into the circulation. The absorption 
of Pi across the epithelium probably occurs both transcellularly and paracellularly. Besides 
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NaPi-IIb, Pit-1 and Pit-2 mRNAs are also expressed in the small intestine and NaPi-llb and Pit-
2 proteins have been detected in the apical membrane of enterocytes [74].  
 
The segmental distribution of NaPi-IIb along the small intestine is species specific. In mice, 
the expression of NaPi-IIb (mRNA and protein) is highest in distal intestine (ileum) and 
gradually decreases in the jejunum [163]. In contrast, in rats the highest expression of NaPi-
IIb and Pi absorption was observed in the jejunum and the duodenum and is almost absent 
from the ileum [164]. In humans maximal Pi- uptake was observed in BBMVs isolated from 
the jejunum [165]. 
 
The ontogenic expression of NaPi-IIb in the small intestine of mice and rats was also 
reported. The transport of Pi was higher in intestinal BBM vesicles isolated from young (14-
day old) mice compared to adults. These changes were paralleled by increased expression of 
NaPi-IIb mRNA and protein in young mice [166]. The expression decreases progressively with 
age and this reduction has been associated with an increase in the N-glcosylation status 
[167]. However, there is no clear evidence whether age dependent regulated glycosylation 
also plays a role in the regulation of other SLC34 transporters. These effects were paralleled 
by age-dependent downregulation of NaPi-IIb at the protein and mRNA levels [166, 168].  
 
The deletion of NaPi-IIb (NaPi-IIb-/-) leads to increased fecal excretion of Pi with 
hypophosphaturia but no change of serum Pi. Hypophosphaturia was explained by an 
increased expression of NaPi-IIa in kidney, thereby maintaining the normal serum Pi [17]. In 
intestinal BBM vesicles isolated from NaPi-IIb-/- mice the Na+-dependent uptake of Pi was 
reduced by 90%.  The remaining Pi uptake may be mediated by Pit-1 and Pit-2. These 
findings suggest that NaPi-IIb plays a major role in the Pi absorption in the small intestine. 
However, the relative contribution of sodium dependent and independent transport 
mechanisms for overall Pi absorption remains unknown.  
 
Transepithelial transport of Pi in the small intestine might also be mediated by a paracellular 
pathway. The overall transport within the region may also depend on the time course of Pi 
transit along the segments. Intestinal Pi absorption was comparable in the presence or 
absence of 1,25(OH)2D3 in the rats fed with Pi bolus [169]. This suggests that the absorption 
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of Pi might occur through the paracellular transport mechanism which may depend on 
intake of dietary Pi.  
 
3.8 Regulation of Na/Pi-cotransport in the small intestine 
In contrast to the renal reabsorption of Pi less is known about the regulation of small 
intestinal Pi absorption. Several studies described the regulation by dietary Pi and 
1,25(OH)2D3;  these two factors will be discussed in the following paragraphs. Several other 
factors, such as metabolic acidosis, glucocorticoids, estrogens, epidermal growth factor, 
matrix extracellular phosphoglycoprotein and FGF23 also modulate the Pi absorption by 
indirect or direct mechanisms [167, 170-174]. The relative role of these different factors 
under normal physiological condition may require additional studies. 
 
3.8.1 Dietary phosphate and 1,25dihydroxy vitamin D 
The administration of low Pi diet in mice leads to increased abundance of NaPi-IIb, in parallel 
with higher Na/Pi cotransport activity in BBMVs isolated from the small intestine [175]. In 
additioŶ, loǁ Pi diet stiŵulates the eǆpressioŶ of reŶal ϭα-hydroxylase, and thereby the 
synthesis of 1,25(OH)2D3 is increased [175]. Although 1,25(OH)2D3 also regulates the 
abundance of the cotransporter, the expression of NaPi-IIb was increased in VDR deficient as 
well as in 1-α hǇdroǆǇlase defiĐieŶt ŵiĐe challenged with low Pi diet [134, 175]. This suggests 
that low dietary Pi can induce the expression of NaPi-IIb in the intestine independent of 
changes in 1,25(OH)2D3. 
 
 The expression of NaPi-IIb mRNA and the intestinal Na/Pi-cotransport were also increased in 
rats fed with low Pi diet compared to rats on a control diet [176]. Interestingly, it was also 
observed that the abundance of NaPi-IIb changed differently across the segments of the 
small intestine in response to changes in diet. Thus, NaPi-IIb expression was increased in the 
jejunum but not in the duodenum of rats treated with low Pi diet for 7 days. Similarly, the 
Na/Pi-cotransport activity was increased in BBMV isolated from the jejunum. Moreover, rats 
adapted to low Pi diet and then acutely switched to high Pi diet exhibited an increased 
Na/Pi-cotransport and abundance of NaPi-IIb in the duodenum but not in the jejunum [83]. 
Hence, these data suggest that the acute or chronic changes in dietary Pi regulate NaPi-IIb in 
a segmental specific way along the small intestine. Furthermore, hyperphosphatemia with 
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phosphaturia was observed within one hour after administration of different concentrations 
of dietary Pi in humans [177]. These postprandial changes in serum Pi levels suggest that fast 
adaptive changes occurred in response to dietary Pi.  
 
1,25(OH)2D3 is an important hormone known to regulate Pi absorption across the small 
intestine. 1,25(OH)2D3 binds to the vitamin D receptor (VDR) and enhance the expression of 
NaPi-IIb at the level of mRNA and protein [178]. In adult 1,25(OH)2D3 deficient rats, the 
uptake of Pi in intestinal BBMVs was increased after 1,25(OH)2D3 treatment. In addition, Pit-
2 mRNA was also increased in these rats [176]. Treatment of suckling rats with 1,25(OH)2D3 
also resulted in increased Pi uptake in the BBMVs. This increase was higher than the one 
observed in adult rats. Moreover, NaPi-IIb mRNA increased in young but not in adult rats 
upon 1,25(OH)2D3 treatment [166]. Similarly, the expression of NaPi-IIb was increased after 
the administration of 1,25(OH)2D3 into mice whereas NaPi-IIb expression and Na
+/Pi 
transport activity was reduced in the VDR deficient mice [134, 178]. Recently it was reported 
that the 1,25(OH)2D3 analog ED71 (1,25 dihydroxy-Ϯβ-(3-hydroxypropyloxy) vitamin D) 
increased NaPi-IIb mRNA in 1,25(OH)2D3 replete rats. In addition, oral administration of ED71 
in mice leads to enhanced NaPi-IIb mRNA and protein levels [179]. These evidences strongly 
support the presence of a 1,25(OH)2D3 induced transcellular Na/Pi-cotransport mechanism 
in the small intestine. 
 
3.9 Genetic diseases associated with Pi homeostasis 
Mutations in SLC34 and SLC20 Na/Pi-cotransporters have been identified in patients with 
severe Pi wasting phenotypes, bone mineralization defects, or soft tissue calcification. Some 
of these clinical disorders are discussed below.   
In bone, there are several cascades of proteins consisting of PHEX, 7B2/PC2, BMP-1 and 
DMP-1 that regulate transcriptionally or posttranscriptionally the expression of FGF23. In 
addition, GALNT3 glycosylates FGF23 leading to higher resistance against proteolysis.  
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3.9.1 X-linked hypophosphatemia (XLH) 
XLH is an inherited Pi wasting dominant disorder that results in changes in biochemical 
parameters which includes hypophosphatemia, increased serum FGF23 levels and abnormal 
1,25(OH)2D3 levels with normal PTH levels. Patients with XLH are characterized by 
hypophosphatemia, rickets and tooth abscesses. These symptoms are similar to those of 
patients with ADHR. The gene responsible for XLH is PHEX, which encodes a protein that 
belongs to the family of M13 zinc metallopeptidases. PHEX is known to be expressed in 
osteocytes and osteoblasts and is thought to regulate the synthesis and degradation of 
FGF23 [180]. Inactivating mutations in PHEX lead to a loss of functional protein and failure to 
promote degradation of FGF23. In addition, inactivation of PHEX also increases transcription 
of FGF23. Both mechanisms lead to higher circulating level of FGF23. Patients with XLH show 
higher FGF23 levels in serum, which leads to an impaired Pi reabsorption. Similar changes 
were also observed in Hyp mice which represent an animal model for XLH [181]. The 
abundance of NaPi-IIa protein is reduced by approximately 50% in Hyp mice compared to 
wild type. 
 
3.9.2 Autosomal dominant hypophosphatemic rickets (ADHR) 
Gain of function mutations in the FGF23 gene are responsible for ADHR. The proteolysis and 
inactivation of FGF23 occurs at the subtilisin-like proprotein convertase (SPC) site 
Arg176HisThrArg179/Ser180 (RXXR/S motif) which cleaves the FGF-like domain from the C-
terminal tail. The mutation in this specific site at Arg176Gln, Arg179Gln and Arg179Trp results in 
FGF23 that is resistant to proteolysis. ADHR is a Pi wasting disorder characterized by higher 
circulating levels of FGF23, hypophosphatemia and abnormal serum 1,25(OH)2D3 levels 
without any changes in the serum calcium and PTH [182]. In general, patients with ADHR 
show clinical symptoms including bone fractures, pain in bones, osteomalacia and tooth 
abscesses. Apparently, adult and young patients with ADHR exhibit different symptoms. 
Children with ADHR exhibit severe bone pain, weakness and fractures. In adult patients 
maximum tubular reabsorption of Pi per glomerular filtration rate (TmP/GFR) was lower, and 
they also exhibited bone deformities and pseudofractures [182]. The progression of the 
ADHR in patients depends on the circulating levels of FGF23 and correlates with severity 
[183]. As mentioned above (Section 3.6.6.1) that transgenic mice over expressing FGF23 
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leads to decreased abundance of NaPi-IIa in the kidney [149]. In contrast, 
hyperphosphatemia was observed in the absence of FGF23 in mice [132].  
  
3.9.3 Autosomal recessive hypophosphatemic rickets (ARHR) 
Inactivating mutations in dentin matrix protein (DMP1) lead to ARHR [184, 185]. The 
biochemical phenotypic changes observed in patients with ARHR were comparable to ADHR 
and XLH affected individuals. DMP-1 belongs to the family of SIBLING proteins and is highly 
expressed by osteocytes [186]. IŶ ARHR patieŶts’ FGF23 was elevated in serum and 
increased expression was similar to patients with PHEX mutation. The deletion of DMP1 in 
mice results in severe hypophosphatemia, increased serum FGF23 and defects in bone 
mineralization associated with diminished osteocyte maturation [186-188]. These data 
indicated that DMP1 participates in the regulation of hydroxyapatite formation as well as in 
the regulation of FGF23 synthesis. DMP1 deficient mice exhibit a phenotype comparable to 
Hyp mice. 
 
3.9.4 Tumor-induced osteomalacia (TIO) 
TIO is an acquired disorder associated with loss of Pi in urine. Most tumors originate from 
the mesenchymal tissue in TIO patients [189]. Several studies have observed that FGF23 
mRNA and circulating protein was increased in tumors isolated from TIO patients. Hence, 
increased FGF23 inhibits Pi reabsorption in the kidney which results in biochemical and bone 
phenotype. These changes are parallel to the phenotypes observed in patients with ADHR, 
XLH and ARHR, and were reverted after surgical removal of tumors from TIO patients [190]. 
 
3.9.5 Fibrous dysplasia of McCune-Albright syndrome (MAS/FD) 
This syndrome is caused by gain of function mutations in GNAS1. MAS is characterized by 
hypophosphatemia and renal Pi wasting with increased FGF23 levels in serum. Patients with 
MAS develop hypophosphatemic rickets with replacement of bone with fibrous tissue 
leading to swelling of bone [191]. Patients with MAS also show pigment patches on the skin, 
bone fractures and early puberty.  
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3.9.6 Hereditary hypophosphatemic rickets with hypercalciuria 
(HHRH) 
Hereditary hypophosphatemic rickets with hypercalciuria was identified by Tieder et al. 
[192] in patients for the first time. HHRH is a rare autosomal recessive syndrome 
characterized by hypophosphatemia due to impaired renal reabsorption of Pi, 
hypercalciuria, increased serum 1,25(OH)2D3, rickets, and osteomalacia. To identify the gene 
carrying the mutation associated with HHRH, Bergwitz et al. [193, 194] performed 
homozygosity mapping and nucleotide sequence analysis. They identified patients carrying 
homozygous single nucleotide mutations in the SLC34A3 gene. Moreover, compound 
heterozygous missense and deletion mutation were also reported in unrelated individuals 
with HHRH. Heterozygous mutations do not show the disease phenotype [194]. Up to now 
20 different types of mutations have been identified throughout the SLC34A3 gene that 
cause HHRH (Figure 4). These mutations are thought to cause a loss of  NaPi-IIc at the BBM, 
due to defects in trafficking, or reduced stability of the mutated protein [195]. However, 
mice with constitutive deletion of NaPi-IIc exhibited hypercalcemia, hypercalciuria and 
increased 1,25(OH)2D3, but they did not display hypophosphatemia or hypophosphaturia 
and rickets [69]. Together these observations suggest that, unlike in rodents, NaPi-IIc has a 
major contribution to Pi homeostasis in humans.  
 
3.9.7 Renal Fanconi syndrome 
Renal Fanconi syndrome is a generalized disturbance of proximal tubular functions with 
many different genetic and acquired forms. It is characterized by excessive wasting of 
glucose, amino acids, uric acid, bicarbonate in the urine. Patients with this syndrome also 
suffer from rickets due to a massive excretion of Pi. Recently a homozygous in-frame 
duplication of 21-bp in SLC34A1 was reported in two siblings from an Israeli family that had 
autosomal recessive hypophosphatemic Fanconi syndrome and rickets. This mutation leads 
to impaired trafficking to the membrane and therefore inactivation of NaPi-IIa [64]. This 
provides information regarding a role of NaPi-IIa in renal reabsorption of Pi in humans.  
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3.9.8 Familial idiopathic basal ganglia calcification (IBGC) 
IBGC, also kŶoǁŶ as Fahr’s disease, is aŶ iŶherited autosoŵal doŵiŶaŶt sǇŶdroŵe. It is a 
neurodegenerative disorder characterized by calcification (calcium phosphate deposits) of 
vascular tissue in the basal ganglia of the brain region. Typical neuropsychiatric clinical 
symptoms include parkinsonism, psychosis, dementia, dystonia, tremor, ataxia, seizures and 
headache. Recently Wang et al. [92] identified different mutations in Pit-2 (SLC20A2) in 
different families affected by IBGC. These mutations associated with the loss of Pit-2 
function [92]. The Pit-2 transcript is known to be expressed abundantly in the basal ganglia 
of the brain region. In addition, mutational analysis data reported that 41% of IBGC patients 
exhibited mutations in Pit-2 and these mutations were non-sense, deletion, missense and 
site directed [196]. These data indicate that Pit-2 might be responsible for Pi handling in the 
brain. The tissue specific importance of these mutations in Pit-2 remains unclear.    
 
3.10 Contribution of NaPi-IIa and NaPi-IIc to Pi reabsorption 
in the kidney 
Several studies indicated the importance of Na/Pi-cotransporters to Pi reabsorption in the 
kidney (see introduction). Based on these studies it is important to consider the species and 
developmental stages of animals to investigate the relative contribution of Na/Pi- 
cotransporters in the kidney. Inhibition of NaPi-IIa by RNase H-mediated hybrid depletion 
using X.laevis oocytes as expression system suggest that NaPi-IIa mediates most of the 
Na/Pi- cotransport activity in the adult rat kidney whereas NaPi-IIc seems to have a minimal 
contribution [7]. In agreement with this observation, the highest abundance of NaPi-IIa was 
observed in weaning animals whereas it expression was reduced gradually in older animals 
[57]. In contrast, the relative abundance of NaPi-IIc is higher in weaning animals compared 
to adult animals [7]. The uptake of Pi is higher in renal BBM isolated from young animals and 
declines with age, suggest the renal reabsorption of Pi is an age-regulated process [67]. 
Furthermore, the different pattern of regulation of NaPi-IIa and NaPi-IIc in response to 
dietary Pi, PTH and FGF23 (see introduction) suggests the presence of different signaling 
mechanisms. NaPi-IIa deficient mice show hyperphosphaturia with hypophosphatemia, 
which suggests that, the reabsorption of Pi is largely mediated by NaPi-IIa. Indeed the uptake 
of Pi in isolated BBMVs was reduced by 70%  in NaPi-IIa-/- mice compared to wild type 
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animals, although NaPi-IIc expression was increased [59]. The remaining 30% Pi uptake in 
NaPi-IIa-/- mice should be mediated by other Na/Pi-cotransporters expressed in the kidney, 
i.e. NaPi-IIc and/or Pit-2 [197]. Furthermore, NaPi-IIa-/- mice displayed reduced PTH and 
FGF23 with hypercalcemia and hypercalciuria associated with higher levels of circulating 
1,25(OH)2D3 resulting in increased Ca
2+ absorption in the small intestine [198]. Constitutive 
NaPi-IIc deficient mice (NaPi-IIc-/-) mice are characterized by hypercalcemia and 
hypercalciuria without disturbances in serum Pi levels [69]. A double knockout (DKO) mouse 
model deficient for NaPi-IIa and NaPi-IIc shows a more severe hypophosphatemia than NaPi-
IIa-/- mice [71], suggesting that the, relative contribution of both cotransporters to Pi 
handling is nonredundant. The data from gene deficient mouse models suggests that, NaPi-
IIa has a major quantitative role to Pi reabsorption whereas NaPi-IIc is considered to play a 
minor role or is restricted to young animals.   
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4. Aim of the study 
To date, it is known that, in mice, NaPi-IIa plays a major role to maintain Pi homeostasis by 
reabsorbing the bulk of Pi from primary urine. NaPi-IIc and/or other proximal tubular apical 
Na/Pi-cotransporters appear to have minimal contribution to Pi reabsorption. However, in 
humans, NaPi-IIc might be more important as suggested by the genetic defects in NaPi-IIc 
that lead to hereditary hypophosphatemic rickets with hypercalciuria (Figure 4).  
 
In mice, the relative contribution of NaPi-IIa and NaPi-IIc to renal Pi reabsorption is based on 
deficient models in which these cotransporters have been knocked out in a constitutive 
manner. These mouse models however could not explain the relative contribution of these 
cotransporters to Pi reabsorption in the kidney. In this situation, compensatory changes may 
have a masking initial effect on Pi handling. Therefore, our aim was to investigate the renal 
contribution of NaPi-IIc and we generated and characterized a mouse model in which NaPi-
IIc can be knocked out in a tissue specific (here kidney) and in an inducible manner.  
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5. Material and Methods 
5.1 Generation of renal-specific and inducible NaPi-IIc 
knockout mice  
A floxed-NaPi-IIc gene was generated by gene-targeting strategy in embryonic stem cells 
(ESC). Briefly, a targeting vector was constructed (Figure 9A) to replace the NaPi-IIc genomic 
sequence by homologous recombination upon injection into ESC. The targeting vector 
consisted of floxed Slc34a3 genomic sequence along with a neomycin resistant cassette 
(PGK-neo) and the thymidine kinase gene from herpes simplex virus (HSV-TK). Two loxP sites 
were inserted in 5` to 3` direction between within introns 3 and 12. This loxP flanked 
sequence has about 2.3 Kb (Figure 9A), and encodes residues 58 to 447 of the NaPi-IIc 
protein. As a positive selection marker the neomycin resistant gene driven by the 
phosphoglycerate kinase promoter (PGK-neo) was inserted downstream of the 5` 
homologous arm of NaPi-IIc and upstream of the floxed fragment. The PGK-neo was flanked 
by the two frt sites. As negative selection marker the HSV-TK was inserted downstream of 
the 3` homologous arm. Both the 5` and 3` homologous arms consist of around 1.9 kb. 
 
To allow homologous recombination, the vector was linearized with PacI and transfected by 
electroporation into 129SV ESC. ESC clones that survived in G148 but not in ganciclovir were 
then analyzed by Southern blots using 5` and 3` probes to further confirm the homologous 
recombination (Figure 9A, B). The 5` probe consisted of the last 700 bp of the 5` homologous 
arm. The 3` probe consisted of 550 bp located at the middle of 3` homologous arm. In brief, 
we performed the restriction digestion with KpnI or EcoR1 of the genomic DNA isolated from 
4 selected clones and from untransfected ESC.  The digested DNA was separated on an 
agarose gel and transferred to nitrocellulose membranes. Then, hybridization was done 
according to the standard protocol using 32P labeled probes. In addition, PCR was performed 
to confirm the presence of loxP sites on the same DNA samples. The presence of 5` loxP site 
was detected with a sense primer that anneals to the loxP sequence flanking exon 4 (S1: 
CTTCGTATAGCATACATTATAC) and an antisense primer that anneals to intron 12 (AS1: 
GCATGAGATGACCACAGG). The PCR reaction to detect the 3` loxP site was performed with a 
sense primer anneals within the sequence of intron 3 (S2: GGAGATCCTGTGCTCTG) and 
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antisense primer that anneals to the loxP sequence located in exon 12 (AS2: 
CTTCGTATAATGTATGCTATAC).  
 
The selected recombinant clone was microinjected into C57BL/6 mice blastocysts. Chimeric 
offsprings were produced upon blastocysts implantation into NMRI pseudopregnant female 
mice. The transfection of the targeting vector in ESC, blastocyst injection, and implantation 
were performed in collaboration with Dr. E. Hummler from the Transgenic Animal Facility of 
the University of Lausanne (TAF UNIL). Floxed- heterozygous mice were bred with 64FlpeB6 
mice in order to delete the neo-cassette. Floxed-homozygous mice devoid of the neo-
cassette were bred with Pax8rtTA/LC1 double transgenic mice (kindly provided by 
Dr.Koester, University of Heidelberg). In this model the renal expression of Cre-recombinase 
(under the control of the Pax8 promoter) can be induced by doxycycline (Doxy) (Figure 8). 
Further mating resulted in the generation of conditional homozygous (NaPi-IIcf/f) and 
conditional heterozygous mutants (NaPi-IIcf/+) as well as wild type (NaPi-IIc+/+) mice positive 
for both Pax8-rtTA and Cre.  
              
Figure 8 Pax8-rtTA-mediated, doxycycline-induced Cre-recombinase (Cre) expression in the kidney of NaPi-IIc
f/f
 mice. The 
Pax8 promoter controls the expression of the reverse tetracycline-dependent transactivator (rtTA). In the presence of 
doxycycline (Doxy) as a cofactor rtTA binds and transactivates the tetracycline-responsive element (TRE) which is a 
bidirectional Ptet promoter. Upon binding of Doxy, rtTA activates the TRE and induces the expression of Cre. The Doxy 
induced activation of Cre should result in the removal of the Floxed NaPi-IIc sequence flanked by loxP sites [199]. (Image 
adapted from Traykova-Brauch et al., 2008, Nature Medicine). 
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5.2 Genomic DNA isolation and genotyping  
Genomic DNA was isolated from ear biopsies. Each ear biopsy was incubated in a digestion 
solution (750µl) containing  50 mM Tris-HCl (pH 8.0), 100 mM EDTA, 100 mM NaCl, 1% SDS, 
0.5 mg/ml Proteinase K (Roche, Germany). The incubation was performed at 370C overnight. 
After incubation, the samples were gently mixed and 250µl of 5.5 M sodium chloride were 
added. Upon centrifugation at 13000 rpm for 10 min at 40C the supernatants (800 µl) were 
collected and transferred to fresh tubes. Isopropanol (530 µl) was added to each tube and 
mixed gently. Samples were centrifuged at 13,000 rpm for 15 min at 40C. The supernatant 
was removed and the pellet washed with 70% ethanol (750 µl) and centrifuged again at 
13,000 rpm for 20 min at 40C. Ethanol was removed carefully using a vacuum pump and the 
pellet was air dried until ethanol was evaporated completely. The dry pellet was 
resuspended in 50 µl of a buffer containing 10 mM Tris, 1 mM EDTA (TE) and pH 7.4 adjusted 
with HCl. The samples were incubated for 2 hours at 370C in an Eppendorf mixer and the 
resuspended genomic DNA was stored at -200C.  
 
Genotyping was performed by PCR using genomic DNA as a template. Genotyping of NaPi-IIc 
was done with a forward primer annealing within exon 3 and a reverse primer that anneals 
on the exon 4 (Figure 9A, C). The presence of Cre and Pax8-rtTA was analyzed with the 
primers described in the original manuscript (see Table 3). The template DNA was amplified 
with TaKaRaLa Taq polymerase (RR002A, TAKARA Bio Inc.). The PCR reaction mixture 
contained dNTPs (10µM), MgCl2 (25µM), forward and reverse primer (10 µM; Microsynth 
AG). The amplification was performed using a thermo cycler (Robocycler 40) and the 
following reaction conditions were applied: 95°C for 2 min / 40 cycles of 940C for 1 min / 
550C for 1 min / 680C for 1 min followed by 720C for 5 min and holding at 4°C. The PCR 
reactions were mixed with loading dye (Thermo scientific) and loaded on 1% agarose gel. 
Then, the amplified product together with a DNA ladder (1 kb; Fermentas) was separated by 
gel electrophoresis and observed under the ultraviolet light. The lengths of PCR fragments 
were recognized by comparing to DNA ladder.  
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Gene Forward (FW) and reverse (RV) Primers 
Slc34a3 FW: 5` - GAAGAACGCTGACCAACTG - 3` 
RV:  5` - CTCACTGCCTAGTAGCTG – 3`  
Cre FW: 5` - TCGCTGCATTACCGGTCGATGC - 3` 
RV:  5` - CCATGAGTGAACGAACCTGGTCG - 3` 
Pax8 FW: 5` - CCATGTCTAGACTGGACAAGA - 3` 
RV:  5` - CTCCAGGCCACATATGATTAG - 3` 
     Table 3: List of primers used for genotyping 
 
5.3 Experimental study with mice and sample collection 
Mice were kept in accordance with the Swiss Animal Welfare Laws and project license 
restrictions with the approval of the local veterinary authority (Kantonales Veterinäramt 
Zürich). Expression of Cre-recombinase was induced in the 3 genotypes (NaPi-IIc+/+, NaPi-
IIcf/+, NaPi-IIcf/f) of both genders by providing Doxycycline (Sigma, Switzerland) in the 
drinking water sweetened with 2% sucrose, whereas the controls drank 2% sucrose alone. 
The Doxy was prepared freshly every two days and was protected from light by wrapping the 
bottles with black plastic. To optimize the amount of Doxy required to induce the expression 
of Cre recombinase the following protocols were used. 
 
 Protocol 1: Mice received drinking water supplemented with either 2% sucrose alone or in 
combination with 2 mg/ml Doxy for 10 days. 
Protocol 2: Mice received drinking water supplemented with either 2% sucrose alone or in 
combination with different concentrations of Doxy (1 mg/ml, 0.5 mg/ml and 0.25 mg/ml) for 
10 days. After treatment, all mice drank normal tap water for two additional weeks 
(recovery period).  
Protocol 3: Mice received drinking water supplemented with either 2% sucrose alone or in 
combination with 0.5 Doxy for 5 days followed by 0.25 mg/ml during the next 5 days. After 
treatment, all mice received normal tap water for two additional weeks (recovery period).  
As discussed below, this was the final protocol. 
 
The treatment with Doxy was initiated after weaning (3-4 weeks old) and throughout the 
experiment mice were fed with standard diet (KLIBA, SA) containing 0.8% Pi. Three days 
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before the end of the treatment or recovery period, mice were placed in individual 
metabolic cages, having free access to food and liquid (Doxy, sucrose or water). After two 
days of adaptation to the new housing conditions, last 24 hours urine was collected under 
mineral oil. Then, animals were anesthetized with a mixture of 10% ketamine and 10% 
xylazin in 0.9% sodium chloride. The blood was collected from vena cava and immediately 
centrifuged (in the presence of heparin) at 8000 rpm. for 6 min to separate plasma. Then 
kidneys and ileum mucosa were collected. All the samples were immediately frozen in liquid 
nitrogen and stored at -80°C.  
 
5.4 Analysis of urine and blood parameters 
 
5.4.1 Determination of Pi in urine and plasma 
Concentration of Pi in urine and plasma was determined according to the Fiske and 
Subbarow method (Fiske & Subbarow., 1925). Urinary samples were diluted 1:50 in milliQ 
water. Plasma Pi was determined without prior dilution of the samples.  
To prepare the Pi standards, lyophilized Pi (Randox® Laboratories, United Kingdom) was 
dissolved in 5 ml of milliQ water to obtain a Pi concentration of 11.70 mM. From this stock, 
serial dilutions were made resulting in concentrations of 5.85, 2.92, 1.46, 0.73, 0.36 and 0.18 
mM. All the urinary, plasma and standard samples were prepared in triplicates.  
All samples (10 μl) were mixed with 90 μl of 20% TCA and shortly vortexed. Then, 900 μl of 
milliQ water were added and the tubes vortexed shortly again. Samples were incubated on 
ice for 10 min folloǁed ďǇ ĐeŶtrifugatioŶ ;ϭϯ’ϬϬϬ rpm) for 20 min at 4°C. Supernatants (125 
μl) were transferred into a 96-ǁell plate ;NuŶĐloŶ™ “urfaĐe, DeŶŵarkͿ. Then, 50 μl of 
ammonium molybdate (1.25 gm dissolved in 2.5 N H2SO4) and 12.5 μl of Fiske & Subbarrow 
reducer (Sigma F5428-25; 1 g/6.3 ml of milliQ water) were added to each well. The plate was 
gently rotated to mix the solutions and incubated at room temperature (RT) for 15-20 min. 
The absorbance was read at 620 nm in a micro plate reader (µQuantTM, BioTek Instriments, 
USA). The standard curve was obtained by plotting the standard concentrations versus the 
corresponding absorbance. Urinary or plasma Pi concentrations were calculated from the 
slope value of graph. 
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5.4.2 Determination of creatinine (Cr) in urine  
Urinary creatinine was determined according to the Jaffé method (63) for standardization of 
excretion by kidneys. Before performing the assay, the following reagents, standard 
concentrations of creatinine and urinary dilutions were prepared. 
Reagent A: 4.4 g of NaOH, 9.5 g trisodium phosphate (Na3PO4.12H2O) and 9.5 g sodium 
tetraborate (Na2B4O710H2O) in 500 ml milliQ water with pH >10.  
Reagent B: 5 % sodium dodecyl sulfate (SDS: Fluka, Germany) in milliQ water  
Reagent C: 1.4% crystal picric acid (Sigma) in milliQ water.  
Creatinine standards were prepared by serial dilutions in milliQ water to given final 
concentrations of 12, 10, 6, 3, and 1.5 mg/dl.  
Prior to the assay, a working solution was prepared by mixing equal volumes of reagent A, B 
and C. Urine samples were diluted 1:20 in milliQ water. All the standards and urine samples 
were prepared in triplicate.  
 
Briefly, 10 µl of urine and standard samples were pipetted into a 96-ǁell plate ;NuŶĐloŶ™ 
Surface, Denmark) and 150 μl of working solution were added to each well. The plate was 
rotated gently to mix the contents and incubated at RT for 30 minutes. The intensity of 
colour ǁas read at 5Ϭ5 Ŷŵ ǁith a ŵiĐro plate reader. UpoŶ additioŶ of ϭϬ μl of ϯϬ% aĐetiĐ 
acid samples were further incubated at RT for 5 minutes. The absorbance was read again at 
505 nm. Final absorbance was calculated by subtracting the second from the first reading. 
The standard curve was obtained by plotting standard concentration versus the 
corresponding absorbance. The concentrations of creatinine in the urine samples were 
obtained from the slope value of graph. 
 
5.4.3 Determination of Ca
2+
 in urine and plasma 
The concentration of Ca2+ in urine and plasma was measured with the QauntichromTM 
Calcium Assay Kit (DICA-500, Bioassay System). All the reagents (reagent A and reagent B) 
and Ca2+ standard stock (20 mg/dl) were provided with the kit. Before beginning with the 
assay, a working solution was prepared by mixing equal volumes of reagent A and reagent B. 
The standard stock was diluted in milliQ water to give concentrations of 20, 16, 12, 8, 6, 4 
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and 2 mg/dl. Urine samples were diluted in 1:3 milliQ water and plasma samples were 
measured undiluted. Standards and test samples were prepared in duplicates.  
 
To measure the Ca2+ concentration, 5 μl of each urine or plasma samples as well as 
standards were pipetted into a 96-well plate. Immediately, 200 μl of working solution were 
added and the plate was gently rotated to mix the contents. Upon incubation at RT for 3 
minutes, the absorbance was read at 612 nm using a micro plate reader. The absorption of 
the standards was plotted against the standard concentrations. The Ca2+ concentrations in 
urine and plasma were obtained from the slope value the graph. 
  
5.4.4 Determination of PTH in plasma 
The concentration of PTH in plasma was quantified with a mouse 1-84 PTH ELISA (Enzyme-
Linked Immuno-Sorbent Assay) kit (Immunotopics). The kit contains streptavidin coated 
strips that can be fixed in a 96 multi well holder as well as antibodies and wash solutions. 
According to manufacturer protocol, 20 µl of plasma samples, standards and controls were 
added in duplicates in the wells of the coated strips. The samples were incubated with 50 µl 
working antibody solution. This solution contains equal volumes of mouse PTH biotinylated 
antibody and mouse PTH horseradish peroxidase (HRP) conjugated antibody. The 
biotinylated antibody recognizes the C-terminal peptide (39-84) of PTH whereas the HRP 
conjugated antibody recognizes the N-terminal peptide (1-34). Incubation was done at RT for 
3 hours in a horizontal rotator (Heidolph promax 1020, FAUST Switzerland) with speed of 
180-220 rpm. After incubation, the contents from each well were removed and the samples 
were washed four times with 350 µl of wash solution to remove unbounded antibodies. 
Then, 100 µl of ELISA HRP substrate were added into each well and the plate was further 
incubated at RT for 30 minutes on the horizontal rotator with the same speed as before. This 
incubation as performed in the dark. The absorbance was read at 620 nm using the micro 
plate reader. Immediately, the reaction was stop by adding 100 µl of ELISA stop solution and 
the plate was incubated on the horizontal rotator for 1 minute. The absorbance was read 
again at 450 nm. The standard curve was generated by plotting the absorbance values read 
at 620 nm against the standard concentrations (1045, 336, 102, 32 and 0 pg/mL). The 
concentrations of PTH in plasma were obtained from the slope value of the standard curve.  
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5.4.5 Determination of FGF-23 in plasma 
The concentration of FGF23 (C-terminal fragment) in plasma was determined by using a 
Mouse/Rat FGF-23 (C-Term) ELISA kit (Immunotopics). All the materials (streptavidin coated 
strips, standards, controls and wash solutions) were supplied by the kit and the experiment 
was done according to manufacturer protocol. In brief, 25 µl of plasma, standards and 
controls were pipetted in duplicates into the streptavidin coated wells (strips) fixed by a 
holder. Then, each well was filled with 50 µl of antibody working solution which contains 
equal volumes of biotinylated and HRP conjugated antibody. The plate was then incubated 
at RT for 3 hours on a horizontal rotator with speed at 180-220 rpm.  The unbound antibody 
solution was decanted and the wells washed 5 times by pipetting 350 µl of wash solution. 
Then, 100 µl of HRP substrate were added to all wells and the plate further incubated at RT 
for 30 minutes on the rotator. During this incubation, the plate was kept in the dark. The 
absorbance was read at 620 nm. Immediately, 50 µl of ELISA stop solution were added to 
each well and the reaction incubated on the rotator for 1 min at RT before reading the 
absorbance at 450 nm. 
 
The standard curve was generated by plotting the absorbance values read at 450 nm against 
the standard concentrations (1000, 300, 100, 30 and 0 pg/mL). The concentrations of FGF-23 
in plasma were obtained from the slope value of the standard graph.  
 
5.4.6 Determination of 1,25 dihydroxy vitamin D in plasma 
Active 1,25 dihydroxy vitamin D (1,25(OH)2D3) in plasma was determined with a radio 
immune assay (RIA) kit (Immunodiagnostic Systems). All the calibrators, controls, reagents 
and wash buffers were provided with the kit. Briefly described, the assay was performed in 
three steps: delipidation, extraction of immunopurified active 1,25(OH)2D3, and reaction 
with the quantification assay. For the delipidation process, 100 µl of plasma samples were 
diluted with 400 µl of distilled water. Then, 50 µl of delipidation reagent (mix of dextran 
sulphate and MgCl2) were added to the diluted plasma samples and to the internal controls. 
Samples were vortexed shortly and centrifuge at 10, 400 rpm (10, 000 g) for 10 minutes.  
 
During the immunopurification step, 100 µl of delipidated samples were transferred into 
SORB capsules containing a monoclonal antibody to 1,25(OH)2D3 linked to solid phase 
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particles. SORB capsules were incubated for 3 hours at RT on a foam rack fixed to a rotator, 
with rotation speed of 10-20 rpm. Then, SORB capsules were left upright on the rack for 5-6 
minutes to allow the gel to settle down. After removal of top screw caps and breaking of the 
bottom stopper, the SORB capsules were placed on glass tubes and immediately centrifuged 
at 1200 rpm for 1 minute to washout the samples. After two washes with 500 µl of washing 
buffer the SORB capsules were transferred to borosilicate glass tubes. Immobilised 
1,25(OH)2D3 was eluted by adding 150 µl elution buffer into the SORB capsules followed by 
centrifugation at 1200 rpm for 1 min. The elution step was repeated 2 more times. The 
eluate containing the purified active 1,25(OH)2D3 was evaporated by passing nitrogen gas 
through the glass tubes placed in a water bath at 300C. After complete evaporation, the 
samples were dissolved in 100 µl of assay buffer. For the quantification assay, 100 µl of 
standard calibrated solutions were transferred to glass tubes. Immunopurified samples and 
standards were incubated with 200 µl sheep anti-1,25(OH)2D3 antibody for 16-18 hours at 
40C. For non-specific binding (NSB) determination, 300 µl of assay buffer were incubated in 
parallel without antibody. After overnight incubation, 200 µl of radioactive 125I-1,25(OH)2D3 
were pipetted to all the tubes including 2 additional tubes as total counts. Samples were 
incubated for 1 hour at RT. Then, 100 µl of Sac-Cel (cellulose suspended in buffer with 0.09% 
sodium azide) containing anti-sheep IgG coupled to cellulose were added to all the tubes 
except total counts, vortex shortly and incubated for 30 minutes at RT. Later, 4 ml of 
washing solution were added to all the tubes (except total counts) and centrifuged at 2400 
rpm for 20 minutes. After complete removal of the supernatants the radioactivity in all the 
tubes was measured in a gamma counter. The bound radioactivity present in samples is 
inversely proportional to the concentration of active 1,25(OH)2D3.  
 
The percentage of binding (B/Bo %) was calculated for all samples, calibrators and controls.   
The standard curve was calculated by plotting the B/Bo % against the standard 
concentrations. The concentrations of 1,25(OH)2D3 in plasma were obtained from the slope 
value of the standard graph. 
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5.5 Determination of cations in urine by ion 
chromatography 
We analyzed the concentration of sodium (Na+), potassium (K+) and magnesium (Mg2+) in the 
urinary samples using ion exchange chromatography (Metrohm ion chromatography, 
Herisau, Switzerland). In order to remove any sediment in urine, samples were centrifuged 
at 10, 000 rpm for 7 minutes. Centrifuged urine samples were diluted 1:300 in nitric acid 
(HNO3; 1.7 mM). All the dilutions were made in screw cap vials (allTech, Switzerland). 
Cations in each sample was separated through cation exchanger column (Metrosep C4 150, 
Metrohm) with flow rate of 0.9-2.0 ml/minute and pressure of 15.0 MPa (150 bar). Samples 
were eluted from the column by passing a elution buffer containing a mix of HNO3 (1.7 mM) 
and dipicolinic acid (0.7 mM). For each cation, three different standard concentrations were 
prepared (Table 4) in 1.7 mM HNO3.  
 
Sodium (Na+) 
(mM) 
Potassium (K+) 
(mM) 
Magnesium 
(Mg2+) (mM) 
4.34 0.51 0.82 
1.08 0.12 0.20 
0.27 0.03 0.05 
                       Table 4 standard concentrations of each cation 
 
After analysis by ion chromatography system, each peak in the graph represents the 
concentration of the corresponding cation. The concentration of ions was estimated by 
calculating the area of each peak. The surface area of each peak was calculated by the 
software connected to the ion chromatography system and quantified against standard 
concentrations of each ion.  
           
5.6 Total RNA isolation from kidneys 
Frozen kidney (¼) tissue was homogenized with the help of a glas-teflon potter (B.Braun, 
MelsuŶgeŶ AG, GerŵaŶǇͿ iŶ ϭŵl RLT ďuffer™ ;QiageŶ, GerŵaŶǇͿ ĐoŶtaiŶiŶg ϭ% β-
mercaptoethanol (Sigma, USA). The total RNA was isolated from 200 μl of homogenized 
sample according to the ŵaŶufaĐturer’s protoĐol ;RNAeasy Mini extraction kit from Qiagen, 
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Germany). Total RNA was eluted with 30 μl of nuclease free water. The concentration of 
total RNA (ng/μl) was determined by using the Nanodrop ND-1000 system (ND-1000 
version 3.7.1, Thermo Fisher Scientific Inc.). Quality was determined based on the ratio 
between 260 nm/280 nm. 
 
5.7 Semi-quantitative real time RT-PCR (qPCR) 
Prior to performing qPCR, purified total RNA (300 ng) was transcribed to cDNA using random 
hexamer primers and multi reverse transcriptase enzyme provided with TaqMan® Reverse 
Transcription Kit (Applied Biosystems). Reverse transcription was performed using the 
thermo cycler (Robocycler 40) with the following reaction conditions:  25°C for10 min / 48°C 
for 30 min / 95°C for 5min/ holding  at 4°C. The generated cDNA was used as template for 
PCR. qPCR was performed in a 96-well plate (Applied Biosystems) using TaqMan® Universal 
master mix containing AmpliTaq Gold® DNA polymerase and dNTPs (Applied Biosystems, 
USA).  Gene expression of NaPi-IIc was analysed with a set of primers (forward and reverse) 
and probe that anneal to the sequence of the mRNA that should be missing upon removal of 
the floxed-fragment. The forward primer anneal to exon 8, whereas both the reverse primer 
and the probe anneal to exon 9. The primers and probes for NaPi-IIc, Cyp24a1 and HPRT 
(hypoxanthine-guanine phosphoribosyltransferease) were designed using primer-3 software 
and reference DNA sequence was taken from the mouse genome database (Ensembl). The 
probes were labelled at the 5` end with a reporter dye (FAM) and at the 3` end with a 
quencher dye (TAMRA) (Microsynth, Switzerland). The expression of ϭα- 
hydroxylase/Cyp27b1 was quantified using commercial primers and probes (Taqman Gene 
Expression Assays). The qPCR was performed using the 7500 Fast Real Time PCR System 
(Applied Biosystems) with the following reaction conditions; 500C for 2 min, 950C for 10 min 
and 40 cycles of 950C for 15 seconds/ 600C for 1 min. The amplification curve was analysed 
using 7500 Fast Real-Time PCR System Sequence Detection Software v1.4 (Applied 
Biosystems, USA). The expression of the gene of interest was normalized to the expression 
of HPRT as housekeeping gene. The relative fold change (R) was calculated according to 
formula 2(Ct (HPRT)-Ct (gene of interest)) where Ct indicates the cycle number at which the threshold 
of 0.75 was achieved.   
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Gene Forward (FW) and reverse (RV) primers and oligonucleotide (Probe) 
Slc34a3 FW: 5` - CAACGGTATTACCAGCAACA - 3` 
RV:  5` - CTGTCCTCCTCTGGAGATGC – 3`  
Probe: 5` - GTGGCCTCTTCAGCTCTTGCACAGA - 3` 
CYP27b1 Mm01165921_g1 – FAM  
CYP24a1 FW: 5` - CCAGCGGCTAGAGATCAAAC - 3` 
RV:  5` - CACGGGCTTCATGAGTTTCT - 3` 
Probe: 5` - TACGGGCTGATGATCCTGGAAGGA - 3` 
HPRT FW: 5` - TTATCAGACTGAAGAGCTACTGTAATGATC - 3` 
RV:  5` - TTACCAGTGTCAATTATATCTTCAACAATC - 3` 
Probe:  5` - TGAGAGATCATCTCCACCAATAACTTTTATGTCCC - 3` 
      Table 5 List of primer and probes used for Semi-quantitative real time RT-PCR  
 
5.8 Isolation of brush border membrane vesicles (BBMVs) 
from kidney  
BBMVs were isolated from frozen kidneys according to a previously described method [200]. 
In brief, for each membrane preparation one and a half kidneys were placed in 12 ml silicon 
tubes and homogenized in homogenization buffer (2 ml) containing mannitol (300mM), 
EGTA (5mM), Tris (12mM), pH 7.1 adjusted with HCl. Homogenization was performed using a 
polytron homogenizer (model PT 10/35, KINEMATICA GmbH, Switzerland) at setting 5 
(15000 rpm) for 2 min on ice. After homogenization, ice-cold distilled water (2.8 ml) was 
added to the tube and vortex shortly. An aliquot (approximately 200µl) of homogenate was 
frozen for further analysis. Then, 58 µl of 1M MgCl2 were added to the rest of the 
homogenate and the sample was incubated for 20 min on ice. Upon transfer into 2 ml 
eppendorf tubes, samples were centrifuged in a SS34 rotor at 4,500 rpm (3000 gav) for 15 
minutes at 40C. Supernatants were collected in fresh tubes and subsequently centrifuged in 
the same rotor at 16,000 rpm (30,000gav) for 30 minutes at 4
0C. The pellet was resuspended 
in membrane buffer (2 ml) containing mannitol (300mM), Hepes (20mM), Tris (12mM), pH 
7.4 adjusted with HCl. The resuspension was done by using a syringe equipped with a 22G 
needle. A final centrifugation was performed at 16,000 rpm (30,000gav) for 30 minutes at 
40C. The pellet was resuspended again in membrane buffer (300µl) using a syringe equipped 
with a 25G needle. To inhibit proteases both buffers were mixed with protease inhibitor 
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cocktail tablets (Complete Mini EDTA free, Roche). The final resuspended pellet is enriched 
in BBMVs.   
 
5.9 Isolation of brush border membrane vesicles (BBMVs) 
from intestinal mucosa  
Intestinal BBMVs were isolated according to a previously described method from frozen 
ileum mucosa [200]. In brief, the mucosa was homogenized in the homogenization buffer 
(200 µl) described above. Homogenization was performed in a micro attached chamber 
connected to the Omnimixer (model 17106, DIGITANA AG, Horgen, Switzerland) at speed 5 
(15000 rpm) for 2 min on ice. Immediately after homogenation 1 ml of ice-cold distilled 
water and 11 µl of 1M MgCl2 were added. Samples were incubated for 30 min on ice and up 
on transfer to 2 ml eppendorf tubes centrifuged in a SS34 rotor at 4,500 rpm (3000 gav) for 
15 minutes. Supernatants were collected in fresh tubes and centrifuged at 18,500 rpm 
(32,500gav) for 30 minutes at 4
0C. Pellets were resuspended in the same membrane buffer 
(100 µl) described above using a syringe equipped with a 22G needle. The pellet is enriched 
with BBMVs.   
 
5.10 Uptakes of [
32
P]-HPO4 and [
3
H]-D-Glucose into renal 
BBMVs  
Uptake of [32P] H2PO4
-
 into BBMV was performed according to the filtration technique as 
described [201]. Uptakes were performed in triplicates using three different conditions: in 
the presence of Na+ (buffer A), in presence of Na+ and phosphonoformic acid (PFA) (buffer B) 
and with Na+ replaced by K+ (buffer C).  All the buffers contained 0.1 mM KH2PO4 and 
radioactive 32P (NEX011010MC, PerkinElmer, USA) as tracer. The full composition of each 
buffer is indicated in the Table 4. The uptakes were initiated by mixing 10 µl of BBMV with 
40 µl of each buffer. After 1 minute incubation at 250C, 20 µl of the reaction mix was 
transferred to 1 ml of ice-cold stop solution. Samples were vortexed shortly and immediately 
filtered through nitrocellulose filters (pore size 0.45 µm) that have been prewashed with 
stop solution. Filtration was performed through a vacuum filtration setup (vacuum pump, 
vacuum flask and filter support). After filtration, filters were washed with 5 ml ice-cold stop 
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solution and transferred to scintillation vials. To determine the blank-value, 10 µl of each 
cocktail buffer were pipetted into 1 ml of cold-stop solution, filtered, washed and placed in 
vials. In order to calculate the specific activity, 2.5 µl of each of the three uptake buffers 
were transferred into scintillation vial directly without filtration. Finally, 3 ml of scintillation 
fluid (Emulsifier-Safe, Perkline Elmer, USA) were added to all the scintillation vials and the 
radioaĐtiǀitǇ ǁas ŵeasured iŶ a β-counter (Packard Tri-Carb 2900TR).  
 
 
Buffer A: Mannitol – 300 mM, Hepes – 20 mM, Sodium chloride  - 125 mM, KH2PO4 -  0.1 
mM; adjust to pH 7.4 with Tris. 
 
Buffer B: Mannitol – 300 mM, Hepes – 20 mM, Sodium chloride  - 125 mM, PFA – 7.5 
mM,  KH2PO4 -  0.1 mM; adjust to pH 7.4 with Tris. 
 
Buffer C: Mannitol – 300 mM, Hepes – 20 mM, Potassium chloride  - 125 mM, PFA – 7.5 
mM,  KH2PO4 -  0.1 mM; adjust to pH 7.4 with Tris. 
 
Stop solution: Mannitol – 100 mM, Sodium chloride  - 150 mM, Tris – 5 mM   KH2PO4 - 5 
mM; adjust to pH 7.4 with HCl. 
    Table 6 Composition of buffers used for phosphate (32P) uptake studies. 
 
The uptake of 32P detected in the presence of Na+ reflects the total Pi uptake, i.e transport 
mediated by Na+-dependent and independent transporters. The Na+-dependent uptake was 
calculated by subtracting the values obtained in the absence of Na+ (Na+-independent) from 
those in the presence of Na+ (total uptake). The SLC34-mediated component of the Na+-
dependent uptake was calculated by subtracting the values measured in the presence of Na+ 
plus PFA from those obtained in the presence of Na+ without the inhibitor, whereas the 
SLC34-independent component was calculated by subtracting the values in the absence of 
Na+ from those obtained in the presence of Na+ plus PFA. 
 
To determine the uptake of [3H]-D-Glucose BBMVs were incubated for 20 seconds in two 
different buffers: in the presence of Na+ (buffer A) or with Na+ replaced by K+ (buffer B). The 
full composition of each buffer is shown in Table 5. Buffer A and B contain 0.1 mM D-glucose 
and radioactive [3H]-D-Glucose as tracer. The filtration procedure was performed similar to 
the one described for 32P uptakes. As for the 32P uptakes, blanks and total counts were also 
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prepared. Blanks and vials for determination of specific activity were processed as indicated 
for 32P uptakes.   
 
 
Buffer A: Mannitol – 300 mM, Hepes – 20 mM, Sodium chloride  - 125 mM, D-
glucose -  0.1 mM; adjust to pH 7.4 with Tris. 
 
Buffer B: Mannitol – 300 mM, Hepes – 20 mM, Potassium chloride  - 125 mM, PFA – 
7.5 mM,  D-glucose -  0.1 mM; adjust to pH 7.4 with Tris. 
 
Stop solution: Mannitol – 100 mM, Sodium chloride - 150 mM, Tris – 5 mM   D-
glucose - 5 mM; adjust to pH 7.4 with HCl. 
 
           Table 7 Composition of buffers used for glucose (
3
H –D-Glucose) uptake studies 
 
To calculate the transport activity of the BBMVs, we need to know the specific activity of the 
radioactive substrate, the amount of protein and how much radioactive 32P or 3H was 
incorporated on the filters. Therefore, the specific activity (cpm/picomoles) was calculated 
dividing the total counts present in 1 µl of buffer by the amount of cold phosphate contained 
in 1 µl of buffer. The blank values indicate the amount of radioactive 32P or 3H bound to the 
nitrocellulose filters in the absence of BBMVs. To determine the correct counts, the blank 
counts were subtracted from all samples. Final calculation was made by dividing the 
corrected counts at a given time by the specific activity and the amount of protein. The 
uptakes are given as picomoles/mg/minute.   
 
5.11 Determination of protein concentration 
The concentration of protein in homogenates and isolated BBMV`s was quantified with the 
Bio-Rad protein assay (Bio-Rad Laboratories, USA) in 96-well plate using bovine serum 
albumin (BSA) as a standard. In brief, BBMV and homogenate samples were diluted in 
distilled water (1:5 and 1:10 respectively). Diluted samples and standards were pipetted (5 
µl) into a 96-well plate as triplicates. Then, 25 µl of reagent A and 200 µl of reagent B were 
added in to all the wells. Upon incubation at RT for 15 minutes the absorbance was detected 
in a spectrophotometer at wavelength of 595 nm. The standard curve was calculated by 
plotting the absorbance of the standards against the standard concentrations (2, 1, 0.5 and 
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0.25 mg/ml). The protein concentration in renal homogenates and BBMVs was calculated 
from the slope of the standard curve.  
 
5.12 Westernblot analysis 
Homogenate (40 µg) or BBMV samples (15 µg) were solubilized in Laemmli buffer containing 
dithiothreitol (DTT, Sigma) and boiled (950C) for 2 minutes. The protein samples were loaded 
and separated on 9% polyacrylamide gel (Tris-HCl at pH 7.4, 0.2% SDS, 
tetramethylethylenediamine (TEMED) with ammonium persulfate and running buffer: 
dissolved Tris - 3 g, glycine – 14.4 g, 20% SDS – 5 ml; adjust to 1000 ml of milliQ water). After 
electrophoresis, the proteins were transferred (Transfer buffer: dissolved Tris - 3 g, glycine – 
14.4 g, methanol – 200 ml; adjust to 1000 ml with milliQ water) to polyvinylidene fluoride 
(PVDF) membranes (Immobilon-P, Millipore, Bedford, MA). After transfer, non-specific 
antibody binding was blocked by incubating the membranes for 30 minutes with 5% milk 
powder (Rapilait, Migros, Switzerland) in Tris-buffered saline (TBS) containing 0.1% Tween-
20. Membrane blots were then incubated overnight at 40C with the following primary 
antibodies: rabbit affinity-purified anti-NaPi-IIc (1:3000) raised against C-terminal amino 
acids 588–601 (NH2–CYENPQVIASQQL–COOH; Pineda Antibody services, Berlin, Germany) 
[68], rabbit polyclonal anti-NaPi-IIa (1:3000) [55], rabbit polyclonal anti NaPi-IIb (1:5000) [6] 
and  mouse monoclonal anti-β-actin (1:12,000; Sigma).  After overnight incubation, 
membranes were washed three times with TBS and blocked for 30 min at RT. Upon three 
washes with TBS, membranes were incubated for 2 hours at RT with goat anti-rabbit or 
donkey anti-mouse (1:10,000) secondary antibodies conjugated with horseradish peroxidase 
(HRP) (GE Healthcare, UK). After 3 times washes for each 10 minutes, secondary antibodies 
were detected with a chemiluminescent HRP substrate (Millipore). The chemilumenscence 
signal was detected with a LAS-4000 Fujifilm image analyzer. The signal intensities were 
quantified using Advanced Image Data Analyzer software (Ray test) and were normalized to 
β-actin.  
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5.13 Immunohistochemistry  
Mice were anesthetised with isoflurane and perfused-fixed via the left ventricle. The 
perfusion solution contained 0.9% NaCl, heparin (5000 U/ml), 1% procain-HCl, 3.2% CaCl2. 
Fixative consisted of freshly prepared 10 ml tissue fixation solution containing 3% 
paraformaldehyde in 0.1 M sodium-cacodylate. After perfusion with the fixative, kidneys 
were removed and incubated in the same fixative solution for 1 hour at 4o C followed by the 
incubation in 1% PFA in 0.1 M sodium-cacodylate for an additional hour. Kidneys were 
washed 3 times in cold PBS for 5 minutes of each wash, cut in 2 pieces and stored overnight 
at 40C in PBS containing 30% sucrose. In the morning kidneys were quickly washed by 
immersion in cold PBS. The fixed kidneys were embedded with medium O.C.T (Optimal 
cutting temperature; Miles, Elkart) in issue-tek® cryomolds (Sakura Finetek, CA, USA) and 
immediately frozen in liquid propane cooled with liquid nitrogen. Samples were stored at -
800C.  Consecutive tissue sections (5 µm) were prepared on a cryomicrotome at -20o C and 
mounted on chromalum/gelatin coated glass slides and kept in cold PBS until they were used 
for immunostaining. 
 
For immunofluorescence analysis, serial sections were pretreated with blocking solution (1% 
BSA with 0.02% sodium azide in PBS) for 15 minutes at RT. Immediately after blocking, 
sections were incubated overnight at 4oC with either affinity purified anti rabbit NaPi-IIc 
antibody diluted 1:500 or with anti-rabbit NaPi-IIa antibody diluted 1:1000. Primary 
antibodies were diluted in PBS with 0.02% sodium azide. After overnight incubation, the 
sections were immersed twice (5 min each time) in hypertonic PBS (18 g sodium chloride in 
PBS) followed by a single wash in PBS. All the tissue sections were incubated with secondary 
antibodies for 1 hour at RT. Secondary antibodies (donkey- anti rabbit IgG 1:1000; 
Invitrogen) were conjugated with Alexa Fluor 594. FITC phalloidin (1:200; Life technologies) 
and diamino-2-phenylindole (DAPI; 1:1000; Sigma, St Louis, MO) were added together with 
secondary antibody. Finally, the sections were washed similarly to the step after incubation 
with primary antibody and mounted in coverslips using mounting medium DaKO-glycergel 
(DaKO, USA). 
 
All the tissue sections were visualized and images were acquired with a fluorescence 
microscope (Leica DM 6000, Leica, Wetzlar, Germany) connected with a charged-coupled 
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device camera (Leica DFC490). Microscopic images with 40X magnification and overlays 
were processed by Adobe Photoshop.  
 
5.14 Statistical analysis 
All statistical analysis was done by using GraphPad Prism 6.0 (GraphPhad Software, USA). All 
the results from urine or plasma determinations and mRNA expression data were expressed 
as ±SEM and significance was calculated by one-way ANOVA. The quantified westernblots 
signal intensities were analysed by unpaired t-test. A P value of < 0.05 was considered as 
significant.  Significance indicated as *P < 0.05, **P < 0.01 and ***P < 0.001.  
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6 Results 
6.1 Renal specific and inducible deletion of the NaPi-IIc gene  
To generate renal specific and inducible NaPi-IIc/Slc34a3 knockout (KO) mice, we first 
generated a conditional Slc34a3 allele that was produced by the insertion of loxP sites within 
introns 3 and 12 of the Slc34a3 gene. To achieve this, the Slc34a3 targeting vector (shown in 
Figure 9A) replaced the corresponding genomic sequence by homologous recombination in 
embryonic stem cells (ESC). To confirm the homologous recombination, DNA was isolated 
from the ESC clones selected based on their neomycin/gancyclovir resistance and digested 
with Kpn1 and EcoR1. Southern blots were performed with digested DNA samples by 
hybridization with 32P labeled probes (Figure 9B). In addition, PCR was performed to confirm 
the presence of loxP sites on the same DNA samples (Figure 9B). Positive embryonic cells 
were injected into blastocysts and these were implanted in pseudopregnent female mice. 
 
The generated floxed mice were then bred with 64FlpB6 mice in order to delete the neo-
cassette from the floxed allele. Neo negative mice harboring both NaPi-IIc alleles flanked by 
loxP sites were further bred with double transgenic Pax8rtTA-LC1 mice [199]. In this model, 
the Pax8 promoter controls the expression of the reverse tetracycline-dependent 
transactivator (rtTA). In the presence of doxycycline (Doxy) as a cofactor rtTA recognizes and 
activates the tetracycline responsive element (TRE) which is a bidirectional Ptet promoter. 
The activated TRE then induces the expression of luciferase (L) and Cre-recombinase (C). 
NZL-2 mice coŶtaiŶ as reporters the luĐiferase aŶd β-galactosidase genes. It has been shown 
earlier that the administration of Doxy to Pax8rtTA/NZL-Ϯ ŵiĐe leads to eǆpressioŶ of β-
galactosidase in all renal tubular cells and in a small population of hepatocytes [199]. 
Therefore, a similar restricted expression of Cre-recombinase was expected in our renal 
specific Pax8rtTA/LC1 inducible model. A potential expression of Cre in the liver should not 
be problematic as NaPi-IIc mRNA expression in this organ is very low. Further cross-breeding 
generated wild type (NaPi-IIc+/+), conditional heterozygous (NaPi-IIcf/+) and conditional 
homozygous mice (NaPi-IIcf/f) which contain both Pax8rtTA and Cre (Figure 9C).  
 
Genotyping was done by using genomic DNA isolated from ear biopsies as template. To 
analyse the presence or absence of the loxP sites in the NaPi-IIc alleles, a sense primer that 
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anneals within the exon 3 and antisense primer that anneals on the exon 4 of NaPi-IIc gene 
were used. The expected size of the amplified DNA fragments is 710 base pairs (bp) for 
homozygous NaPi-IIcfl/fl and 615 bp for wild type NaPi-IIc+/+ whereas heterozygous NaPi-IIcfl/+ 
mice should show both 615+720 bp amplicons (Figure 9C). To detect the presence of the 
Pax8rtTA and Cre elements the specific primers described in the original manuscript were 
used to amplify DNA. The expected sizes of amplified fragments for Cre and Pax8 are around 
400 bp (data not shown).  
 
The expression of Cre was induced in both genders and 3 genotypes by administrating Doxy 
in the drinking water. Induction was initiated immediately after weaning as the expression of 
NaPi-IIc is highest after weaning and decreases with age [7]. The Doxy induced activation of 
Cre should result in the removal of the NaPi-IIc sequence flanked by loxP sites. Upon 
removal of the loxP flanked sequence the truncated mRNA would consist of only exon 1-3 
and exon 13 (Figure 9D). This truncated mRNA only encodes for the first 57 amino acids of 
NaPi-IIc which constitute the intracellular N-terminal region (Figure 9D).  
                  
Figure 9 Establishment of a renal-specific and inducible NaPi-IIc deficient mice. Generation of floxed Slc34a3 allele and 
introduction into embryonic stem cells (ESC) was done by gene-targeting methods. A) Structure of the Slc34a3 gene (top), 
targeting vector (middle) and floxed allele (bottom). The gene consists of 13 exons (E), with the codon for the starting 
methionine (*) in exon 2 and the stop codon (*) at the end of exon 13. We constructed a conditional Slc34a3 by introducing 
the loxP sites (shaded triangles) within introns 4 and 13. In addition, a neomycin cassette (PGK-neo) flanked by FRT sites 
(black ellipses) was inserted upstream of the 5` loxP site and the herpes simplex virus thymidine kinase (HSV-TK) was 
inserted at the 3` end of the construct. The vector was transfected into ESC. Lines at the bottom of floxed allele (a, b) 
indicate the position of the probes used for Southern blot, whereas the location of the KpnI (K) and EcoRI sites (R) are 
indicated at the top. The first KpnI and the last EcoRI sites are located outside the Slc34A3 gene. The presence of LoxP sites 
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was confirmed by PCR using specific primers indicated with arrows. B) To confirm the homologous recombination (5` and 
3`) genomic DNA was isolated from 4 positive ESC clones that had survived in the presence of neomycin but not ganciclovir 
and from untransfected ESC. Upon digestion with KpnI (K) or EcoRI (R) the DNA was analyzed by Southern blot (top). PCR 
was used to confirm the presence of 5` and 3` loxP sites on the same DNA samples (bottom). C) Structure of the conditional 
allele upon removal of the neo-cassette indicating the location of the primers used to discriminate between wild type 
(Slc34a3
+/+
), conditional heterozygous (Slc34a3
f/+
) or conditional homozygous mice (Slc34a3
f/f
). Genotyping was done by 
PCR using genomic DNA isolated from ear biopsies D) Structure of the gene upon Doxy-induced removal of the floxed-
sequence (top) and proposed NaPi-IIc topology (bottom): only the intracellular N-terminus would be expressed in mutant 
mice. 
 
6.2 Experimental analysis of mice treated with 2 mg/ml 
doxycycline 
Initially, in order to induce Cre-recombinase and to delete the NaPi-IIc gene in floxed-NaPi-IIc 
mice, the drinking water was supplemented with 2 mg/ml doxycycline (Doxy) plus 2% 
sucrose; control animals drank 2% sucrose. The drinking protocol lasted 10 days, after which 
the following experiments were performed.  
 
6.2.1 Gene expression of NaPi-IIc upon doxycycline induction 
To analyze if the Doxy-induced activation of Cre resulted in the depletion of NaPi-IIc at the 
mRNA level in the kidneys of NaPi-IIcf/f mice, we performed gene expression analysis by 
semi-quantitative real-time RT-PCR (qPCR). Males and females of all three genotype were 
investigated. The expression of NaPi-IIc mRNA was normalised to the expression of a 
housekeeping gene namely the hypoxanthine-guanine phosphorybosyl transferase (HPRT). 
 
The expression of NaPi-IIc mRNA was almost completely abolished in the kidneys of NaPi-
IIcf/f male mice drinking Doxy as compared with the sucrose controls whereas approximately 
50% reduction was observed in the NaPi-IIcf/+ mice (Figure 10A). In contrast the expression 
of the cotransporter was comparable in NaPi-IIc+/+ animals drinking Doxy and sucrose alone 
(Figure 10A). The changes in the expression of NaPi-IIc in females were similar to those of 
males (Figure 10B). The extent of the reduction on mRNA expression indicated that Cre-
recombinase was successfully induced by a treatment with 2 mg/ml Doxy and that the 
activated Cre efficiently depleted NaPi-IIc mRNA from the kidney in both genders. 
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Figure 10 Expression of NaPi-IIc mRNA upon administration of Doxycycline (D) or sucrose (S) to A) males and B) females. 
Mice received water supplemented either with 2 mg/ml Doxy plus 2% sucrose alone (grey bars) or 2% sucrose (white bars) 
for 10 days. Kidneys were collected immediately after treatments. Expression of NaPi-IIc mRNA was analyzed in the kidney 
of NaPi-IIc
+/+
, NaPi-IIc
f/+
 and NaPi-IIc
f/f
 mice (n=6 to 8 per group) and it was corrected by control gene HPRT. The relative 
expression of NaPi-IIc was calculated and data are presented as mean ± SEM and significance were calculated by ANOVA. *P 
< 0.05, ***P < 0.001, no significance (ns).                  
 
6.2.2 Expression of NaPi-IIc and NaPi-IIa proteins in renal BBM of 
doxycycline/sucrose treated mice 
To investigate if the Doxy treatment also induced the depletion of NaPi-IIc at the protein 
level, we analysed the expression of NaPi-IIc in renal BBM. The westernblot analysis shows 
that the expression of the cotransporter was comparable in Doxy and sucrose treated NaPi-
IIc+/+ male mice (Figure 11A). In contrast, NaPi-IIc was heavily reduced in kidneys from NaPi-
IIcf/f male mice treated with Doxy compared to sucrose controls (Figure 11B). The induction 
with Doxy did not affect the expression of NaPi-IIa in either NaPi-IIc+/+ or NaPi-IIcf/f mice as 
similar amounts were observed in the Doxy and corresponding sucrose controls (Figure 11, A 
and B). Similar results were observed in females regarding both the expression of NaPi-IIc 
and NaPi-IIa (data not shown). In all cases actin was used as reference protein and its 
expression was similar in the Doxy and sucrose groups. Together these results suggested 
that the Doxy induction effectively downregulated the expression of NaPi-IIc protein by 
reducing the mRNA expression in the kidney of both male and female mice. 
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Figure 11 Westernblot analysis of NaPi-IIc and NaPi-IIa in brush border membrane (BBM). BBM were isolated from kidneys 
of A) male NaPi-IIc
+/+
 mice and B) male NaPi-IIc
f/f 
mice after treatment with either 2 mg/ml Doxy plus 2% sucrose or 2% 
sucrose alone for 10 days. The expression of actin was used as a control (n=5 to 6 per group).  
 
6.2.3 Urinary excretion of Pi in doxycycline/sucrose treated mice 
To investigate if NaPi-IIc deficiency affects the handling of Pi by the kidney, we analysed the 
concentration of Pi and creatinine in the urine. Surprisingly, Doxy treatment increased the 
urinary excretion of Pi in wild type males, as we observed significant increased Pi excretion 
in NaPi-IIc+/+ Doxy (+/+ D) compared to NaPi-IIc+/+ sucrose (+/+ S) treated controls (Figure 
12A). Similarly, the excretion of Pi was significantly increased in NaPi-IIcf/f Doxy (f/f D) 
treated mice compared to their corresponding sucrose (f/f S) control mice (Figure 12A). 
Similar changes were also observed in female mice (Figure 12B). These results suggest that 
the administration of 2 mg/ml Doxy for 10 days had a nonspecific effect which is an 
independent from the activation of Cre-recombinase.   
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Figure 12 Urinary excretion of Pi in A) males and B) females treated with Doxy (D) or sucrose (S). Mice received water 
supplemented with either 2 mg/ml Doxy plus 2% sucrose (grey bars) or 2% sucrose alone (white bars) for 10 days. Urinary 
samples were collected over the last 24 hours of Doxy or sucrose treatment. The concentration of urinary Pi (mM) was 
A) B) 
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corrected by the creatinine (mg/dl) (n = 6 to 8 mice per group). The data are presented as mean ± SEM and significance 
were calculated by ANOVA. *P < 0.05, ***P < 0.001.     
 
6.2.4 Urinary excretion of Ca
2+
 in doxycycline/sucrose treated mice 
To investigate whether the NaPi-IIc deficiency affects calcium (Ca2+) reabsorption in the 
kidney, we analysed the concentration of Ca2+ in urine. In males, the excretion of Ca2+ was 
significantly increased in NaPi-IIc+/+ mice treated with Doxy (+/+ D) compared to their 
corresponding sucrose (+/+ S) controls (Figure 13A). A similar tendency was also observed in 
NaPi-IIcf/f Doxy mice (f/f D) compared with sucrose (f/f S) treated controls. In NaPi-IIcf/f and 
NaPi-IIc+/+ females, urinary excretion of Ca2+ was increased in Doxy treated mice compared 
with their control groups (Figure 13B). The increased excretion of Ca2+ in all Doxy 
administered mice indicated again a non-specific effect of Doxy.  
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Figure 13 Urinary excretion of Ca
2+
 in A) males and B) females treated with Doxy (D) or sucrose (S). Mice received water 
supplemented with either 2 mg/ml Doxy plus 2% sucrose (grey bars) or 2% sucrose alone (white bars) for 10 days. The 
urinary samples were collected over last 24 hours of Doxy or sucrose treatment protocol. The concentration of urinary Ca
2+
 
(mM) was corrected by creatinine (mg/dl). The data are presented as mean ± SEM (n = 6 to 8 mice per group) and 
significances between the groups were calculated by ANOVA. **P < 0.01, ***P < 0.001.     
 
6.2.5 Urinary excretion of Na
+
 and K
+
 in doxycycline/sucrose treated 
mice 
As shown above, administration of Doxy to both NaPi-IIc+/+ and NaPi-IIcf/f mice resulted in 
increased urinary excretion of Pi and Ca2+. These changes are likely due to non-specific 
effects of doxycycline.  To investigate whether these nonspecific effects of Doxy also impair 
the excretion of other ions, the urinary excretions of Na+ and K+ were also analyzed. The 
urinary excretion of Na+ was reduced by approximately 70% in both NaPi-IIcf/f and NaPi-IIc+/+ 
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Doxy treated male mice compared with sucrose controls (Figure 13A). Although less, the 
concentration of K+ was also reduced significantly in both NaPi-IIc+/+ and NaPi-IIcf/f Doxy 
treated mice (Figure 13B). The changes in Na+ and K+ excretions were identical in both males 
(Figure 14, A and B) and females (data not shown). These data strongly support a nonspecific 
effect of Doxy although we do not know whether the kidney is the primarily affected organ. 
Therefore, it was important to optimise the minimal concentration of Doxy and treatment 
period which can induce Cre-recombinase activity without causing the non-specific effects.  
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Figure 14 Urinary excretions of A) Na
+
 and B) K
+
 in male mice treated with Doxy (D) or sucrose (S). Mice received water 
supplemented with either 2 mg/ml Doxy plus 2% sucrose (grey bars) or 2% sucrose alone (white bars) for 10 days. The 
urinary samples were collected over the last 24 hours of Doxy or sucrose treatment. The concentration of urinary Na
+
 and 
K
+ 
(mM) were corrected by creatinine (mg/dl) (n = 6 to 8 mice per group). The data are presented as mean ± SEM and 
significances between the groups were calculated by ANOVA. *P < 0.05, ***P < 0.001.    
  
6.3 Optimization of doxycycline concentration 
In order to find an optimal concentration of Doxy able to induce the knockdown of NaPi-IIc 
efficiently in the kidney of NaPi-IIcf/f mice without the non-specific effects observed after a 
treatment with 2mg/ml, we performed a second round of experiments. We administrated 
water supplemented with different concentrations of Doxy (1, 0.5 and 0.25 mg/ml) plus 2% 
sucrose or sucrose alone for 10 days to NaPi-IIcf/f and NaPi-IIc+/+ male mice. The 
administration of Doxy was followed by a recovery phase of 15 days during which mice 
received normal tap water. 
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6.3.1 Gene expression of NaPi-IIc and urinary excretion of Na
+ 
in 
response to several concentrations of doxycycline  
We analyzed the expression of NaPi-IIc mRNA in the kidney of NaPi-IIcf/f mice and the 
concentration of Na+ in the urine collected from NaPi-IIc+/+ mice. The expression of NaPi-IIc 
mRNA was almost fully depleted in the NaPi-IIcf/f mice that received 1 and 0.5 mg/ml Doxy 
whereas approximately 25% expression remained in mice receiving 0.25 mg/ml compared 
with NaPi-IIcf/f mice drinking sucrose (Figure 15A). The urinary excretion of Na+ was still 
reduced significantly in the NaPi-IIc+/+ mice that received 1 and 0.5 mg/ml Doxy whereas no 
significant reduction was observed with 0.25 mg/ml (Figure 15B). Together, these data 
indicated that the protocols with 1 and 0.5 mg/ml Doxy were able to fully deplete NaPi-IIc 
mRNA expression in NaPi-IIcf/f but still altered the Na+ excretion in NaPi-IIc+/+ mice (Figure 15, 
A and B). At a concentration of 0.25 mg/ml, Doxy reduced NaPi-IIc mRNA expression only 
partially in NaPi-IIcf/f mice, whereas it did not lead to any reduction of Na+ excretion in NaPi-
IIc+/+ mice. Based on these observations, we setup a final Doxy induction protocol consisting 
of 5 days administration of 0.5 mg/ml Doxy followed by 5 days with 0.25 mg/ml Doxy. After 
these 10 days of Doxy administration, mice were left to recover for 15 days drinking normal 
tap water. The results obtained with this final protocol are described in the next section.   
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Figure 15 Expression of NaPi-IIc mRNA in the kidneys of NaPi-IIc
f/f
 (A) and urinary excretion Na
+
 of NaPi-IIc
+/+
 (B)  in response 
to different dosage of Doxy. Mice received for 10 days either 1, 0.5 and 0.25 mg/ml Doxy in the drinking water 
supplemented with 2% sucrose (grey bars) or 2% sucrose alone (white bars) followed by 15 days recovery period during 
which mice received normal drinking water. Urinary samples were collected during the last 24 hours upon which kidneys 
were harvested. The relative expression of NaPi-IIc was calculated and data are presented as mean ± SEM (n = 6 to 8 per 
group) and significances between the groups were calculated by ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, no 
significance (ns).  
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6.4 Experimental analysis of mice subjected to the final 
doxycycline protocol 
 
6.4.1 Urinary excretion of Na
+
 and K
+
 in doxycycline/sucrose treated 
mice 
In order to test whether the final Doxy protocol affected the urinary excretion of Na+ and K+, 
we measured the concentration of these two cations in urine. In males, the excretion of Na+ 
and K+ were comparable in all the groups of mice (Figure 16, A and B) that received Doxy and 
their corresponding sucrose controls. Similar results were observed in the female mice (data 
not shown). This result indicated that the final protocol used for the Doxy treatment did not 
induce the non-specific effects which we observed with previous protocols. 
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Figure 16 Urinary excretions of A) Na
+
 and B) K
+
 in male mice treated with Doxy (D) or sucrose (S). Mice received 0.5 + 0.25 
mg/ml Doxy in the drinking water supplemented with 2% sucrose (grey bars) or 2% sucrose alone (white bars) for 10 days 
followed by 15 days recovery period. The concentration of urinary Na
+
 and K
+ 
(mM) were corrected by creatinine (mg/dl). 
The data are presented as mean ± SEM (n = 6 to 8 mice per group) and statistical significance were calculated by ANOVA. 
No significant (ns) differences were observed between the groups.  
 
6.4.2 Gene expression of NaPi-IIc upon doxycycline induction 
To quantify the depletion of NaPi-IIc at the mRNA level in response to the final protocol of 
Cre induction, we performed again the gene expression analysis. In males, the expression of 
NaPi-IIc mRNA was comparable in NaPi-IIc+/+ mice drinking Doxy and sucrose. However NaPi-
IIc mRNA expression was reduced by 50% in NaPi-IIcf/+ and approximately by 90% in NaPi-
IIcf/f mice drinking Doxy compared with sucrose treated mice (Figure 17A). In females, NaPi-
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llc mRNA expression was similarly affected as in male mice (Figure 17B). These results 
suggested that the administration of 0.5 + 0.25 mg/ml Doxy followed by a recovery of 15 
days successfully induced the depletion of NaPi-IIc in NaPi-IIcf/f mice without causing non-
specific changes such as decreased urinay excretion of sodium ions.                                                                           
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Figure 17 Expression of NaPi-IIc mRNA in kidneys of males (A) and females (B) treated with Doxy or sucrose. Mice received 
0.5 + 0.25 mg/ml Doxy in the drinking water supplemented with 2% sucrose (grey bars) or 2% sucrose alone (white bars) for 
10 days followed by 15 days recovery period. mRNA expression of NaPi-IIc in NaPi-IIc
+/+
, NaPi-IIc
f/+
 and NaPi-IIc
f/f
 mice was 
corrected by control gene HPRT. The relative expression of NaPi-IIc was calculated and data are presented as mean ± SEM 
(n = 8 to 10 per group) and significances between the groups were calculated by ANOVA. *P < 0.05, ***P < 0.001. 
 
6.4.3 Expression of NaPi-IIc in renal brush border membranes and 
homogenates after doxycycline treatment 
To investigate if the final Doxy protocol induced depletion of NaPi-IIc at the protein level, we 
analysed the expression of NaPi-IIc in renal BBM by westernblots. The abundance of the 
ĐotraŶsporter ǁas Ŷorŵalised to the aďuŶdaŶĐe of β-actin. In males, the abundance of NaPi-
IIc was similar in NaPi-IIc+/+ drinking Doxy and sucrose whereas it was reduced by 50% in 
NaPi-IIcf/+ and by 90% in NaPi-IIcf/f mice treated with Doxy compared with their 
corresponding sucrose controls (Figure 18, A and B). The Doxy treatment induced similar 
downregulation of NaPi-IIc in males (Figure 18, A and B) and females (Figure 18, C and D).  
These changes in the expression of NaPi-IIc at the protein level were paralleled by the 
changes observed at the mRNA level. All together, the down regulated mRNA and protein 
expression of type IIc Na/Pi-cotransporter suggested that the Doxy induction effectively 
depleted the abundance of NaPi-IIc protein in NaPi-IIcf/f and reduced it in NaPi-IIcf/+ mice, 
which was paralleled by changes in mRNA expression.  
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Figure 18 Abundance of NaPi-IIc protein in renal BBM of) males (A,B) and females (C, D) subjected to the final Doxy 
induction protocol. Quantification of NaPi-IIc expression was corrected by actin. The data are presented as mean ± SEM (n = 
6 to 7 per group) and significances between the two groups were calculated by t-test. *P < 0.05, ***P < 0.001, no 
significance (ns). 
 
In addition to the BBM we also analyzed the expression of NaPi-IIc protein in total 
homogenates. As expected the abundance of NaPi-IIc protein was similar in all NaPi-IIc+/+ 
(Figure 19A), whereas the cotransporter was almost completely absent in NaPi-IIcf/f mice 
treated with Doxy (Figure 19B). The downregulated expression of NaPi-IIc in homogenates 
was similar in males and females (data not shown).  
                                        
 Figure 19 Abundance of NaPi-IIc protein in total renal homogenates of male NaPi-IIc
+/+
 (A) and NaPi-IIc
f/f 
(B) mice subjected 
to the final Doxy induction protocol. (n = 6 to 7 per group). 
A) B) 
C) D) 
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6.4.4 Localization of Na/Pi-cotransporters in kidneys upon 
doxycycline induction   
Immunofluroscence staining was performed in kidney sections to observe the expression 
pattern of renal Na/Pi- cotransporters NaPi-IIa and NaPi-IIc in our renal specific NaPi-IIc 
deficient mice. The sections were also labeled with phalloidin (green) in order to stain the 
brush borders. These studies were performed only in NaPi-IIcf/f and NaPi-IIc+/+ mice that had 
drunk water supplemented with Doxy and 2% sucrose. The expression of NaPi-IIc was 
observed at the BBM of proximal tubules of NaPi-IIc+/+ mice and this signal was completely 
abolished in kidneys obtained from NaPi-IIcf/f mice (Figure 20A). This observation confirmed 
our previous results of mRNA and protein levels, indicating that the Doxy induced Cre-
activation abrogated the expression of NaPi-IIc in NaPi-IIcf/f mice. The expression of NaPi-IIa 
was abundant in apical membranes of proximal tubules and its expression was similar in 
both NaPi-IIcf/f and NaPi-IIc+/+ mice (Figure 20B).  
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Figure 20 Pattern of expression of NaPi-IIc and NaPi-IIa protein in kidney. Immunostaining of NaPi-IIc (A) and NaPi-IIa (B) on 
renal cryosections of NaPi-IIc
+/+
 and NaPi-IIc
f/f 
mice treated with 0.5 + 0.25 mg/ml Doxy. The Na/Pi-cotransporters signals 
were shown in red. The renal sections were stained with phalloidin (green) to indicate the brush borders. The fluorescent 
signal was detected with a fluorescence microscope (Leica Microsystems) using 40X magnification (50 µm). 
 
6.4.5 Effect of NaPi-IIc depletion on Pi uptake into isolated BBMVs 
In kidney, active reabsorption of Pi takes place across the proximal tubule. The reabsorption 
is mediated by members of the SLC34 (NaPi-IIa and NaPi-IIc) and SLC20 (Pit-2) families of 
Na+/Pi cotransporters. These cotransporters are predominantly expressed at the BBM of 
proximal tubules. To assess the relative contribution of NaPi-IIc to the total Pi transport in 
the proximal tubule, we performed 32P uptake assay into isolated renal BBMVs from NaPi-
IIc+/+ and NaPi-IIcf/f males treated with Doxy and sucrose. The uptake of 32P assay was 
performed under three different conditions:  in the presence or absence of Na+-ions and in 
the presence of Na+-ions but with PFA (PFA is an inhibitor of SLC34 but not of SLC20 
transporters; [34, 202]). These three conditions allowed us calculate the total 32P uptake as 
well as the uptakes mediated by Na+- independent and Na+ - dependent (mediated by SLC34 
and SLC20 transporters) mechanisms. The PFA sensitivity gives us the difference between 
the SLC34 and SLC20 mediated Pi uptake. The uptake 3H glucose was also performed in 
parallel as a negative control. Equilibrium values has been determined (Data not shown) and 
were similar in all vesicular preparations indicating that same vesicles were prepared from 
the different mice.  
 
f/f 
+/+ 
NaPi-IIa (red) phalloidin (green) NaPi-IIa + phalloidin  
B) 
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Total and Na+ dependent 32P uptakes did not show significant differences between BBM`s 
isolated from NaPi-IIc+/+ and NaPi-IIcf/f Doxy-treated mice compared to BBM’s isolated froŵ 
sucrose controls (Figure 21, A and B). Similarly, there were no significant changes in the PFA-
sensitive or PFA-insensitive 32P uptake neither between genotypes nor between the 
Doxy/sucrose groups (Figure 21, C and D). The data suggest that the absence of NaPi-IIc did 
not change the Na+-dependent, PFA- sensitive or PFA-insensitive 32P uptake in NaPi-IIcf/f 
Doxy treated mice. As expected the depletion of NaPi-IIc did not affect the uptake of 3H-D-
glucose that was comparable in NaPi-IIc+/+ and NaPi-IIcf/f Doxy or sucrose treated mice 
(Figure 21E). 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 21 Transport of Pi into renal BBMVs isolated from the kidney of NaPi-IIc
+/+
 and NaPi-IIc
f/f 
mice treated with Doxy or 
sucrose. A) Total uptake of Pi was measured in the presence and absence of Na
+
 B) Na
+
-dependent uptake of Pi: represents 
the transport mediated by SLC34 and SLC20 transporters. C) PFA sensitive uptake of Pi: represents the transport of Pi 
mediated only by SLC34 transporters D) PFA insensitive uptake of Pi: represents the uptake mediated only by SLC20 
transporters. E) Total uptake of D-glucose measured in the presents of Na+ with 3H-D-glucose. The data are presented as 
mean ± SEM (n = 7 to 8 per group) and statistical significances were calculated by ANOVA. No significant differences (ns) 
were observed between groups.  
 
6.4.6 Effect of NaPi-IIc depletion on the expression of other Na/Pi-
cotransporters  
As shown above, the absence of NaPi-IIc did not affect Pi uptake of BBMVs. The transport 
activity mediated by NaPi-IIa and NaPi-IIc cannot be discriminated by 32P uptake studies 
since both transporters are inhibited by PFA. The absence NaPi-IIc in the proximal tubular 
A) B) C) 
D) E) 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
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BBM may lead to compensatory mechanism by increasing the expression of other known 
Na/Pi-cotransporters which also mediate the active reabsorption of Pi. Therefore, we were 
interested to analyse the BBM abundance of NaPi-IIa and Pit-2 in the kidney.  
 
The abundance of NaPi-IIa in renal BBM was identical in Doxy and sucrose treated NaPi-IIc+/+ 
mice and similar expression was also found in NaPi-IIcf/f mice (Figure 22A). In addition, the 
abundance of Pit-2 in NaPi-IIc+/+ and NaPi-IIcf/f was also similar in Doxy treated mice 
compared with the corresponding sucrose treated controls (Figure 22B).  
 
It is known that the intestine may compensate for impaired renal reabsorption of Pi by 
either increasing or decreasing the expression of NaPi-IIb. Therefore, we also analyzed the 
expression of NaPi-IIb in the ileum of Doxy/sucrose treated mice. The abundance of NaPi-IIb 
in intestinal BBM did not show differences between the groups (Figure 22C), similar to the 
observations on the renal cotransporters. Similar data were obtained in both male (Figure 
22A - 22C) and female mice (data not shown). These data suggest that the absence of NaPi-
IIc in the kidney did not alter expression of other known Na+/Pi cotransporters in the kidney 
and intestine.  
                                   
Figure 22 Effect of NaPi-IIc knockdown on the abundance of other Na
+
/Pi cotransporters. Expression of A) NaPi-IIa, B) Pit-2 
and C) NaPi-IIb in renal (A, B) or intestinal (C) BBM isolated NaPi-IIc
+/+
 and NaPi-IIc
f/f
 mice treated with Doxy or sucrose.  
Mice received 0.5 + 0.25 mg/ml Doxy or sucrose alone for 10 days followed by 15 days recovery period. All the membrane 
ďlots ǁere iŶĐuďated ǁith β-actin (n = 7 per group).   
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6.4.7 Effect of NaPi-IIc depletion on plasma and urinary Pi  
To analyse potential phenotypic changes upon Doxy induced depletion of NaPi-IIc, we 
measured the concentration of Pi in the urine and plasma.  Urine samples were collected 
during the last 24 hours and plasma samples were collected after termination of the 
experimental protocol.  
 
The urinary excretion of Pi did not change significantly in the NaPi-IIc+/+ Doxy treated mice 
compared with their corresponding sucrose controls. Moreover, the excretion Pi was also 
identical in the NaPi-IIcf/+ and NaPi-IIcf/f Doxy and sucrose treated mice (Figure 23A). The 
serum concentration of Pi was also similar in all groups of mice (Figure 23B). Similar results 
for urinary and plasma Pi were observed in both male (Figure 23 A and B) and female mice 
(data not shown). Therefore the deletion of NaPi-IIc in the kidney did not alter the plasma 
and urinary concentrations of Pi. Together these data indicate that the NaPi-IIc deficiency 
did not affect Pi homeostasis. 
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Figure 23 Effect of NaPi-IIc knockdown on the urinary excretion of Pi and plasma Pi.  Pi concentration in A) urine and B) 
plasma of NaPi-IIc
+/+
, NaPi-IIc
f/+
 and NaPi-IIc
f/f
 mice treated with Doxy (D) or sucrose (S).  Urine was collected during the last 
24 hours in metabolic cages and plasma was collected immediately after termination of experimental protocol. Mice 
received 0.5 + 0.25 mg/ml Doxy (gray bars) or sucrose alone (white bars) for 10 days followed by 15 days recovery period. 
The excretion of Pi (mM) was normalized to the concentration of creatinine (mg/dl). The data are presented as mean ± SEM 
(n = 8 to 10 per group) and statistical significances were calculated by ANOVA. No significant (ns) differences were observed 
between groups.     
 
6.4.8 Effect of NaPi-IIc depletion on phosphaturic hormones 
The maintenance of normal serum Pi depends, among other factors, on the balance 
between the phosphaturic hormones PTH and FGF23. PTH and FGF23 are known regulators 
of Pi homeostasis and act in response to different physiological stimuli. These hormones 
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regulate Pi reabsorption in the proximal tubules by controlling the abundance of apically 
located Na/Pi-cotransporters. To identify potential changes of these phosphaturic hormones 
due to the absence of NaPi-IIc, we determined the concentration of PTH and FGF23 in the 
plasma collected from NaPi-IIc+/+, NaPi-IIcf/+ and NaPi-IIcf/f mice.  
 
The plasma levels of FGF23 (Figure 24A) and PTH (Figure 24B) were not changed significantly 
in NaPi-IIc+/+ and NaPi-IIcf/f mice administered with Doxy compared to their corresponding 
sucrose controls. Together these data suggests that the depletion of NaPi-IIc did not affect 
the plasma levels of the phosphaturic hormones. The absence of changes in the hormonal 
levels correlates with the absence of changes in the urinary and serum Pi and with NaPi-lla 
abundance.  
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Figure 24 Effect of NaPi-IIc knockdown on circulating levels of phosphaturic hormones.  Concentration of A) FGF-23 and B) 
PTH in plasma collected from NaPi-IIc
+/+
, NaPi-IIc
f/+
 and NaPi-IIc
f/f
 mice drinking Doxy (D) or sucrose (S). Mice received 0.5 + 
0.25 mg/ml Doxy (gray bars) or sucrose alone (white bars) for 10 days followed by 15 days recovery period. Plasma samples 
were collected immediately after termination of Doxy induction protocol.  The data are presented as mean ± SEM (n = 6 to 
8 per group) and statistical significances were calculated by ANOVA. No significant (ns) differences were observed between 
all the groups of mice. 
 
6.4.9 Effect of NaPi-IIc depletion on plasma and urinary Ca
2+ 
Recently it was reported that the constitutive depletion of NaPi-IIc in mice causes 
hypercalcemia with hypercalciuria [69]. The changes in the calcium balance were probably 
due to the effect of increased circulating levels of 1,25(OH)2D3. Furthermore, expression of 
24-hǇdroǆǇlase ŵRNA ǁas reduĐed aŶd ϭα-hydroxylase remained unchanged in the 
described mutant mice. Therefore the increased 1,25(OH)2D3 levels in constitutive NaPi-IIc 
depleted mice is probably due to reduced catabolism rather than increased production.  
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The urinary excretion of Ca2+ remained unchanged in NaPi-IIc+/+ and NaPi-IIcf/f Doxy treated 
mice compared with their sucrose treated controls (Figure 25A). The plasma Ca2+ 
concentration was also not affected and was similar in all groups of mice (Figure 25B). 
Similar results were observed in both male (Figure 25 A and B) and female mice (data not 
shown). 
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Figure 25 Effect of NaPi-IIc knockdown on the excretion of Ca
2+
 and plasma Ca
2+
 concentrationCa
2+
 concentration in urine 
A)and plasma B) of NaPi-IIc
+/+
, NaPi-IIc
f/+
 and NaPi-IIc
f/f
 mice drinking Doxy (D) or sucrose (S). Urine was collected during the 
last 24 hours in metabolic cages and plasma was collected immediately after termination of experimental protocol. Mice 
received 0.5 + 0.25 mg/ml Doxy (gray bars) or sucrose alone (white bars) for 10 days followed by 15 days recovery period. 
The excretion of Ca
2+
 (mM) was normalized to the concentration of creatinine (mg/dl). The data are presented as mean ± 
SEM (n = 8 to 10 per group) and statistical significances were calculated by ANOVA. No significant (ns) differences were 
observed between groups.      
 
6.4.10 Effect of NaPi-IIc depletion on plasma 1,25(OH)2D3 and mRNA 
expression of 1,25(OH)2D3 regulating genes 
Finally we determined the concentration 1,25(OH)2D3 in plasma and also analyzed the 
expression of mRNA’s of 1,25(OH)2D3 regulating genes in the kidney. As expected, the 
concentration of 1,25(OH)2D3 was similar in NaPi-IIc
+/+ mice drinking Doxy and sucrose alone 
(Figure 26A). The renal specific depletion of NaPi-IIc did not lead to significant differences in 
1,25(OH)2D3 as similar concentrations were found in NaPi-IIc
f/f mice drinking Doxy and 
sucrose (Figure 26A). In addition, we did not observe significant changes in the expression of 
both 1α- hydroxylase (Cyp27b1) and 24-hydroxylase (Cyp24a1) mRNAs between all the 
groups of mice (Figure 26B, C). Together, the absence of changes the mRNA expression of 
both 1α-hydroxylase and 24-hydroxylase correlates with the levels of 1,25(OH)2D3 that were 
similar in all groups. Hence these data indicate that the renal specific depletion of NaPi-IIc 
did not alter circulating 1,25(OH)2D3 which is in agreement with the absence of changes in 
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Figure 26 Effect of NaPi-IIc knockdown on the 1,25(OH)2D3 metabolism in the kidney.  A) Concentration of 1,25(OH)2D3 in 
plasma and mRNA expression of 1,25(OH)2D3 regulating enzymes B) 1α-hydroxylase and C) 24-hydroxylase in the kidney of 
NaPi-IIc
+/+
 and NaPi-IIc
f/f
 mice. Mice received 0.5 + 0.25 mg/ml Doxy (gray bars) or sucrose alone (white bars) for 10 days 
followed by 15 days recovery period. The relative expression of ϭα-OHase and 24OHase was calculated and data are 
presented as mean ± SEM (n = 6 to 8 per group) and significances were calculated by ANOVA. No significant (ns) differences 
were observed between groups.   
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7 Discussion  
Inorganic phosphate (Pi) is essential for cellular functions in the organism. The concentration 
of Pi in plasma is regulated by the modulation of intestinal absorption from the dietary 
source, renal reabsorption and storage of Pi in the skeleton and soft tissues (Figure 1). The 
maintenance of plasma Pi concentration is mainly achieved by the rate of Pi reabsorption in 
the proximal tubule of the kidney and to a limited extend by the intestinal absorption of 
dietary Pi. The renal reabsorption of Pi depends on the abundance of the Na/Pi-
cotransporters NaPi-IIa, NaPi-IIc and Pit-2 that are localized at the brush border membrane 
(BBM) of proximal tubular epithelial cells [24]. In addition, the control of Pi homeostasis 
relies on secretory factors which regulate the abundance of these Na/Pi-cotransporters at 
the BBM. These factors are secreted by different organs including the parathyroid gland 
(PTH), bone (FGF-23) and kidney (1,25(OH)2D3) (see introduction). As mentioned in the 
introduction, these regulatory mechanisms form feedback networks such as the intestine-
kidney or kidney-bone axis (Figure 7).  
 
The renal reabsorption of Pi is an age-dependent process. In BBMVs isolated from kidneys of 
young animals Na/Pi cotransport activity is higher than in samples obtained from adult 
animals. Increased transport of Pi reflects a higher abundance of NaPi-IIa and NaPi-IIc 
proteins [7, 57]. It is thought that NaPi-IIa is the most important renal cotransporter in mice, 
since its absence in the kidney cannot be compensated by other cotransporters. Constitutive 
depletion of NaPi-IIa in mice leads to severe renal Pi wasting with hypophosphatemia 
although NaPi-IIc abundance is increased. In addition, the Pi uptake into renal BBMVs is 
reduced by 70% in the absence of NaPi-IIa [59]. This suggests that, in mice, the contribution 
of NaPi-IIa to Pi reabsorption is higher compared to NaPi-IIc and/or other apical 
cotransporters that altogether may reabsorb the remaining 30%. However, genetic defects 
in NaPi-IIc in humans lead to hereditary hypophosphatemic rickets with hypercalciuria 
(HHRH) suggesting a more important role  of NaPi-IIc in Pi handling compared to mice [193].  
 
In mice, the estimation of the relative contributions of NaPi-IIa and NaPi-IIc to renal Pi 
reabsorption is based on deficient models in which these cotransporters were constitutively 
knockedout [59, 69]. In these mouse models, compensatory upregulation of other 
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cotransporters in the intestine or kidney may have masked an initial effect on Pi handling. 
Therefore, the aim of this study was to investigate the role of NaPi-IIc by characterising a 
mouse model in which this cotransporter can be knocked out in an inducible and renal-
specific manner. The inducible system used in this work is based on the activation of Cre-
recombinase. In order to induce the recombinase activity, doxycycline (Doxy) was 
administered to 3 weeks old mice. It has been shown earlier that the abundance of NaPi-llc 
is highest after weaning and continuously decreases with age [7]. 
 
Initially, mice received drinking water supplemented with 2 mg/ml Doxy and 2% sucrose or 
sucrose alone for 10 days.  Compared to the sucrose controls, this protocol resulted in a 
decrease of 50% of the abundance of the NaPi-llc protein and NaPi-llc mRNA in NaPi-IIcf/+ 
mice and an almost complete absence  of NaPi-IIc protein and mRNA in NaPi-IIcf/f mice 
(males and females)  (Figure 10, A and B, Figure 11).  
 
Surprisingly, the urinary excretion of Pi was increased in both NaPi-IIc+/+ and NaPi-IIcf/f after 
Doxy treatment (2mg/ml) (Figure 12, A and B). Furthermore, urinary excretion of several 
cations was changed. Thus, the excretion of Ca2+ was also higher in both NaPi-IIc+/+ and NaPi-
IIcf/f Doxy treated mice compared to the sucrose controls (Figure 13A, B) whereas the 
excretion of Na+ was reduced by 75% in all the groups of mice treated with Doxy (Figure 14 
A). Similarly, K+ was also decreased significantly in urine collected from mice treated with 
Doxy compared to sucrose controls (Figure 14B). Together, these alterations in the urinary 
excretion of Pi and Ca2+ along with other cations (Na+ and K+)  in mice drinking 2mg/ml Doxy 
indicated that, this concentration of the antibiotic has nonspecific effects either in the 
kidney or in the intestine. A previous study indicated that, the treatment with Doxy at high 
concentration might have possible effects in the intestine by creating disturbances in the 
intestinal flora that lead to diarrhoea and colitis [203]. Thus, changes in the excretion of ions 
in urine might be secondary to disturbances in the intestine. We did not determine the 
concentration of Na+ and K+ in the feces. Nevertheless, these changes are unrelated to the 
deficiency of NaPi-IIc in the kidney.   
 
Due to the nonspecific effects of the initial concentration of 2 mg/ml Doxy used, we had to 
optimize the concentration of the antibiotic in order to find a dosage which can efficiently 
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induce the depletion of NaPi-IIc without causing nonspecific effects. For that, we 
administered to NaPi-IIc+/+ and NaPi-IIcf/f male mice different concentrations of Doxy (1, 0.5 
and 0.25 mg/ml) for 10 days followed by a recovery period of 15 days during which mice 
drank normal tap water. Then, the NaPi-IIc mRNA expression was analysed in kidneys from 
NaPi-IIcf/f mice and the concentration of Na+ was determined in urine of NaPi-IIc+/+ mice. The 
expression of NaPi-IIc mRNA was almost completely depleted in mice that received 1 and 0.5 
mg/ml Doxy whereas 25% expression remained in mice treated with 0.25 mg/ml Doxy 
compared with corresponding sucrose treated mice (Figure 15A). To monitor whether these 
concentrations of Doxy still lead to nonspecific effects, we determined the concentration of 
Na+ in urine, which was used as an indicator for possible nonspecific effects. The urinary 
excretion of Na+ was still reduced in NaPi-IIc+/+ mice that received 1 and 0.5 mg/ml Doxy but 
no differences were observed in mice that received 0.25 mg/ml Doxy compared to sucrose 
controls (Figure 15B). Hence, the concentration of Doxy at which the NaPi-IIc mRNA 
expression was abolished still showed nonspecific effects whereas normal excretion of Na+ 
was only found at the concentration of Doxy (0.25 mg/ml ) at which NaPi-llc mRNA 
expression was not fully depleted. It may be of interest that even after a recovery phase of 
10 days the effect on Na+ excretion was still observed.  
 
Therefore a new (and final Doxy) treatment was defined, consisting of administration of 0.5 
mg/ml for 5 days followed by 0.25 mg/ml for the next 5 days, and extra 15 days as recovery 
period during which mice drank only normal tap water. Upon treatment with the final Doxy 
protocol, urinary excretion of Na+ was comparable in all the Doxy treated animals and their 
respective sucrose controls (Figure 16A). Similarly, excretion of K+ remained unchanged in all 
Doxy and sucrose mice (Figure 16B). The absence of changes in the urinary Na+ excretion 
indicated that the final induction protocol (0.5 + 0.25 mg/ml Doxy + 15 days recovery) did 
not induce the non-specific effects which we observed in the mice treated with higher 
concentrations of Doxy. All results discussed below were obtained with animals treated with 
this final protocol. 
  
In both males and females, the mRNA expression of NaPi-IIc was comparable in NaPi-IIc+/+ 
mice drinking Doxy and sucrose. Instead, expression was reduced by 50% in NaPi-IIcf/+ and 
almost fully absent in NaPi-IIcf/f Doxy treated mice compared with their corresponding 
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sucrose controls (Figure 17, A and B). The expression of NaPi-IIc protein in isolated renal 
BBM and total homogenates was also quantified. The results were similar to those of mRNA 
levels in all groups. Thus, while Doxy did not alter the abundance of NaPi-IIc in NaPi-IIc+/+ 
mice, the expression was reduced by 50% and almost 100% in NaPi-IIcf/+ and NaPi-IIcf/f mice 
respectively (Figure 18A - 18D). In addition, the abundance of NaPi-IIc protein in total 
homogenates paralleled the one observed in the BBM (Figure 19, A and B). The amount of 
NaPi-IIc protein in the renal BBM was highly variable in all the groups. In contrast, we did not 
observe such heterogeneity for other cotransporters namely NaPi-IIa and Pit-2. This suggests 
that the intra group variability of NaPi-IIc protein expression may not be due to a variable 
degree of protein degradation. The feeding behaviour may have an effect on expression of 
Na/Pi-cotransporters in the kidney. As mentioned earlier (see introduction) in response to 
dietary Pi restrictions the abundance of NaPi-IIa is regulated faster compared to changes of 
NaPi-IIc.  Thus, the intra group variability of NaPi-IIc expression may not apply to changes in 
the diet. Circadian rhythm is also known to affect the expression of a number of proteins, 
although its potential effects on the translational regulation of NaPi-IIc are not known. 
Nevertheless, we collected samples between 9-11 am, so the heterogenic expression of the 
cotransporter may not relate to circadian variations. 
 
In addition to Westernblot analysis, we also analysed the expression of NaPi-IIc by 
immunofluorescence. This study showed that the expression of NaPi-IIc in the proximal 
tubules remained detectable in kidneys from NaPi-IIc+/+ mice, whereas the signal was absent 
in kidneys from NaPi-IIcf/f mice treated with Doxy (Figure20A). In contrast, NaPi-IIa protein 
was comparable in NaPi-IIc+/+ and NaPi-IIcf/f mice treated with Doxy (Figure 20B). All together 
these results suggested that the optimized Doxy induction protocol efficiently depletes the 
expression of NaPi-IIc in NaPi-IIcf/f mice without non-specific effects and therefore allowed 
us to study the relative contribution of NaPi-IIc to Pi homeostasis in the kidney of weaning 
mice.  
 
To study the effect of NaPi-IIc deficiency on the capacity of the kidney to reabsorb Pi, we 
isolated BBMVs from kidneys of NaPi-IIc+/+ and NaPi-IIcf/f mice and measured Na/Pi-
cotransport activity. We did not observe changes in the total, Na+-dependent or Slc34-
mediated Na/Pi-cotransport activity between the NaPi-IIc+/+ and NaPi-IIcf/f Doxy treated mice 
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compared with their corresponding sucrose controls (Figure 21A - 21D). The transport of D-
glucose which was used as a control for the integrity of the isolated membrane vesicles was 
also similar in BBMVs isolated from both NaPi-IIc+/+ and NaPi-IIcf/f mice (Figure 21 E). These 
observations were similar to the previously reported data indicating that the constitutive 
depletion of NaPi-IIc did not alter Na/Pi-cotransport activity into renal BBMVs isolated from 
9 weeks old mice [69]. Together, this data suggest that the deficiency of NaPi-IIc in the 
kidney did not alter Na/Pi-cotransport activity into proximal tubular BBMVs, suggesting a 
minimal role of this cotransporter in renal reabsorption of Pi, even in young animals. 
However, the transport studies in the BBMVs, discussed above cannot discriminate between 
the transport mediated by NaPi-IIa and NaPi-IIc as both proteins are sensitive to PFA. 
Therefore, we could not rule out a potential compensatory mechanism even though NaPiIIa 
abundance and total Pi transport activity into BBMV was unaltered.  
 
In this regard, it has been demonstrated that the depletion of NaPi-IIa results in increased 
abundance of NaPi-IIc in the BBM probably to compensate urinary Pi losses [197]. However, 
this increased NaPi-IIc is not able to replace the lack of NaPi-IIa function, and the mice show 
hypophosphatemia secondary to renal loss of Pi. Similarly, compensatory mechanisms were 
also reported in mice deficient for NaPi-IIb, the SLC34 cotransporter responsible for the Na+-
dependent transcellular absorption of Pi across the small intestine. NaPi-IIb deficient mice 
did not exhibit changes in the serum Pi although faecal excretion was higher. The 
maintenance of normal serum Pi in these mice is achieved by a compensatory increased 
abundance of NaPi-IIa in the kidney [17]. Thus, the depletion of NaPi-IIc in the kidney could 
also lead to upregulation of other Na/Pi-cotransporters in order to maintain the Pi 
homoeostasis. However, renal-specific deficient NaPi-IIc mice did not show changes in the 
abundance of NaPi-IIa in the BBM as the amount of NaPi-IIa was similar in NaPi-IIf/f mice 
treated with Doxy compared with respective sucrose controls (Figure 22A). In addition to 
NaPi-IIa and NaPi-IIc, Pit-2 is also expressed in the BBM of proximal tubules [8]. Pit-2 is also a 
Na/Pi-cotransporter, but belongs to the SLC20 family of solute carriers. Although its 
contribution to Pi reabsorption might be minimal, previous studies indicated that the 
expression of Pit-2 was regulated in response to dietary Pi, PTH and metabolic acidosis, three 
conditions known to regulate renal Pi reabsorption [8, 106].This data indicated the potential 
importance of Pit-2 activity in the kidney. The abundance of Pit-2 was not altered in NaPi-
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IIcf/f mice treated with Doxy compared to sucrose controls (Figure 22B). Furthermore, the 
abundance of NaPi-IIb in the small intestine was also similar in NaPi-IIcf/f Doxy treated mice 
compared to corresponding sucrose controls (Figure 22C). Hence, the depletion of NaPi-IIc 
did not affect expression of other renal (NaPi-IIa and Pit-2) or intestinal (NaPi-IIb) Na/Pi-
cotransporters. 
 
Renal specific NaPi-IIc deficient mice had normal plasma concentration as well as urinary 
excretion of Pi (Figure 23, A and B). Thus, the absence of NaPi-IIc did not affect Pi 
homeostasis. These results were similar to previous findings observed in a constitutive NaPi-
IIc deficient model, where the cotransporter deficiency did not induce changes in the urinary 
excretion and plasma concentration of Pi [69]. In contrast, constitutive NaPi-IIa deficient 
mice exhibited increased excretion of Pi and hypophosphatemia. In addition, the absence of 
NaPi-IIa affected Na/Pi-cotransport activity that was reduced by 70% in renal BBMVs [59] 
indicating the major role of NaPi-IIa. Together, the absence of changes in the urinary 
excretion of Pi and the normal expression levels of other cotransporters supports the 
conclusion that the contribution of NaPi-IIc to renal reabsorption of Pi must be minimal.  
 
Several reports indicated that both PTH and FGF23 target the kidney to induce phosphaturia 
by reducing the BBM expression of NaPi-IIa and NaPi-IIc [116, 118, 122, 124, 204, 205]. In 
constitutive NaPi-IIa deficient mice both plasma PTH and FGF23 levels were reduced [59] 
whereas in constitutive NaPi-IIc deficient mice, FGF23 was reduced but PTH was unchanged 
[69]. Therefore, we measured the concentration of PTH and FGF23 in plasma. Both PTH and 
FGF23 levels were similar in NaPi-IIcf/f mice drinking either sucrose or Doxy (Figure 24, A and 
B). These results were consistent with the absence of changes in the expression of NaPi-IIa at 
the BBM.  
 
We observed high variability of PTH within the groups. Recently it was reported that PTH 
levels could change rapidly in response to dietary Pi restrictions [110]. We know that the 
food intake was similar for all our mice because they were kept in single metabolic cage 
during the last 24 hours of the experimental protocol and food intake was recorded. 
However, we cannot estimate the latest time at which each mouse ate. Therefore, this 
variability in PTH levels could be the result of different feeding behaviours of the animals. 
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Together, these data indicate that renal-specific depletion of NaPi-IIc in weaning mice does 
not result in changes in Pi balance, circulating levels of PTH and FGF23, Na/Pi-cotransport 
activity of renal BBM and expression of other cotransporters.  
 
As mentioned above that constitutive NaPi-IIc deficient mice showed lower FGF23 levels in 
plasma. In addition, expression of DMP-1 was increased in bone [69]. DMP-1 is a bone matrix 
protein known to inhibit the transcription of FGF23 and therefore might affect FGF23 
synthesis [143]. In agreement with this hypothesis, it was also reported that the loss of DMP-
1 in mice is associated with elevated plasma FGF23 levels and impaired maturation of 
osteocytes [184]. In humans, inactivating mutations in DMP-1 are associated with autosomal 
recessive hypophosphatemic rickets (ARHR) which leads to increased FGF23 production 
[184, 185]. This suggests that, the decreased FGF23 levels in constitutive NaPi-IIc deficient 
mice might be the effect of increased DMP-1 expression. However, is not clear how the 
NaPi-IIc deficiency leads to increased DMP-1 in the bone. Taken together, these observations 
suggest that the expression of NaPi-IIc in extra-renal tissues for instance like bone might be 
related to the changes in expression of DMP-1. Expression of NaPi-llc mRNA has been 
observed in osteoclasts (personal communication from D.Fuster, University of Bern, 
Switzerland). Further work, such as osteoclast specific knock outs will be needed to clarify 
the role of NaPi-llc in bone cells. 
 
The constitutive depletion of either NaPi-IIa or NaPi-IIc in associated with hypercalcemia, 
hypercalciuria and elevated 1,25(OH)2D3 in plasma [59, 69]. In the kidney, the active 
1,25(OH)2D3 is produced by the aĐtioŶ of the aŶaďoliĐ eŶzǇŵe ϭα-hydroxylase and it is 
catabolised by the 24-hydroxylase. The absorption of calcium (Ca2+) in the intestine is 
controlled by 1,25(OH)2D3 via an increase of expression of TRPV6, a channel involved in the 
absorption of Ca2+ in the intestine [60]. In addition, 1,25(OH)2D3 induces the expression of 
NaPi-IIb to promote the intestinal absorption of Pi [60]. Both PTH and FGF23 are known to 
regulate the plasma levels of 1,25(OH)2D3 ďǇ ŵodulatiŶg the eǆpressioŶ of ϭα- hydroxylase 
and 24-hydroxylase [206, 207]. In response to lower levels of plasma Ca2+ the synthesis of 
PTH iŶĐreases ǁhiĐh iŶ turŶ aĐts oŶ the kidŶeǇ to eŶhaŶĐe the ϭα hǇdroǆǇlase ŵRNA leǀels 
leading to higher 1,25(OH)2D3. In contrast, FGF23 reduces 1,25(OH)2D3 by decreasing the 
eǆpressioŶ of ϭα-hydroxylase and increasing 24-hydroxylase mRNA levels [208, 209].   
  Discussion 
86 
  
Results obtained with a constitutive NaPi-IIĐ defiĐieŶt ŵouse ŵodel iŶdiĐated that ϭα-
hydroxylase mRNA levels were unchanged whereas 24-hydroxylase mRNA levels were 
significantly increased [69]. Furthermore, patients with mutations in the NaPi-IIc gene that 
are associated with hypophosphatemia and hypercalciuria showed elevated 1,25(OH)2D3 
levels [193]. Together these data suggest that a (constitutive) loss of NaPi-IIc function is 
associated with abnormal regulation of 1,25(OH)2D3 metabolism which leads to changes in 
the Ca2+ homeostasis. Interestingly the urinary excretion and plasma Ca2+ were normal in 
NaPi-IIcf/f Doxy treated mice (Figure 25, A and B). Moreover, plasma 1,25(OH)2D3 levels were 
similar in all groups of mice treated either with Doxy or sucrose (Figure 26A). Furthermore, 
the mRNA expression of the two key enzyŵes ϭα-hydroxylase and 24-hydroxylase was 
undistinguishable in all the groups (Figure 26, B and C).  
 
The marked differences in the Ca2+ phenotypes between constitutive and renal-specific NaPi-
IIc deficient mouse models may result from an extra-renal knockdown of the cotransporter 
in the constitutive model. The expression of NaPi-IIc in several human and rat tissues was 
investigated by Northernblot [7]. In both species the expression of NaPi-IIc mRNA was 
detected only in the kidney. Recently, Nishimura et al. [70] analysed the mRNA expression of 
all the SLC members in several human tissues by real-time PCR. They observed highest 
mRNA expression levels of NaPi-IIc in the kidney whereas lower levels were detected in 
other tissues like testis, brain, lung and spinal cord [70]. Recently, NaPi-IIc mRNA has been 
also observed in osteoclasts (personal communication from D. Fuster). Thus, extra renal 
expression of NaPi-IIc might explain the disturbed Ca2+ metabolism observed in constitutive 
NaPi-IIc deficient mice. The distribution of NaPi-IIc protein in the other tissues is not known 
and needs to be examined. Our floxed-NaPi-IIc mouse model may be helpful to investigate 
the role of NaPi-IIc in different organs other than in kidney which might be responsible for 
the differences in the Ca2+ metabolism.   
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8. Conclusion 
In summary, we have generated an inducible knockout mouse model that allows to knock-
out NaPi-IIc in a tissue specific manner. Here NaPi-llc was knocked out specifically in renal 
proximal tubules in order to investigate its role renal handling of Pi and in overall Pi 
homeostasis. Our findings show that the absence of renal NaPi-IIc does not disturb Pi 
homeostasis in mice. These results are in agreement with previous studies performed with a 
constitutive NaPi-IIc deficient mouse model. Both, results obtained from a constitutive and 
renal-specific NaPi-IIc deficient mouse model suggest that NaPi-IIc might have a minor role in 
renal Pi reabsorption in mice. Interestingly, in humans, the deficiency of NaPi-llc 
cotransporter function leads to hereditary hypophosphatemic rickets with hypercalciurea. 
Thus, NaPi-IIc might be more important to renal reabsorption of Pi in humans as compared 
to mice. 
 
Unlike the constitutive NaPi-IIc deficient mouse model, the renal-specific ablation of the 
cotransporter in weaning mice does not alter  Ca2+ homeostasis, suggesting that extra-renal 
expression of NaPi-IIc may be responsible for changes in the Ca2+ metabolism that have been 
reported in the constitutive mouse model. The mouse model (floxed NaPi-llc) described in 
this work may be of help to investigate the role of the Na/Pi-cotransporter NaPi-llc in 
extrarenal tissues. 
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9 Future perspectives 
PTH is one of the key regulatory phosphaturic factors that decrease the abundance of NaPi-
IIa and NaPi-IIc at the BBM of proximal tubular cells. The regulation pattern of NaPi-IIa and 
NaPi-IIc in response to PTH is different. It has been described that PTH-induced 
internalization and lysosomal degradation of NaPi-IIa occurs by activating PKA and PKC 
signalling pathways [24, 118, 124]. NaPi-IIc is also internalized and degraded upon PTH 
treatment but degradation does not take place in lysosomes [119]. The intravenous injection 
of PTH leads to internalization of NaPi-IIa within 20 min and the cotransporter completely 
disappears from the BBM one hour after PTH administration [106]. In contrast, NaPi-IIc was 
observed in sub-apical compartments after 4 hours of PTH injection and complete 
degradation required up to 8 hours [119]. Our experimental data suggest that NaPi-IIc in 
weaning mice may not be accountable for significant Pi reabsorption in kidney. In contrast, 
and as already indicated NaPi-IIa deficient mice show a 70% reduction in Pi reabsorption. 
The remaining 30% must be reabsorbed by other Na/Pi-cotransporters and based on the 
present knowledge they are most probably NaPi-IIc and/or Pit-2. As indicated above NaPi-IIa 
is fully internalized 1 hour upon PTH injection whereas internalization of NaPi-IIc and Pit-2 
takes 4 to 8 hours. This means that BBM isolated from kidneys of wild type mice acutely 
treated with PTH should contain NaPi-IIc and Pit-2 whereas BBM isolated from NaPi-IIcf/f 
would express only Pit-2. Therefore, short administration of PTH to NaPi-IIc+/+ and NaPi-IIcf/f 
mice may be helpful to clearly define whether or not NaPi-IIc contributes, through minimally, 
to Pi reabsorption in the kidney.  
 
As mentioned above that the NaPi-IIc mRNA expression was identified in several other 
organs like spinal cord, brain, lungs and testis where the cotransporter function was not yet 
characterized. Therefore, the generation of tissue-specific Cre-lines and our floxed-NaPi-IIc 
model may further helpful to investigate the NaPi-IIc function in different organs.  For 
instance, NaPi-IIc mRNA was observed in osteoclasts. It is interesting to generate osteoclast 
specific knock outs to clarify the role of NaPi-llc in bone cells. 
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11. Appendix 
Renal-specific and inducible depletion of NaPi-IIc/Slc34A3, the cotransporter mutated in 
HHRH, does not affect phosphate or calcium homeostasis in mice 
Komuraiah Myakala, Sarah Motta, Heini Murer, Carsten A Wagner, Robert Koesters, Jürg 
Biber and Nati Hernando 
Institute of Physiology and Zurich Center for Integrative Human Physiology (ZIHP). University 
of Zurich, Switzerland 
The proximal renal epithelia express three different Na-dependent inorganic phosphate (Pi) 
cotransporters: NaPi-IIa/SLC34A1, NaPi-IIc/SLC34A3, and PiT2/SLC20A2. Constitutive mouse 
knockout models of NaPi-IIa and NaPi-IIc suggested that NaPi-IIa mediates the bulk of renal 
reabsorption of Pi whereas the contribution of NaPi-IIc to this process is minor and probably 
restricted to young mice. However, many reports indicate that mutations of NaPi-IIc in 
humans lead to hereditary hypophosphatemic rickets with hypercalciuria (HHRH). Here, we 
report the generation of a kidney-specific and inducible NaPi-IIc-deficient mouse model 
based on the loxP-Cre system. We found that the specific removal of the cotransporter from 
the kidneys of young mice does not impair the capacity of the renal epithelia to transport Pi. 
Moreover, the levels of Pi in plasma and urine as well as the circulating levels of parathyroid 
hormone, FGF-23, and vitamin D3 remained unchanged. These findings are in agreement 
with the data obtained with the constitutive knockout model and suggest that, under 
steady-state conditions of normal dietary Pi, NaPi-IIc is not an essential Na-Pi cotransporter 
in murine kidneys. However, and unlike the constitutive mutants, the kidney-specific 
depletion of NaPi-IIc does not result in alteration of the homeostasis of calcium. This 
suggests that the calcium-related phenotype observed in constitutive knockout mice may 
not be related to inactivation of the cotransporter in kidney 
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